

Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. HHSA-290-2007-10057-I, Task Order No. 8

Prepared by:

Oregon Evidence-based Practice Center
Oregon Health & Science University
3181 SW Sam Jackson Park Road
Portland, OR 97239
www.ohsu.edu/epc

Investigators:

Roger Chou, MD
Amy Cantor, MD, MPH
Christina Bougatsos, MPH
Bernadette Zakher, MBBS

**AHRQ Publication No. 12-05173-EF-2
November 2012**

This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0024). The investigators involved have declared no conflicts of interest with objectively conducting this research. The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

The report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

Acknowledgements: The authors acknowledge Tracy Dana, MLS, for conducting literature searches, and Ian Blazina, MPH, and Laurie Hoyt Huffman, MS, for contributions to the report. The authors also thank AHRQ Medical Officer Jennifer Croswell, MD, MPH, as well as the U.S. Preventive Services Task Force Leads, Susan Curry, PhD, Virginia Moyer, MD, MPH, Wanda Nicholson, MD, MPH, MBA, and Timothy Wilt, MD, MPH.

Suggested Citation: Chou R, Cantor A, Bougatsos C, Zakher B. Screening for HIV in Pregnant Women: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 96. AHRQ Publication No. 12-05173-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; November 2012.

Structured Abstract

Background: A 2005 U.S. Preventive Services Task Force (USPSTF) review found good evidence that prenatal HIV screening is accurate and can lead to interventions that reduce the risk of mother-to-child transmission.

Purpose: To systematically update the 2005 USPSTF review on benefits and harms of prenatal HIV screening, focusing on research gaps previously identified and new evidence on treatments.

Data Sources: We searched MEDLINE (2004 to June 2012) and the Cochrane Library Database (2005 to the second quarter of 2012) and manually reviewed reference lists.

Study Selection: We selected randomized trials and cohort studies of pregnant women that reported risk of mother-to-child transmission or maternal or infant harms associated with prenatal HIV screening or antiretroviral therapy during pregnancy. We also selected studies that reported the yield of repeat prenatal screening or the positive predictive values and harms associated with rapid versus standard HIV testing during pregnancy.

Data Extraction: Two reviewers abstracted and confirmed study details and quality using predefined criteria, based on methods developed by the USPSTF.

Data Synthesis (Results): No study directly evaluated effects of prenatal screening for HIV infection versus no screening on risk of mother-to-child transmission or maternal or infant clinical outcomes. One fair-quality, large cohort study (0.7% HIV prevalence) found rapid testing during labor associated with a positive predictive value of 90 percent. New cohort studies of nonbreastfeeding women in the United States and Europe confirm that full-course combination antiretroviral therapy reduces risk of mother-to-child transmission (<1% to 2.4% vs. 9% to 22% with no antiretroviral therapy). New cohort studies found antiretroviral therapy during pregnancy associated with increased risk of preterm (prior to 37 weeks' gestation) delivery, with no clear association with low birth weight, congenital abnormalities, or infant neurodevelopment.

Although some studies found an association between in utero exposure to antiretroviral therapy and subsequent echocardiographic abnormalities, hematologic abnormalities, and markers of mitochondrial dysfunction, the clinical significance of these findings remains unclear. Evidence on long-term maternal harms associated with short-term exposure to antiretroviral therapy during pregnancy, or antiretroviral therapy started during pregnancy and continued after pregnancy, remains sparse.

Limitations: Only English-language articles were included. Due to limited evidence from randomized trials, we included cohort studies of treatments. Studies conducted in resource-poor settings may be of limited applicability to screening in the United States.

Conclusions: Antiretroviral therapy in combination with avoidance of breastfeeding and elective Cesarean delivery in women with viremia reduces risk of mother-to-child transmission. Use of certain antiretroviral therapy regimens during pregnancy may increase risk of preterm delivery, but more evidence is needed to fully understand short- and long-term maternal and infant effects.

Table of Contents

| | |
|---|----|
| Chapter 1. Introduction | 1 |
| Purpose of Review and Prior USPSTF Recommendation | 1 |
| Condition Definition | 1 |
| Prevalence and Burden of Disease | 1 |
| Etiology and Natural History | 2 |
| Risk Factors | 2 |
| Rationale for Screening | 3 |
| Interventions/Treatment | 3 |
| Current Clinical Practice | 3 |
| Recommendations of Other Groups | 4 |
| Chapter 2. Methods | 5 |
| Key Questions and Analytic Framework | 5 |
| Search Strategies | 6 |
| Study Selection | 6 |
| Data Abstraction and Quality Rating | 6 |
| Data Synthesis | 7 |
| External Review | 7 |
| Chapter 3. Results | 8 |
| Key Question 1. What Are the Benefits of HIV Screening Versus No Screening in Asymptomatic Pregnant Women on Maternal or Child Morbidity, Mortality, or Quality of Life or Rates of Mother-to-Child Transmission? | 8 |
| Key Question 2a. What Is the Yield (Number of New Diagnoses) of Repeat HIV Screening in Asymptomatic Pregnant Women? | 8 |
| Key Question 2b. What Are the Adverse Effects (Including False-Positive Results and Anxiety) of Rapid Versus Standard HIV Testing in Asymptomatic Pregnant Women? | 8 |
| Summary | 8 |
| Evidence | 9 |
| Key Question 3a. What Is the Effectiveness of Newer Antiretroviral Regimens for Reducing Mother-to-Child Transmission? | 9 |
| Summary | 9 |
| Evidence | 10 |
| Key Question 3b. What Are the Effects of Antiretroviral Regimens in Pregnant, HIV-Positive Women on Long-Term Maternal Morbidity, Mortality, or Quality of Life? | 11 |
| Summary | 11 |
| Evidence | 11 |
| Key Question 3c. What Are the Harms (Including Longer-Term Harms) to the Mother or Child Associated With Antiretroviral Therapy During Pregnancy? | 12 |
| Summary | 12 |
| Evidence | 12 |
| Infant Harms | 12 |
| Maternal Harms | 14 |

| | |
|------------------------------------|----|
| Chapter 4. Discussion | 16 |
| Summary of Review Findings | 16 |
| Limitations | 17 |
| Emerging Issues | 17 |
| Future Research..... | 17 |
| Conclusions | 17 |

| | |
|-------------------------|----|
| References | 18 |
|-------------------------|----|

Figures

Figure. Analytic Framework for Screening for HIV in Pregnant Women

Summary Tables

- Table 1. Diagnostic Accuracy and Acceptability of Rapid Versus Standard HIV Testing in Pregnant Women
- Table 2. Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
- Table 3. African-Based Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
- Table 4. Preterm Birth Outcomes
- Table 5. Summary of Evidence

Appendix

Appendix A. Detailed Methods

- Appendix A1. Search Strategies
- Appendix A2. Inclusion and Exclusion Criteria per Key Question
- Appendix A3. Literature Flow Diagram
- Appendix A4. Excluded Studies List
- Appendix A5. U.S. Preventive Services Task Force Quality Rating Criteria
- Appendix A6. Expert Reviewers of the Draft Report

Appendix B. Evidence and Quality Tables

- Appendix B1. Key Question 2b: Quality Ratings of Diagnostic Accuracy Studies
- Appendix B2. Key Question 3a: Evidence Table of Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
- Appendix B3. Key Question 3a: Quality Ratings of Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
- Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
- Appendix B5. Key Question 3a: Quality Ratings of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
- Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

Appendix B7. Key Question 3c: Quality Rating of a Randomized, Controlled Trial of Adverse Outcomes Associated With Antiretroviral Therapy

Appendix B8. Key Question 3c: Quality Ratings of Cohort Studies of Adverse Outcomes Associated With Antiretroviral Therapy

CHAPTER 1. INTRODUCTION

Purpose of Review and Prior USPSTF Recommendation

The purpose of this report is to update a previous evidence review^{1,2} commissioned by the U.S. Preventive Services Task Force (USPSTF) on screening for asymptomatic HIV infection in pregnant women, including adolescents. In 2005, based on the earlier review, the USPSTF recommended that clinicians screen all pregnant women for HIV (grade A recommendation).³ Although the USPSTF found no studies that directly evaluated prenatal HIV screening versus no screening on risk of mother-to-child transmission or other clinical outcomes, it found good evidence that prenatal testing is accurate and acceptable to women and that treatment with recommended interventions (combination antiretrovirals, elective Cesarean delivery in women with viral loads >1,000 copies/mL near the time of delivery, and avoidance of breastfeeding) is associated with major reductions in risk of mother-to-child transmission (from 14% to 25% in untreated women to 1% to 2% with treatment). The USPSTF concluded that benefits of treatments in reducing perinatal transmission substantially outweighed short-term harms, though evidence on long-term maternal or infant harms associated with screening and subsequent interventions was limited.^{1,2} The current report will be used by the USPSTF to update its 2005 recommendation on prenatal HIV screening.

This update focuses on newer evidence on the accuracy and acceptability of rapid versus standard testing, the effectiveness of newer antiretroviral regimens for reducing mother-to-child transmission, long-term maternal outcomes following use of antiretroviral regimens during pregnancy, and maternal and infant harms associated with use of antiretroviral medications. Because perinatal practices and interventions related to prevention of HIV infection are substantially impacted by the availability of resources, the report will emphasize evidence applicable to typical practice in the United States.

Condition Definition

HIV is a ribonucleic acid (RNA) retrovirus that infects the immune cells of its human hosts, in particular, CD4 helper T cells. HIV infection leads to acquired immune deficiency syndrome (AIDS) in most patients if left untreated. HIV is a communicable disease with two types: HIV-1 and HIV-2. HIV-2 infection is very uncommon in the United States, primarily affects persons from West Africa, and is less likely to progress to AIDS.⁴ AIDS is a life threatening disease defined by severe immune dysfunction (CD4 T cell count $\leq 0.200 \times 10^9$ cells/L) or one or more AIDS-defining opportunistic infections or neoplastic conditions.⁵

Prevalence and Burden of Disease

In 2009, women represented 24 percent of all diagnoses of HIV infection among adults and adolescents in the United States.⁶ About 300,000 U.S. women were living with HIV infection in 2008,⁷ with 11,200 new cases in 2009.⁶ The prevalence of HIV infection increases from 0.03 percent in women ages 15 to 19 years to 0.7 percent in women ages 40 to 44 years, though estimates vary depending on geographic area, demographic characteristics, and presence of risk factors.⁸ The

prevalence of HIV infection is higher in black and Latina women compared with women of other races/ethnicities. An estimated 18 percent of women with HIV infection are unaware of their status.^{6,7}

Between 6,000 and 7,000 HIV-positive women give birth each year in the United States,⁹ with approximately 30 percent of women unaware of their HIV-positive status prior to pregnancy.¹⁰ From 2001 to 2004, approximately 7 percent of HIV-infected women in the United States were undiagnosed at the time of delivery.¹⁰ Mother-to-child transmission is responsible for more than 90 percent of pediatric HIV infections in the United States.^{8,11} Through 2008, there have been nearly 5,000 cumulative deaths of individuals with perinatally acquired HIV infection, with recent estimates of 60 to 70 deaths per year.¹² The number of cases of perinatal HIV infections in the United States peaked at about 1,650 in 1992, but has declined dramatically with the widespread adoption of routine prenatal screening coupled with the use of more effective therapies for preventing mother-to-child transmission, and was estimated at between 215 to 370 cases in 2005.¹³

Etiology and Natural History

Peripartum transmission of HIV infection can occur during pregnancy (intrauterine), during labor and delivery (intrapartum), and following delivery (postpartum). In the absence of breastfeeding, intrauterine transmission is thought to account for 25 to 40 percent of vertically infected infants, with the remainder occurring during labor and delivery.¹⁴ A high proportion of intrauterine transmission is thought to occur shortly before delivery.¹⁵ HIV is present in and transmitted through breast milk,¹⁶ and breastfeeding is thought to be the only important mode for postpartum transmission to newborns and infants.^{17,18} In resource-poor settings in which women breastfeed for prolonged periods, postpartum transmission accounts for about 44 percent of infant cases.¹⁹ Antiretroviral treatment of the mother and infant does not completely eliminate breastfeeding transmission risk.²⁰ In the United States, HIV-infected women are advised against breastfeeding, given the risk of transmission and the availability of affordable and safe alternatives.¹⁵

Risk Factors

About 50 percent of HIV-infected pregnant women are exposed to HIV through heterosexual contact, 8 percent through injection drug use, and 8 percent through some other exposure category (such as blood transfusion or perinatal exposure).¹⁰ In about one third of women, exposure is unknown.

Well-established risk factors for perinatal transmission include high viral load, immunologically or clinically advanced disease in the mother, prolonged rupture of membranes, maternal infection with other sexually transmitted diseases, and labor and delivery procedures and events (such as abruptio placentae, fetal scalp electrode use, episiotomy, and second degree or greater perineal laceration) associated with an increased probability of bodily fluid contact between mother and infant.²¹

Risk factors for clinical progression of HIV infection (in particular, high viral load and low CD4 count) appear to be similar for pregnant and nonpregnant women. In developed countries, pregnancy itself does not appear to be an important independent predictor of clinical progression in

chronically infected HIV-positive women.^{22, 23}

Rationale for Screening

A major goal of prenatal screening for HIV is to reduce the risk of mother-to-child transmission through subsequent interventions. Other important goals are to improve long-term clinical outcomes in HIV-infected women, facilitate early identification of infected newborns, help women to make more informed future reproductive choices, and reduce risk of horizontal transmission through effects on risky behaviors.

Interventions/Treatment

The current standard of care to prevent perinatal transmission of HIV infection in the United States is a three-drug antiretroviral regimen started at the beginning of the second trimester of pregnancy or earlier (followed by treatment of the infant in the postnatal period) in all HIV-infected women (regardless of viral load or CD4 count), elective Cesarean delivery before labor or rupture of membranes in women with HIV RNA levels >1,000 copies/mL near the time of delivery, and avoidance of breastfeeding in all women.^{14, 24} The choice of antiretroviral drugs is based on evidence regarding effectiveness for reducing perinatal transmission, risks to the fetus, side effect profile, and other factors, such as the potential for drug interactions or the possibility of inducing antiretroviral drug resistance.

HIV-positive women identified during pregnancy may also benefit from other interventions that would be considered in nonpregnant persons with HIV infection, including long-term antiretroviral therapy, prophylaxis for opportunistic infections, immunizations, and counseling to reduce high-risk behaviors for horizontal transmission.

Current Clinical Practice

The use of repeatedly reactive enzyme immunoassay (EIA) for an office-based venipuncture specimen followed by confirmatory Western blot or immunofluorescent assay for positive tests is associated with a sensitivity and specificity >99 percent, and is the standard test for diagnosing HIV infection.²⁵ The diagnostic accuracy of standard HIV testing is thought to be similar for pregnant and nonpregnant persons, though indeterminate results may occur slightly more frequently among parous and pregnant women.²⁶ A revised Centers for Disease Control and Prevention (CDC) HIV testing algorithm is expected in 2012. The algorithm, which will utilize combination immunoassays that screen simultaneously for both the p24 antigen and HIV antibody and test for HIV RNA without requiring Western blot confirmation, is intended to detect acute HIV infection earlier and to differentiate HIV-2 from HIV-1 infection.²⁷

Rapid HIV antibody tests on blood or oral fluid specimens provide results in 5 to 40 minutes compared with 1 to 2 weeks for standard testing, and are associated with diagnostic accuracy comparable with standard testing.²⁸⁻³⁰ A large, prospective cohort study of 5,744 pregnant women presenting in labor in six U.S. cities between 2001 and 2003 (HIV prevalence, 0.59%) found rapid

testing (prior to confirmation) associated with a sensitivity of 100 percent, specificity of 99.9 percent, positive predictive value of 90 percent, and negative predictive value of 100 percent.²⁸ Point-of-care rapid tests are recommended for women presenting in labor who received no prenatal care or who were not tested earlier in pregnancy for other reasons.³¹ Basing therapeutic decisions on a positive rapid test result prior to confirmation is only recommended in situations in which decisions to initiate treatments cannot wait, such as in women presenting in active labor. Otherwise, confirmation of positive rapid test results prior to initiating interventions is recommended due to the possibility of false-positive results,²⁸ which could result in unnecessary exposure to antiretroviral or other therapies.

Current U.S. practice for HIV screening in pregnant women includes “opt-out” HIV screening at the initial prenatal visit as part of the standard prenatal test panel. Opt-out screening refers to screening that is performed after informing the women about the test, unless the woman specifically declines. The CDC recommends that clinicians consider repeat testing in all women in the third trimester for those who test negative initially, and recommends repeat testing for women who continue to practice high-risk behaviors or are in a high-incidence setting.³¹

In the United States, antiretroviral therapy is received during the prenatal and intrapartum period in about 85 percent of HIV-infected women, with about 40 percent undergoing elective Cesarean delivery.¹⁰ Over 95 percent of infants born to HIV-infected women receive antiretroviral therapy during the postnatal period.

Recommendations of Other Groups

Many groups, including the American Congress of Obstetricians and Gynecologists,^{14, 32} the American Academy of Family Physicians,³³ the American Academy of Pediatrics,^{34, 35} the American College of Physicians,³⁶ and the CDC³¹ recommend voluntary opt-out testing for HIV in all pregnant women as part of routine prenatal care. Although the CDC recommends that clinicians consider repeat testing for all women who are negative early in pregnancy and recommends repeat testing in women with risk factors and who are in high-incidence settings,³¹ the USPSTF did not address repeat testing in its 2005 recommendation.³

CHAPTER 2. METHODS

Key Questions and Analytic Framework

Using the methods developed by the USPSTF,³⁷ the USPSTF and the Agency for Healthcare Research and Quality (AHRQ) determined the scope and key questions for this review. Investigators created an analytic framework with the key questions and patient populations, interventions, and outcomes reviewed (**Figure**). The target population for HIV screening was pregnant women without signs or symptoms of HIV infection.

Key Questions

Key Question 1. What are the benefits of HIV screening versus no screening in asymptomatic pregnant women on maternal or child morbidity, mortality, or quality of life or rates of mother-to-child transmission?

Key Question 2a. What is the yield (number of new diagnoses) of repeat HIV screening in asymptomatic pregnant women?

Key Question 2b. What are the adverse effects (including false-positive results and anxiety) of rapid versus standard HIV testing in asymptomatic pregnant women?

Key Question 3a. What is the effectiveness of newer antiretroviral regimens for reducing mother-to-child transmission?

Key Question 3b. What are the effects of antiretroviral regimens in pregnant, HIV-positive women on long-term maternal morbidity, mortality, or quality of life?

Key Question 3c. What are the harms (including longer-term harms) to the mother or child associated with antiretroviral therapy during pregnancy?

Key question 1 focuses on direct evidence that prenatal screening for HIV infection improves important health outcomes compared with not screening. Such direct evidence on the effectiveness of screening interventions may not be available. Therefore, the remainder of the analytic framework (key questions 2a through 3c) evaluates the chain of indirect evidence needed to link screening for HIV infection with improvement in important health outcomes. Links in the chain of indirect evidence include the performance, yield, and acceptability of the screening test for identifying HIV infection, the effectiveness of interventions for reducing perinatal transmission as well as effects on other clinical outcomes (such as long-term maternal outcomes), and any harms associated with screening and subsequent interventions. The general diagnostic accuracy of standard HIV testing was not re-reviewed for this update, since it is well established as highly accurate.^{1,2} Rather, the update focuses on research gaps identified in the prior review, such as harms (including false-positive results and anxiety) of alternative testing methods (rapid vs. standard testing) and the yield of repeat screening. This update also does not re-review effects of avoidance of breastfeeding and elective Cesarean delivery in women with viremia on risk of perinatal transmission, as the

effectiveness of these interventions is well established^{1,2} and part of standard U.S. practice. Rather, the update focuses on new evidence on effectiveness of combination antiretroviral regimens on perinatal transmission, as well as evidence on long-term clinical outcomes in the mother and harms to either the mother or infant.

Search Strategies

We searched Ovid MEDLINE from 2004 to June 2012 and the Cochrane Library Database from 2005 through the second quarter of 2012 and reviewed reference lists to identify relevant articles published in English. Search strategies are shown in **Appendix A1**.

Study Selection

At least two reviewers independently evaluated each study to determine eligibility for inclusion. We selected studies on the basis of inclusion and exclusion criteria developed for each key question (**Appendix A2**). Articles were selected for full review if they were about HIV infection in pregnancy, were relevant to a key question, and met the predefined inclusion criteria. We restricted inclusion to English-language articles and excluded studies only published as abstracts. Studies of nonhuman subjects were also excluded, and studies had to include original data.

For all key questions, we included studies of pregnant women without signs or symptoms of HIV infection or HIV-positive pregnant women receiving treatment. For key question 3c, we also included infants exposed to antiretroviral drugs in utero or postnatally. The screening interventions were standard or rapid HIV antibody testing. For treatment interventions, we focused on antiretroviral drug therapy. Outcomes were mother-to-child transmission, morbidity, mortality, quality of life, and harms from antiretroviral therapy (such as adverse pregnancy outcomes; adverse congenital, neurodevelopmental, cardiovascular, metabolic, or hematologic outcomes in exposed children; and adverse clinical outcomes in mothers), including long-term (defined as 1 or more years after birth for women and 2 or more years after birth for children) outcomes. We included randomized, controlled trials and cohort studies for all key questions. For key questions related to harms and other long-term maternal and infant outcomes, we also included case-control studies and intervention series if randomized trials and cohort studies were unavailable or lacking. Although the target intervention was full-course combination antiretroviral regimens (started by the second trimester and continued through delivery, with postnatal treatment of the infant) and the target population was nonbreastfeeding women, we included studies from resource-poor settings that evaluated short-course antiretroviral regimens or breastfeeding populations, as these may provide some information about the effectiveness of antiretroviral therapies in women who present late in pregnancy or about the general effectiveness of combination antiretroviral therapy. **Appendix A3** shows the results of our literature search and selection process and **Appendix A4** lists excluded studies with reasons for exclusion.

Data Abstraction and Quality Rating

One investigator abstracted details about the study design, patient population, setting, screening

method, treatment regimen, analysis, followup, and results. A second investigator reviewed data abstraction for accuracy. Two investigators independently applied criteria developed by the USPSTF³⁷ to rate the quality of each study as good, fair, or poor (**Appendix A5**). Discrepancies were resolved through a consensus process.

Data Synthesis

We assessed the aggregate internal validity (quality) of the body of evidence for each key question (good, fair, poor) using methods developed by the USPSTF, based on the number, quality, and size of studies, consistency of results between studies, and directness of evidence.³⁷ Meta-analysis was not attempted as the data could not be pooled, due to differences across studies in design, interventions, populations, and other factors.

External Review

The draft report was reviewed by content experts, USPSTF members, AHRQ Project Officers, and collaborative partners prior to finalization (**Appendix A6**).

CHAPTER 3. RESULTS

Key Question 1. What Are the Benefits of HIV Screening Versus No Screening in Asymptomatic Pregnant Women on Maternal or Child Morbidity, Mortality, or Quality of Life or Rates of Mother-to-Child Transmission?

No randomized trial or observational study compared clinical outcomes (including risk of perinatal transmission) between pregnant women screened and not screened for HIV infection. Given what is established about HIV screening and transmission, a randomized trial would not be considered ethical at this point. Although the number of infants with perinatally acquired HIV transmission has markedly declined in the United States, this is likely due to a combination of increased screening during pregnancy and increased effectiveness and use of interventions to prevent transmission. Some HIV-positive women may also have been identified before pregnancy. We identified no studies estimating the relative impact of these factors on transmission risk.

Key Question 2a. What Is the Yield (Number of New Diagnoses) of Repeat Screening in Asymptomatic Pregnant Women?

No randomized trial or observational study evaluated the yield of repeat prenatal HIV screening compared with one-time screening, or compared the yield of different strategies for repeat screening (e.g., risk-based repeat screening vs. a routine repeat test). Repeat testing of women who screen HIV-negative during early pregnancy could identify those who are infected after initial testing but before delivery. Repeat screening and the optimal timing of repeat testing during pregnancy would depend, in part, on the frequency of new HIV infections. One modeling study discussed in the 2005 USPSTF review^{1,2} estimated that repeat testing in the third trimester after a negative test in the first trimester would detect 5.3 new infections per 100,000 average-risk women tested and 192 infections per 100,000 high-risk women tested.³⁸

Key Question 2b. What Are the Adverse Effects (Including False-Positive Results and Anxiety) of Rapid Versus Standard HIV Testing in Asymptomatic Pregnant Women?

Summary

One large (n=7,753), prospective study of women presenting in labor with unknown HIV status (HIV prevalence, 0.7%) found the OraQuick rapid HIV test (OraSure Technologies, Inc., Bethlehem, PA) associated with a positive predictive value of 90 percent and the standard EIA test associated with a positive predictive value of 74 percent when each was compared with Western blot as the reference standard. One other, smaller study (n=910) of pregnant women at any gestational age also found rapid testing associated with a higher positive predictive value compared

with standard testing, but only five HIV-positive women were identified. No study compared psychological or other harms associated with rapid versus standard testing or adverse clinical consequences of interventions given as a result of false-positive results.

Evidence

The large (n=7,753), prospective, fair-quality Mother-Infant Rapid Intervention at Delivery (MIRIAD) study provides the strongest evidence on the diagnostic accuracy of the rapid OraQuick test compared with standard EIA HIV testing.^{28, 39} MIRIAD specifically enrolled women in labor with unknown HIV status (HIV prevalence, 0.7% [52/7,753]) for whom immediate test results were needed to help guide treatment decisions. Initial (2-year) results from MIRIAD²⁸ were included in the prior USPSTF review (**Table 1, Appendix B1**).³⁹ Final (40-month) results³⁹ found that compared with Western blot as the reference standard, sensitivity was 100 percent for both tests, and specificity was 99.9 and 99.8 percent for rapid and standard testing, respectively. The positive predictive value for the rapid test was higher (90% [52/58]) than for the standard test (74% [52/70]). In clinical practice, a positive standard test result would not be available in time to inform interventions during labor and delivery, and positive standard test results are typically confirmed with Western blot prior to patient notification.

One other study (n=910) of pregnant, predominantly Hispanic (about 90%) women at any gestational age (HIV prevalence, 0.5%) found the OraQuick test associated with a positive predictive value of 100 percent (5/5) and EIA associated with a positive predictive value of 36 percent (5/14).⁴⁰

No study compared psychological or other harms associated with rapid versus standard tests or adverse clinical consequences of interventions given as a result of initial false-positive rapid test results.

Key Question 3a. What Is the Effectiveness of Newer Antiretroviral Regimens for Reducing Mother-to-Child Transmission?

Summary

Consistent with the prior USPSTF review, three new U.S. and European cohort studies published since 2005 found perinatal full-course triple antiretroviral therapy associated with a risk of mother-to-child transmission that ranged from <1 to 2.4 percent compared with 9 to 22 percent with no antiretroviral therapy. Two randomized trials of breastfeeding women in Africa found triple antiretroviral therapy started at 26 to 28 weeks associated with mother-to-child transmission rates of 1 to 5 percent. Other African trials found shorter courses of perinatal antiretroviral therapy and regimens using fewer than three drugs associated with a lower risk of mother-to-child transmission of HIV infection compared with the expected transmission rate without therapy, but were generally associated with higher transmission rates than full-course, three-drug regimens.

Evidence

The landmark Pediatric AIDS Clinical Trials Group (PACTG) protocol 076 study found that a three-phase maternal and infant zidovudine regimen starting at 14 to 34 weeks' gestation through 6 weeks postpartum decreased the risk of mother-to-child transmission from about 25 percent with placebo to 8 percent in nonbreastfeeding women.⁴¹ The 2005 USPSTF review^{1,2} identified no completed trials of full-course combination antiretroviral therapy during pregnancy. It included four large U.S. or European cohort studies that all found full-course antiretroviral regimens with more drugs superior to regimens with fewer antiretroviral drugs for preventing mother-to-child transmission.⁴²⁻⁴⁵ The only study that specifically evaluated the effectiveness of three-or-more-drug regimens compared with no antiretrovirals reported an odds ratio (OR) of 0.13 (95% confidence interval [CI], 0.06 to 0.27) for prevention of mother-to-child transmission.⁴⁴ Another study reported an adjusted OR of 0.07 (95% CI, 0.02 to 0.23) for two-or-more-drug regimens compared with no antiretrovirals.⁴³ In all of the studies, transmission rates were 1 to 2 percent with combination regimens.⁴²⁻⁴⁵ The 2005 USPSTF review also included several randomized trials that found that shorter courses of antiretroviral prophylaxis were effective at reducing risk of mother-to-child transmission of HIV infection, though they were not as effective as full-course regimens.⁴⁶⁻⁵⁵

We identified no new randomized trials on full-course combination antiretroviral therapy during pregnancy in nonresource poor, nonbreastfeeding settings. Four fair-quality U.S. or European cohort studies published since the 2005 USPSTF review evaluated the effectiveness of combination antiretroviral regimens during pregnancy (**Table 2, Appendix B2**).⁵⁶⁻⁵⁸ Sample sizes ranged from 489 to 7,344. Methodological shortcomings in the studies included inadequate reporting of baseline characteristics⁵⁶⁻⁵⁸ or failure to report adjusted risk estimates⁵⁸ (**Appendix B3**). The proportion of women who had a Cesarean delivery in these cohorts ranged from 51 to 78 percent.

One large (n=7,344) cohort study was based on U.S. surveillance data from 1999 to 2001.⁵⁷ It found full-course single- or multi-drug antiretroviral therapy associated with lower risk of mother-to-child transmission compared with no antiretroviral therapy (2.4% vs. 22%; adjusted OR, 0.09 [95% CI, 0.06 to 0.12]). In women who received antiretroviral therapy, combination regimens with zidovudine plus other drugs were about twice as effective as zidovudine monotherapy for reducing risk of mother-to-child transmission (adjusted OR range, 0.4 to 0.5). Two smaller European cohort studies also reported lower mother-to-child transmission rates with combination antiretroviral therapy (0.6% and 1.0%) compared with no therapy (9% and 18%).^{56,58} A fourth study, which analyzed European surveillance data (n=7,573) over a 9-year period and included one of these cohorts,⁵⁶ found transmission rates of <1 percent with either zidovudine-sparing or zidovudine-containing three-or-more-drug regimens.⁵⁹

One good-quality⁶⁰ and five fair-quality⁶¹⁻⁶⁵ randomized trials published since the 2005 USPSTF review evaluated shorter-course prenatal antiretroviral regimens in primarily breastfeeding African women (**Table 3, Appendixes B4 and B5**).⁶⁰⁻⁶⁵ Sample sizes ranged from 355 to 805 infants. The studies are most applicable in the United States to HIV-infected women identified later in pregnancy, who cannot receive full-course regimens. In general, these studies reported lower transmission rates with antiretroviral therapy than expected without treatment. Studies that evaluated longer courses of treatment and regimens that included at least three drugs reported the lowest transmission rates. One trial of breastfeeding women (n=709) found various three-drug

antiretroviral regimens started at 18 to 34 weeks' gestation (median, 26 to 27 weeks) associated with an overall infant HIV infection rate of 1.1 percent at 6 months.⁶³ Another trial of breastfeeding women (n=805) found zidovudine, lamivudine, and ritonavir-boosted-lopinavir started at 28 weeks' gestation and continued through weaning from breastfeeding associated with lower risk of infant HIV infection at 12 months compared with zidovudine plus single-dose nevirapine (5.4% vs. 9.5%; p=0.03).⁶⁰ Three trials, including one of nonbreastfeeding women,⁶² found shorter-course (starting at 32 to 34 weeks' gestation) perinatal antiretroviral therapy with one or two drugs (with or without the addition of a single maternal dose of an antiretroviral during labor) associated with mother-to-child transmission rates that ranged from 4 to 12 percent.^{61, 62, 64} One other trial (n=609) found high rates of mother-to-child transmission with ultra-short-course zidovudine (during labor and given to the infant for 72 hours after birth) plus single-dose maternal and infant nevirapine versus single-dose nevirapine alone (14% vs. 17%), as well as a high rate of infant mortality (7% at 6 weeks).⁶⁵

Key Question 3b. What Are the Effects of Antiretroviral Regimens in Pregnant, HIV-Positive Women on Long-Term Maternal Morbidity, Mortality, or Quality of Life?

Summary

No study published since the prior USPSTF review evaluated effects of prenatal antiretroviral therapy on long-term maternal clinical outcomes. The prior USPSTF review included one study (n=226) of U.S. women that found no difference in risk of AIDS-defining events or death after a mean of 4.1 years between women randomized to zidovudine during pregnancy versus placebo in risk of AIDS or death, death alone, or AIDS-defining CDC clinical category C events after a mean of 4.1 years.

Evidence

No study published since the prior USPSTF review evaluated effects of prenatal antiretroviral therapy on long-term maternal clinical outcomes. One good-quality study included in the prior USPSTF review of U.S. women (n=226) originally enrolled in a randomized trial of zidovudine monotherapy for reducing mother-to-child transmission (PACTG 076) found no difference between women randomized to zidovudine versus placebo in risk of AIDS or death (19% vs. 25%; relative risk [RR], 0.73 [90% CI, 0.46 to 1.2]), death alone (3% vs. 2%; RR, 1.5 [90% CI, 0.34 to 6.7]), or AIDS-defining CDC clinical category C events (7% vs. 10%; RR, 0.70 [90% CI, 0.34 to 1.4]) after a mean of 4.1 years.⁶⁸ At the time of enrollment, women were not receiving or eligible (based on criteria at the time) for antiretroviral therapy, and zidovudine was discontinued after delivery. Although only about 50 percent of eligible women enrolled in the randomized trial participated in this study, there were few differences in demographic and clinical characteristics between participants and nonparticipants, and baseline characteristic similarity between the zidovudine and placebo groups was preserved during the study. The prior USPSTF review also included a study that found women still benefit from antiretroviral therapy after receiving antiretroviral treatment during pregnancy.⁶⁹

Key Question 3c. What Are the Harms (Including Longer-Term Harms) to the Mother or Child Associated With Antiretroviral Therapy During Pregnancy?

Summary

New evidence (27 studies) on infant and maternal harms associated with perinatal exposure to antiretroviral therapy was generally consistent with the evidence included in the 2005 USPSTF review.^{1,2} Of one randomized trial and 10 cohort studies reporting on the association between perinatal antiretroviral therapy and risk of preterm delivery or low birth weight, the trial and six cohort studies found perinatal antiretroviral therapy associated with increased risk of preterm delivery, but no clear association with low birth weight. Although studies found an association between exposure to perinatal antiretroviral therapy and increased risk during infancy of laboratory markers of mitochondrial dysfunction, hematological abnormalities, and echocardiographic markers of impaired myocardial growth, the clinical significance of these findings remains unclear. Four studies showed no association between perinatal exposure to antiretroviral drugs and risk of congenital abnormalities, and two studies showed no clear association between perinatal exposure to antiretroviral drugs and infant neurodevelopment. A large cohort study found exposure to antiretroviral drugs during pregnancy associated with increased risk of maternal anemia. No study evaluated long-term maternal harms associated with short-term exposure to antiretroviral therapy during pregnancy, or antiretroviral therapy started during pregnancy and continued after pregnancy.

Evidence

Infant harms.

Preterm birth and other birth outcomes. The 2005 USPSTF review^{1,2} identified one good-quality U.S. meta-analysis of five prospective cohort studies and one good-quality, large European prospective cohort study that found no association between exposure to combination antiretroviral therapy and low birth weight.^{70,71} Evidence regarding the association between combination antiretroviral therapy and increased rates of premature delivery was mixed. The meta-analysis found no increase in risk of premature delivery for infants exposed to combination therapy with (adjusted OR, 1.5 [95% CI, 0.72 to 3.0]) or without a protease inhibitor (OR, 0.95 [95% CI, 0.51 to 1.7]) compared with no treatment,⁷⁰ but the large, prospective European Collaborative Study reported an increased risk of premature delivery (before 37 weeks' gestation) associated with combination antiretroviral therapy initiated during pregnancy (RR, 1.9 [95% CI, 1.3 to 2.7]) or prior to pregnancy (RR, 2.0 [95% CI, 1.4 to 3.0]) versus no treatment.⁷¹ Use of monotherapy or dual therapy during pregnancy was not associated with increased risk of premature delivery.

One randomized trial⁷² and 10 cohort studies⁷³⁻⁸² published since the prior USPSTF review reported risk of prematurity, low birth weight, and other birth outcomes following in utero exposure to antiretroviral therapy (**Appendix B6**). Sample sizes ranged from 57 to 8,793. Eight studies, including the randomized trial, were rated fair-quality^{72,73,75,77,78,80-82} and three were rated poor-quality^{74,76,79} (**Appendixes B7 and B8**). Methodological shortcomings included differences in

baseline characteristics between groups and poor reporting of attrition. Six studies reported risk estimates adjusted for important confounders such as maternal age, CD4 count, and viral load.^{73, 75, 77, 79, 81, 82}

The randomized trial (n=530) found protease inhibitor-based antiretroviral therapy associated with greater risk of preterm delivery than nonnucleoside reverse transcriptase-based antiretroviral therapy (OR, 2.0 [95% CI, 1.3 to 3.3]).⁷² Three prospective cohort studies (n=183 to 8,793) also found maternal exposure to combination antiretroviral therapy with a protease inhibitor associated with increased risk of preterm delivery (<37 weeks) compared with combination antiretroviral therapy without a protease inhibitor (adjusted OR, 1.8 [95% CI, 1.1 to 3.0]),⁷⁵ dual therapy (adjusted OR, 1.2 [95% CI, 1.0 to 1.4]),⁸¹ or monotherapy (adjusted OR, 3.4 [95% CI, 1.1 to 10]),⁷⁷ after adjustment for potential confounders (**Table 4**). None found exposure to combination therapy without a protease inhibitor associated with increased risk of preterm delivery. However, a fourth large (n=4,939) cohort study found combination therapy associated with increased risk of preterm delivery (<37 weeks) (adjusted OR, 1.4 [95% CI, 1.1 to 1.8]; p=0.02) and very preterm delivery (<32 weeks) (OR, 2.6 [95% CI, 1.3 to 5.3]; p=0.007) compared with monotherapy or dual therapy, with no difference in risk according to whether the antiretroviral regimen included a protease inhibitor or not.⁸² Among four studies that did not adjust for confounders, one found an association between prenatal antiretroviral therapy and preterm delivery,⁸⁰ but three other studies found no clear association.^{74, 76, 78}

Seven cohort studies (n=352 to 8,192) published since the 2005 USPSTF review found no clear association between maternal use of antiretroviral therapy and low birth weight or intrauterine growth restriction.^{73-76, 78, 81, 82}

Mitochondrial dysfunction. Although molecular evidence of mitochondrial dysfunction has been reported in infants exposed in utero to antiretroviral therapy,^{83, 84} the clinical significance of such dysfunction remains unclear. The 2005 USPSTF review^{1, 2} included three prospective cohort studies that found no clear evidence of clinical mitochondrial dysfunction in infants exposed to antiretroviral therapy in utero, despite evidence of high rates of elevated lactic acid levels.^{71, 85, 86} Population-based studies included in the 2005 USPSTF review reported no deaths due to mitochondrial dysfunction among antiretroviral-exposed, HIV-negative infants.⁸⁷⁻⁸⁹

Three studies published since the 2005 USPSTF review evaluated risk of mitochondrial dysfunction based on laboratory findings following in utero exposure to antiretroviral therapy, but none evaluated clinical outcomes associated with findings of mitochondrial dysfunction.⁹⁰⁻⁹²

Congenital abnormalities. The 2005 USPSTF review^{1, 2} identified one large, good-quality European prospective cohort study that found no association between exposure to any combination of antiretroviral drugs and risk of congenital anomalies.⁷¹

Three fair-quality European cohort studies (n=1,414 to 8,576) published since the 2005 USPSTF review each found no association between perinatal exposure to antiretroviral therapy and congenital abnormalities⁹³⁻⁹⁵ (**Appendixes B6 and B8**). Followup ranged from 6 months to 17 years. One large study (n=7,573) of European surveillance data over a 9-year period found no difference in the risk of infant congenital abnormalities with maternal use of zidovudine-sparing versus

zidovudine-containing three-or-more-drug regimens.⁵⁹

Neurodevelopmental outcomes. The 2005 USPSTF review^{1,2} included one good-quality prospective cohort study that found no association between in utero and postnatal zidovudine exposure and long-term adverse effects on growth or development in exposed infants through age 4 years.⁷¹

We identified two cohort studies published since the 2005 USPSTF review^{1,2} that evaluated neurodevelopmental outcomes following in utero and postnatal exposure to antiretroviral therapy^{96, 97} (**Appendixes B6 and B8**). Both utilized the Bayley Scales of Infant Development-II, which includes a Mental Development Index (MDI) and Psychomotor Development Index (PDI). One good-quality prospective study (n=63) found no statistically significant difference in MDI scores in antiretroviral-exposed children compared with unexposed control groups at ages 18 to 36 months, after adjustment for maternal substance abuse.⁹⁶ A second, larger (n=1,840), fair-quality prospective study found slightly higher (better) MDI and PDI scores in antiretroviral-exposed children compared with unexposed children at age 2 years after adjustment for confounders, but the differences were small (<3 points on a 100-point scale) and did not reach statistical significance.⁹⁷

Other infant harms. The 2005 USPSTF review^{1,2} identified one prospective cohort study that found no association between in utero exposure to zidovudine and acute or chronic abnormalities in left ventricular structure or functioning based on serial echocardiography through ages 10 to 14 months.⁹⁸

One prospective cohort study published since the 2005 USPSTF review found in utero exposure to antiretroviral therapy associated with echocardiographic findings of impaired myocardial growth (decreased left ventricular mass and septal wall thickness) but improved left ventricular contractility compared with no exposure through age 2 years, though the clinical significance of these findings was not evaluated⁹⁹ (**Appendixes B6 and B8**). There were no differences between exposed and unexposed infants in these echocardiographic parameters through ages 2 to 5 years. Three observational studies each found in utero exposure to antiretroviral drugs associated with increased risk of neutropenia or anemia through age 24 months¹⁰⁰⁻¹⁰² (**Appendixes B6 and B8**). Average difference in neutrophil count for exposed versus unexposed children ranged from about 0.150 to 0.550 x 10⁹ cells/L.^{100, 102} No study evaluated the association between lower neutrophil counts following in utero exposure to antiretroviral drugs and adverse clinical outcomes. One study found no difference in incidence of cancer in uninfected infants exposed to perinatal antiretroviral therapy at 5.4 years (10/9,127 children [0.1%]) compared with the general population, though among exposed infants the combination of didanosine and lamivudine was associated with higher risk compared with zidovudine monotherapy (hazard ratio [HR], 14 [95% CI, 2.5 to 74])¹⁰³ (**Appendixes B6 and B8**).

Maternal harms.

Receipt of antiretroviral therapy during pregnancy is associated with the nonobstetric adverse events typically associated with the specific drugs and regimens, but these often resolve after stopping the offending drug or drug combination, and effective alternatives are usually available.²⁴ Regularly updated guidelines summarizing adverse events associated with specific antiretroviral drugs, classes, and combinations are available, and specific antiretroviral combinations associated

with serious complications are not recommended.²⁴

The 2005 USPSTF review^{1,2} included one good-quality meta-analysis that found no association between perinatal zidovudine monotherapy and maternal death or long-term harms.¹⁰⁴ A large observational study found gestational diabetes mellitus the only complication associated with antiretroviral therapy, and was most likely with combination therapy that included a protease inhibitor initiated early in the pregnancy.¹⁰⁵ The 2005 USPSTF review also included one clinical trial that was discontinued early due to a high rate (29%) of treatment-limiting hepatic or cutaneous toxicity with continuous use of nevirapine with zidovudine during pregnancy, including one death and one case of Stevens-Johnson syndrome.¹⁰⁶ These events occurred most frequently in women with CD4 counts $>0.250 \times 10^9$ cells/L. However, three randomized trials found no difference between a single maternal intrapartum dose of nevirapine with or without antiretroviral therapy and no nevirapine in risk of liver function test abnormalities or hepatitis.^{51, 53, 107}

We identified one large (n=2,543), fair-quality U.S. cohort study published since the 2005 USPSTF review that found antiretroviral use associated with increased risk of maternal anemia compared with nonuse (adjusted OR, 1.6 [95% CI, 1.1 to 2.4])¹⁰⁸ (**Appendixes B6 and B8**). It also found late use of antiretroviral therapy (started between 25 and 32 weeks' gestation) associated with increased risk of gestational diabetes compared with nonuse (adjusted OR, 3.5 [95% CI, 1.2 to 10]), but causality was unclear since screening for gestational diabetes is typically performed at 24 to 28 weeks' gestation and women may have been diagnosed prior to initiation of antiretroviral therapy. Another, smaller (n=167) fair-quality cohort study found exposure to combination therapy associated with a trend toward increased risk of gestational diabetes compared with exposure to monotherapy with zidovudine or no antiretroviral therapy, but the difference was not statistically significant (12% vs. 0%; unadjusted RR, 0.11 [95% CI, 0.01 to 1.7])¹⁰⁹ (**Appendixes B6 and B8**).

CHAPTER 4. DISCUSSION

Summary of Review Findings

As in the 2005 USPSTF review,^{1,2} we found no direct evidence on effects of prenatal screening for HIV infection versus no screening on risk of mother-to-child transmission or maternal or infant clinical outcomes. Other evidence reviewed in this update is summarized in **Table 5**.

The 2005 USPSTF review^{1,2} found that HIV tests are accurate. The strongest evidence on potential harms associated with rapid testing is from the large MIRIAD study, which found a lower positive predictive value with standard EIA than for a rapid test (74% and 90%, respectively) in a population of women presenting in labor with 0.7 percent prevalence of undiagnosed HIV infection. This could result in unnecessary maternal and fetal exposure to antiretroviral therapy.³⁹ The positive predictive value would be expected to be lower in lower-prevalence populations, potentially resulting in more unnecessary antiretroviral exposure. No study has evaluated the clinical consequences of unnecessary exposure to antiretroviral therapy as a result of an initially false-positive rapid HIV test result, though any such harms would have to be weighed against the potential benefits of prenatal identification and treatment of undiagnosed HIV infection. As in the 2005 USPSTF review, no study has evaluated the yield of repeated HIV screening during pregnancy, which depends on the incidence of new HIV infection.

New cohort studies of antiretroviral therapy conducted in nonbreastfeeding women in the United States and Europe confirm the findings from the 2005 USPSTF review that full-course combination antiretroviral therapy is highly effective at reducing risk of mother-to-child transmission (<1% to 2.4% with combination antiretroviral therapy vs. 9% to 22% with no antiretroviral therapy).⁵⁶⁻⁵⁸ Randomized trials also found low risk of transmission with combination therapy regimens started around the end of the second trimester in breastfeeding African women.^{60,63} Shorter courses of antiretroviral therapy are not as effective as full-course regimens, but also reduce risk of mother-to-child transmission compared with historical transmission rates without antiretroviral therapy, and are relevant for women who might be started on therapy late due to delayed diagnosis or treatment.^{61,62,64}

Evidence on harms of antiretroviral therapy was also largely consistent with the 2005 USPSTF review. Current evidence continues to suggest that the long-term harms associated with antiretroviral therapy are relatively small. New, primarily observational studies found perinatal antiretroviral therapy associated with increased risk of preterm delivery,^{72,74-82} with no clear association with low birth weight,^{73,75,76,78,81,82} congenital abnormalities,^{59,93-95} or impaired infant neurodevelopment.^{96,97} Although other studies found an association between in utero exposure to antiretroviral therapy and echocardiographic abnormalities,⁹⁹ hematologic abnormalities,¹⁰⁰⁻¹⁰² or markers of mitochondrial dysfunction,⁹⁰⁻⁹² the clinical significance of these findings remains unclear. Evidence on long-term maternal harms associated with short-term exposure to antiretroviral therapy during pregnancy, or antiretroviral therapy started during pregnancy and continued after pregnancy, remains sparse.

Limitations

We excluded nonEnglish-language articles, which could result in language bias, though we identified no nonEnglish-language studies that would have met inclusion criteria. We could not formally assess for publication bias with graphical or statistical methods because of small numbers of studies and differences in study designs, populations, and outcomes assessed. We included observational studies, which are more susceptible to bias and confounding than well-conducted randomized trials, though we focused on results from studies that performed statistical adjustment for potential confounding. Randomized trials of combination antiretroviral therapy have only been conducted in Africa. The applicability of studies conducted in resource-poor and high-prevalence settings to U.S. practice is likely to be limited due to differences in the antiretroviral drugs evaluated, evaluation of shorter regimens, reliance on breastfeeding, and other factors.

Emerging Issues

Antiretroviral therapy regimens for use during pregnancy and indications for initiating long-term antiretroviral therapy continue to evolve. Regularly updated guidelines on selection of antiretroviral therapy in pregnant women are available.²⁴

Future Research

More research is needed on the long-term maternal effects of transient exposure to antiretroviral therapy during pregnancy or use of less-intense antiretroviral regimens during pregnancy. Integrase inhibitors may be a potential option for antiretroviral therapy in women who present late in pregnancy due to potent and rapid virological suppression, but require additional study to determine effects on transmission and safety in pregnancy.¹¹⁰ Children exposed to antiretroviral therapy in utero should continue to be followed to help identify unexpected or emerging long-term harms from combination regimens. More research is also needed to understand the clinical significance of the hematologic abnormalities, echocardiographic abnormalities, and markers of mitochondrial dysfunction observed in some children exposed to antiretroviral therapy.

Conclusions

In summary, prenatal HIV screening is accurate, and antiretroviral therapy in combination with avoidance of breastfeeding and Cesarean delivery in women with HIV RNA levels >1,000 copies/mL near the time of delivery is effective at reducing risk of mother-to-child transmission. Use of certain antiretroviral therapy regimens during pregnancy may be associated with increased risk of preterm delivery, but more evidence is needed to fully understand short- and long-term maternal and infant effects.

REFERENCES

1. Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT. Prenatal screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2005;143(1):38-54.
2. Chou R, Smits AK, Huffman LH, Korthuis PT. Screening for Human Immunodeficiency Virus in Pregnant Women. Evidence Synthesis No. 39. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Accessed at <http://www.ncbi.nlm.nih.gov/books/NBK33383/> on 8 November 2012.
3. U.S. Preventive Services Task Force. Screening for HIV: recommendation statement. *Ann Intern Med.* 2005;143(1):32-7.
4. Centers for Disease Control and Prevention. HIV-2 infection surveillance—United States: 1987–2009. *MMWR Morb Mortal Wkly Rep.* 2011;60(29):985-8.
5. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep.* 1992;41(RR-17):1-19.
6. Centers for Disease Control and Prevention. HIV Among Women. Atlanta: Centers for Disease Control and Prevention; 2011. Accessed at <http://www.cdc.gov/hiv/topics/women/pdf/women.pdf> on 8 November 2012.
7. Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. *MMWR Morb Mortal Wkly Rep.* 2011;60(21):689-93.
8. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2009. Vol. 21. Atlanta: Centers for Disease Control and Prevention; 2011. Accessed at <http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/> on 8 November 2012.
9. Centers for Disease Control and Prevention. STDs & Pregnancy: CDC Fact Sheet. Atlanta: Centers for Disease Control and Prevention; 2012. Accessed at <http://www.cdc.gov/std/pregnancy/STDfact-Pregnancy.htm> on 8 November 2012.
10. Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report: Enhanced Perinatal Surveillance—15 Areas, 2005–2008. Vol. 16. No. 2. Atlanta: Centers for Disease Control and Prevention; 2011. Accessed at http://www.cdc.gov/hiv/surveillance/resources/reports/2010supp_vol16no2/index.htm on 8 November 2012.
11. Centers for Disease Control and Prevention. Achievements in public health: reduction in perinatal transmission of HIV infection—United States, 1985–2005. *MMWR Morb Mortal Wkly Rep.* 2006;55(21):592-7.
12. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2010. Vol. 22. Atlanta: Centers for Disease Control and Prevention; 2012. Accessed at <http://www.cdc.gov/hiv/surveillance/resources/reports/2010report/index.htm> on 8 November 2012.
13. Fowler MG, Gable AR, Lampe MA, Etima M, Owor M. Perinatal HIV and its prevention: progress toward an HIV-free generation. *Clin Perinatol.* 2010;37(4):699-719.

14. American Congress of Obstetricians and Gynecologists, Committee on Obstetric Practice. ACOG committee opinion: scheduled Cesarean delivery and the prevention of vertical transmission of HIV infection. *Int J Gynaecol Obstet*. 2001;73(3):279-81.
15. Read JS; American Academy of Pediatrics Committee on Pediatric AIDS. Human milk, breastfeeding, and transmission of human immunodeficiency virus type 1 in the United States. *Pediatrics*. 2003;112(5):1196-205.
16. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. *Lancet*. 1992;340(8819):585-8. PMID: 1355163
17. Nduati R. Breastfeeding and HIV-1 infection: a review of current literature. In: Koletzko B, Michaelsen KF, Hernell O, eds. *Short and Long Term Effects of Breast Feeding on Child Health*. New York: Kluwer Academic; 2002. pp 201-10.
18. Office of Inspector General. *Reducing Obstetrician Barriers to Offering HIV Testing*. Washington, DC: Department of Health and Human Services; 2002. Accessed at <https://oig.hhs.gov/oei/reports/oei-05-01-00260.pdf> on 9 November 2012.
19. Breastfeeding and HIV International Transmission Study Group; Coutoudis A, Dabis F, Fawzi W, Gaillard P, Haverkamp G, Harris DR, et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. *J Infect Dis*. 2004;189(12):2154-66.
20. Mofenson LM. Antiretroviral drugs to prevent breastfeeding HIV transmission. *Antivir Ther*. 2010;15(4):537-53.
21. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. *Clin Perinatol*. 2010;37(4):721-37.
22. French R, Brocklehurst P. The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. *Br J Obstet Gynaecol*. 1998;105(8):827-35. PMID: 9746374
23. Minkoff H, Hershov R, Watts DH, Frederick M, Cheng I, Tuomala R, et al. The relationship of pregnancy to human immunodeficiency virus disease progression. *Am J Obstet Gynecol*. 2003;189(2):552-9.
24. HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. *Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States*. Rockville, MD: Department of Health and Human Services; 2012. Accessed at <http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/> on 9 November 2012.
25. Centers for Disease Control. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. *JAMA*. 1989;262(24):3395-7.
26. Celum CL, Coombs RW, Jones M, Murphy V, Fisher L, Grant C, et al. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate Western blots: a population-based case-control study. *Arch Intern Med*. 1994;154(10):1129-37.
27. Branson BM. The future of HIV testing. *J Acquir Immune Defic Syndr*. 2010;55(Suppl 2):S102-5.
28. Bulterys M, Jamieson DJ, O'Sullivan MJ, Cohen MH, Maupin R, Nesheim S, et al; Mother-Infant Rapid Intervention at Delivery (MIRIAD) Study Group. Rapid HIV-1 testing during labor: a multicenter study. *JAMA*. 2004;292(2):219-23.

29. Centers for Disease Control and Prevention. Rapid HIV-1 Antibody Testing During Labor and Delivery for Women of Unknown HIV Status: A Practical Guide and Model Protocol. Atlanta: Centers for Disease Control and Prevention; 2004. Accessed at <http://www.cdc.gov/hiv/topics/testing/resources/guidelines/rt-labor&delivery.htm> on 9 November 2012.
30. Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. *Curr Infect Dis Rep.* 2006;8(2):125-31.
31. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep.* 2006;55(RR-14):1-17.
32. American College of Obstetrics and Gynecology Committee on Obstetric Practice. ACOG committee opinion no. 418: prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. *Obstet Gynecol.* 2008;112(3):739-42.
33. American Academy of Family Physicians. Human Immunodeficiency Virus (HIV). Leawood, KS: American Academy of Family Physicians; 2005. Accessed at <http://www.aafp.org/online/en/home/clinical/exam/hiv.html> on 9 November 2012.
34. American Academy of Pediatrics Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. *Pediatrics.* 2008;122(5):1127-34.
35. American Academy of Pediatrics. Policy statement: AAP publications reaffirmed and retired. *Pediatrics.* 2011;128(3):e748.
36. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK; Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. *Ann Intern Med.* 2009;150(2):125-31.
37. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the third U.S. Preventive Services Task Force. *Am J Prev Med.* 2001;20(3 Suppl): 21-35.
38. Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. *Obstet Gynecol.* 2003;102(4):782-90.
39. Jamieson DJ, Cohen MH, Maupin R, Nesheim S, Danner SP, Lampe MA, et al. Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 US hospitals: the MIRIAD experience. *Am J Obstet Gynecol.* 2007;197(3 Suppl):S72-82.
40. Tung CS, Sangi-Haghpeykar H, Levison J. Rapid versus standard testing for prenatal HIV screening in a predominantly Hispanic population. *J Perinatol.* 2010;30(1):30-2.
41. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al; Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *N Engl J Med.* 1994;331(18):1173-80.
42. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr.* 2002;29(5):484-94.

43. Italian Register for Human Immunodeficiency Virus Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. *Arch Pediatr Adolesc Med.* 2002;156(9):915-21.
44. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. *Clin Infect Dis.* 2005;40(3):458-65.
45. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Bénifla JL, Burgard M, et al; Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. *JAMA.* 2001;285(16):2083-93.
46. Lallemand M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al; Perinatal HIV Prevention Trial (Thailand) Investigators. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. *N Engl J Med.* 2000;343(14):982-91.
47. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al; Bangkok Collaborative Perinatal HIV Transmission Study Group. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. *Lancet.* 1999;353(9155):773-80.
48. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2002;359(9313):1178-86.
49. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. *Lancet.* 1999;353(9155):781-5.
50. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al; DITRAME Study Group. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. *Lancet.* 1999;353(9155):786-92.
51. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al; South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. *J Infect Dis.* 2003;187(5):725-35.
52. Taha TE, Kumwenda NI, Gibbons A, Broadhead RL, Fiscus S, Lema V, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. *Lancet.* 2003;362(9391):1171-7.
53. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. *Lancet.* 2003;362(9387):859-68.
54. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. *JAMA.* 2004;292(2):202-9.
55. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child

- transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *Lancet*. 1999;354(9181):795-802.
56. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. *AIDS*. 2008;22(8):973-81.
 57. Harris NS, Fowler MG, Sansom SL, Ruffo N, Lampe MA. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999–2001. *Am J Obstet Gynecol*. 2007;197(3 Suppl):S33-41.
 58. Garcia-Tejedor A, Maiques V, Perales A, Lopez-Aldeguer J. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission. *Acta Obstet Gynecol Scand*. 2009;88(8):882-7.
 59. Tariq S, Townsend CL, Cortina-Borja M, Duong T, Elford J, Thorne C, et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009. *J Acquir Immune Defic Syndr*. 2011;57(4):326-33.
 60. Kesho Bora Study Group; de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. *Lancet Infect Dis*. 2011;11(3):171-80.
 61. Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, et al. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. *J Acquir Immune Defic Syndr*. 2008;48(2):220-3.
 62. Gray G, Violari A, McIntyre J, Jivkov B, Schnittman S, Reynolds L, et al. Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants. *J Acquir Immune Defic Syndr*. 2006;42(2):169-76.
 63. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. *N Engl J Med*. 2010;362(24):2282-94.
 64. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. *AIDS*. 2006;20(9):1281-8.
 65. Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, et al. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. *Clinic Infect Dis*. 2007;44(1):111-9.
 66. Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. *Lancet*. 2007;370(9600):1698-705.
 67. Kesho Bora Study Group. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. *J Acquir Immune Defic Syndr*. 2010;54(5):533-41.
 68. Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, et al; Pediatrics AIDS Clinical Trials Group 288 Protocol Team. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. *J Acquir Immune Defic Syndr*. 2003;32(2):170-81.


69. Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, et al; PACTG 185 Study Team. Progression of HIV disease among women following delivery. *J Acquir Immune Defic Syndr*. 2003;33(5):585-93.
70. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. *N Engl J Med*. 2002;346(24):1863-70.
71. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. *AIDS*. 2001;15(6):761-70.
72. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. *J Infect Dis*. 2011;204(4):506-14.
73. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, et al; ANRS French Perinatal Cohort. No relation between in-utero exposure to HAART and intrauterine growth retardation. *AIDS*. 2009;23(10):1235-43.
74. Carceller A, Ferreira E, Alloul S, Lapointe N. Lack of effect on prematurity, birth weight, and infant growth from exposure to protease inhibitors in utero and after birth. *Pharmacotherapy*. 2009;29(11):1289-96.
75. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? *J Infect Dis*. 2006;193(9):1195-201.
76. El Beitune P, Duarte G, Machado AA, Quintana SM, Figueiró-Filho EA, Abduch R. Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates. *Clinics (Sao Paulo)*. 2005;60(3):207-12.
77. Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al; Multicenter Interdisciplinary Study Group Germany/Austria. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. *HIV Med*. 2008;9(1):6-13.
78. Morris AB, Dobles AR, Cu-Uvin S, Zorrilla C, Anderson J, Harwell JI, et al. Protease inhibitor use in 233 pregnancies. *J Acquir Immune Defic Syndr*. 2005;40(1):30-3.
79. Paul ME, Chantry CJ, Read JS, Frederick MM, Lu M, Pitt J, et al. Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the Women and Infants Transmission Study. *Pediatr Infect Dis J*. 2005;24(1):46-56.
80. Rudin C, Spaenhauer A, Keiser O, Rickenbach M, Kind C, Aebi-Popp K, et al; Swiss Mother & Child HIV Cohort Study (MoCHiV). Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. *HIV Med*. 2011;12(4):228-35.
81. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG; Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989–2004. *Pediatrics*. 2007;119(4):900-6.
82. Townsend CL, Cortina-Borja M, Peckham C, Tookey P. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. *AIDS*. 2007;21:1019-26.
83. Poirier MC. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. *J Acquir Immune Defic Syndr*. 2003;33(2):175-83.

84. Divi RL, Walker VE, Wade NA, Nagashima K, Seilkop SK, Adams ME, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to combivir. *AIDS*. 2004;18:1013-21.
85. Alimente A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. *Pediatr Infect Dis J*. 2003;22(9):782-8.
86. Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. *J Acquir Immune Defic Syndr*. 2000;25(3):261-8.
87. Lindegren ML, Rhodes P, Gordon L, Fleming P; Perinatal Safety Review Working Group; State and Local Health Department HIV/AIDS Surveillance Programs. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. *Ann N Y Acad Sci*. 2000;918(1):222-35.
88. Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. *Ann N Y Acad Sci*. 2000;918(1):212-21.
89. Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, et al; PSD Consortium. Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children ≤ 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA. *Ann N Y Acad Sci*. 2000;918(1):236-46.
90. Aldrovandi GM, Chu C, Shearer WT, Li D, Walter J, Thompson B, et al. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. *Pediatrics*. 2009;124(6):e1189-97. PMID: 19933732
91. Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. *AIDS*. 2007;21(8):929-38.
92. Côté HC, Raboud J, Bitnun A, Alimenti A, Money DM, Maan E, et al. Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants. *J Infect Dis*. 2008;198(6):851-9.
93. Patel D, Thorne C, Fiore S, Newell ML; European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? *J Acquir Immune Defic Syndr*. 2005;40(1):116-8.
94. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. *AIDS*. 2009;23(4):519-24.
95. Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. *J Perinat Med*. 2011;39(2):163-70.
96. Alimenti A, Forbes JC, Oberlander TF, Money DM, Grunau RE, Papsdorf MP, et al. A prospective controlled study of neurodevelopment of HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. *Pediatrics*. 2006;118(4):e1139-45.

97. Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM; PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. *Pediatrics*. 2010;125(2):e250-60.
98. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, et al; Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. Absence of cardiac toxicity of zidovudine in infants. *N Engl J Med*. 2000;343(11):759-66.
99. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children Cohort Study). *J Am Coll Cardiol*. 2011;57(1):76-85.
100. Bunders MJ, Bekker V, Scherpbier HJ, Boer K, Godfried M, Kuijpers TW. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. *Acta Paediatr*. 2005;94(11):1571-7.
101. Mussi-Pinhata MM, Rego MA, Freimanis L, Kakehasi FM, Machado DM, Cardoso EM, et al; NISDI Perinatal Protocol Study Group. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study. *Pediatr Infect Dis J*. 2007;26(11):1032-7.
102. Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, et al; Women and Infants Transmission Study. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the Women and Infants Transmission Study. *J Infect Dis*. 2006;194(8):1089-97.
103. Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, et al; ANRS-Enquête Périnatale Française. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. *AIDS*. 2008;22(16):2165-77.
104. Brocklehurst P. Interventions for reducing the risk of mother-to-child transmission of HIV infection. *Cochrane Database Syst Rev*. 2002;(1):CD000102.
105. Watts DH, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, et al; PACTG 316 Study Team. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. *Am J Obstet Gynecol*. 2004;190(2):506-16.
106. Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al; PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. *J Acquir Immune Defic Syndr*. 2004;36(3):772-6.
107. Lallemand M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al; Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. *N Engl J Med*. 2004;351(3):217-28.
108. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al; Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. *J Acquir Immune Defic Syndr*. 2005;38(4):449-73.
109. Marti C, Peña JM, Bates I, Madero R, de José I, Pallardo LF, et al. Obstetric and perinatal complications in HIV-infected women: analysis of a cohort of 167 pregnancies between 1997 and 2003. *Acta Obstet Gynecol Scand*. 2007;86(4):409-15.

110. Pinnetti C, Barconcelli S, Villani P, Fantoni M, Tozzi V, De Luca A, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. *J Antimicrob Chemother.* 2010;65(9):2050-2.

Figure. Analytic Framework for Screening for HIV in Pregnant Women



Key Questions

1. What are the benefits of HIV screening versus no screening in asymptomatic pregnant women on maternal or child morbidity, mortality, or quality of life or rates of mother-to-child transmission?
- 2a. What is the yield (number of new diagnoses) of repeat HIV screening in asymptomatic pregnant women?
- 2b. What are the adverse effects (including false-positive results and anxiety) of rapid versus standard HIV testing in asymptomatic pregnant women?
- 3a. What is the effectiveness of newer antiretroviral regimens for reducing mother-to-child transmission?
- 3b. What are the effects of antiretroviral regimens in pregnant, HIV-positive women on long-term maternal morbidity, mortality, or quality of life?
- 3c. What are the harms (including longer-term harms) to the mother or child associated with antiretroviral therapy during pregnancy?

Table 1. Diagnostic Accuracy and Acceptability of Rapid Versus Standard HIV Testing in Pregnant Women

| Author, year Quality rating | Rapid vs. standard testing | | | | | | |
|---|---|--|---|---|--|--------------------|-------------------------------|
| | Sensitivity (95% CI) | Specificity (95% CI) | Positive predictive value (95% CI) | Negative predictive value (95% CI) | False positives | False negatives | Acceptability |
| Bulterys et al, 2004 ²⁸ <i>Fair</i> | 100% (90 to 100%) vs. 100% (89 to 100%) | 99.9% (99.8 to 99.9%) vs. 99.8% (99.6 to 99.9%) | 90% (75 to 97%) vs. 76% (61 to 87%) | 100% (99.9-100%) vs. 100% (99.9-100%) | 4 vs. 11 | 0 vs. 0 | 84% accepted and consented |
| Jamieson et al, 2007 ³⁹ <i>Fair</i> | 100% (93 to 100%) vs. 100% (93 to 100%) | 99.9% (99.8 to 100%) vs. 99.8% (99.6 to 99.9%) | 89.7% (78.8 to 96.1%) vs. 74.3% (62.4 to 84%) | 100% (99.9-100%) vs. 100% (99.9-100%) | 6 vs. 18 | 0 vs. 0 | 85% overall |
| Tung et al, 2010 ⁴⁰ <i>Fair</i> | NR | NR | OraQuick vs. EIA* 100% vs. 35.7% (90% CI) | NR | OraQuick vs. EIA* 0/5 (0%) vs. 7/14 (50%) | NR | NR |

*Confirmed by Western blot.

CI = confidence interval; EIA = enzyme immunoassay; NR = not reported.

Table 2. Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Setting | Intervention | Sample | Mother-to-child transmission rates by treatment group | Quality rating |
|--|---|--|---|---|----------------|
| Garcia-Tejedor et al, 2009 ⁵⁸ | Spain Maternity hospitals | ART A: No treatment B: Mono/dual therapy C: ART | 489 mother-infant pairs analyzed Rate of Cesarean section 51% No infants breastfed Followup NR | A: 18% (39/214) B: 8.6% (10/116) C: 0.6% (1/159) p<0.001 | Fair |
| Harris et al, 2007 ⁵⁷ | United States Population surveillance data from areas reporting ≥60 HIV-positive women giving birth per year | ART A: No treatment B: Prenatal, intrapartum and neonatal ART* | 7,344 HIV-exposed infants with ART data Rate of Cesarean section 53% Breastfeeding rate NR Followup by health department every 6 months until HIV status determined Analyses of data over 3 year study period | A: 22% (59/265), OR referent B: 2.4% (139/5757), AOR 0.09 (95% CI 0.06 to 0.12) Prenatal ART regimen and infant infection status among those on 3 arms of treatment: ZDV: OR referent ZDV & other drugs with PI: AOR 0.4, 95% CI 0.3 to 0.7 ZDV & other drugs no PI: AOR 0.5, 95% CI 0.3 to 0.8 Other drugs with PI, no ZDV: AOR 0.6, 95% CI 0.2 to 1.4 Other drugs no PI, no ZDV: AOR 0.3, 95% CI 0.1 to 1.5 n=5,602 due to exclusions | Fair |
| Townsend et al, 2008 ⁵⁶ | Ireland, United Kingdom Population surveillance data from National Study of HIV in Pregnancy and Childhood | Antepartum treatment A: ART therapy B: Dual therapy C: Monotherapy D: No therapy | 5,027 mother-infant pairs with ART data Rate of Cesarean section 78% 0.6% of infants breastfed Followup NR Analyses of data over 6 year study period | A: 1.0% (40/4120) B: 0.8% (1/126) C: 0.5% (3/638) D: 9.1% (13/143) A: AOR 1.0 B: AOR 1.7 (95% CI 0.2 to 13), p=0.61 C: AOR 0.6 (95% CI 0.2 to 1.9), p=0.37 D: AOR 3.2 (95% CI 1.2 to 8.6), p=0.02 n=4,084 due to exclusions | Fair |
| Tariq et al, 2011 ⁵⁹ | United Kingdom, Ireland, Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, Sweden/Population surveillance data from the European Collaborative Study and the National Study of HIV in Pregnancy and Childhood | ART A: ZDV-containing B: ZDV-sparing | 7,573 mother-child pairs analyzed Rate of Cesarean section 74% Breastfeeding rate NR Followup NR Analyses of data over 9 year study period | 0.9% (56/6130; 95% CI 0.7 to 1.0) of infants were infected (infection status available for 80% [6130/7645] of infants at analysis) A: 0.9% (n=5214); AOR 1 B: 0.8% (n=897); AOR 1.8 (95% CI 0.8 to 4.3) p=0.18 | Fair |

*Not all study interventions shown.

AOR = adjusted odds ratio; ART = antiretroviral therapy; CI = confidence interval; NR = not reported; OR = odds ratio; PI = protease inhibitor; ZDV = zidovudine.

Table 3. African-Based Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, year | Setting | Prenatal intervention | Peripartum intervention | Postpartum intervention | Sample | Mother-to-child transmission rates by treatment group | Quality rating |
|--|-----------------------------------|---|--|--|--|--|----------------|
| Chi et al, 2008 ⁶¹ Other publication: Chi, 2007 ⁶⁶ | Zambia | From 32 weeks: ZDV to all groups | A: TDF/FTC + NVP B: NVP | All neonates: NVP dose in hospital + ZDV for one week | 355 mother-infant pairs analyzed 92% of infants breastfed in both groups | 6 weeks postpartum A: 6% B: 8% p=0.4 | Fair |
| de Vincenzi et al, 2011 ⁶⁰ Other publication: Kesho Bora Study Group, 2010 ⁶⁷ | Burkina Faso, Kenya, South Africa | From 28 weeks: A: ZDV + 3TC + ABT-378 + RTV B: ZDV | A: ZDV, 3TC, ABT-378, RTV B: ZDV + sdNVP | A: Maternal ZDV, 3TC, ABT-378, RTV until cessation of breastfeeding (maximum 6.5 months postpartum) B: Maternal 3TC and ZDV for one week postpartum* All neonates: ZDV for one week*, NVP dose within 72 hours of birth, co-trimoxazole from age 6 weeks to 12 months unless not HIV infected after cessation of breastfeeding | 805 live born infants 77% of infants in group A and 78% in group B were ever breastfed | 12 months of age A: 5.4% (21/333), 95% CI 3.6 to 8.1 B: 9.5% (37/305), 95% CI 7.0 to 13 RR reduction 0.43 p=0.03 | Good |
| Gray et al, 2006 ⁶² | South Africa | From 34 weeks gestation: A: d4T B: ddl C: d4T + ddl D: ZDV | A: d4T B: ddl C: d4T + ddl D: ZDV | Infants received same ART regimen as mother until 6 weeks of age | 362 mother-infant pairs analyzed No infants breastfed | 24 weeks postpartum A: 12% (11/91), 95% CI 6.2 to 21 B: 11% (10/94), 95% CI 5.2 to 19 C: 4.6% (4/88), 95% CI 1.3 to 11 D: 5.6% (5/89), 95% CI 1.9 to 13 All groups: 8.3% (30/362), 95% CI 5.7 to 12 | Fair |
| Shapiro et al, 2010 ⁶³ | Botswana | Randomization groups† From 26 weeks: A: ABC + ZDV + 3TC B: ABT-378 + RTV + ZDV + 3TC Observational group‡ From 18 weeks: C: NVP + ZDV + 3TC | A: ABC + ZDV + 3TC B: ABT-378 + RTV + ZDV + 3TC C: NVP + ZDV + 3TC | A: ABC + ZDV + 3TC B: ABT-378 + RTV + ZDV + 3TC Above to continue until weaning or 6 months postpartum, whichever came first C: NVP + ZDV + 3TC to continue indefinitely All neonates: sdNVP at birth + ZDV from birth to 4 weeks | 709 live born infants (including n=156 in the observational group) 97% of live born infants breastfed and 71% continued for >5 months | 6 months of age A: 2.1% (6/283) B: 0.4% (1/270) percentage point difference, 1.7, 95% CI -2.0 to 7.1§ All groups: 1.1% (8/709), 95% CI 0.5 to 2.2 | Fair |
| Shapiro et al, 2006 ⁶⁴ | Botswana | From 34 weeks: ZDV to all groups | A: sdNVP B: placebo | All neonates: NVP at birth and ZDV from birth to one month of age¶ | 694 live first born infants 50% of infants in both groups were breastfed Infant followup until one month of age | 1 month of age A: 4.3%±2.3 (2 SD), 15/345 B: 3.7%±2.2 (2 SD), 13/346 95% CI for difference, -2.4 to 3.8% (met equivalence) | Fair |
| Thistle et al, 2007 ⁶⁵ | Zimbabwe | None | A: ZDV/sdNVP B: sdNVP | A: Infant ZDV for 72 hours after delivery and NVP dose within 72 hours of delivery B: Infant NVP dose within 72 hours of delivery | Study terminated secondary to fertility 609 infants with data 89% of infants in group A and 91% of infants in group B were breastfed at 6 weeks (one infant in group A was breast and formula fed) | 6 weeks of age A: 14% (45/312) HIV+, 7.4% (23/312) mortality, 22% (68/312) met primary outcome (death or HIV infection) B: 17% (49/297) HIV+, 7.1% (21/297) mortality, 24% (70/297) met primary outcome | Fair |

*Began after protocol change in December 2006 (enrollment commenced June 2005).

Table 3. African-Based Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

†Women with CD4 count $>0.200 \times 10^9$ cells/L.

‡Women with CD4 count $<0.200 \times 10^9$ cells/L or with AIDS-defining illness.

§Study not powered for between-group comparisons of transmission rates.

|| ART was offered to women with CD4 counts $<0.200 \times 10^9$ cells/L or AIDS-defining illness at any point in study participation. If women started ART before delivery, they did not receive peripartum nevirapine or placebo.

¶Infants confirmed HIV-infected were also given ART.

3TC = lamivudine; ABC = abacavir; ABT-378 = lopinavir; ART = antiretroviral therapy; CI = confidence interval; d4T = stavudine; ddl = didanosine; FTC = emtricitabine; NVP = nevirapine; RR = relative risk; RTV = ritonavir; sdNVP = single-dose nevirapine; TDF = tenofovir; usZDV = ultra-short zidovudine; ZDV = zidovudine.

Table 4. Preterm Birth Outcomes*

| Study, year | ART regimen (N; %) | Preterm Definition | Gestational age distribution | Magnitude of risk: Adjusted OR (95% CI), p-value |
|---|---|---|--|---|
| Cotter et al, 2006 ⁷⁵ | A: None (n=338; 25%) B: Monotherapy (n=492; 37%) C: Combination therapy with PIs (n=134; 10%) D: Combination therapy without PIs (n=373; 28%) Total N=1,337 | <37 weeks; "Very preterm" <32 weeks | Median at delivery 39 weeks | Combination with vs. without PI: <37 weeks: 1.8 (1.1 to 3.0), p=0.03 Combination + PI: <37 weeks: 36.6% of women (p<0.05) <32 weeks: 2.2% of women (NS) |
| Schulte et al, 2007 ⁸¹ | A: None (n=2565; 29%) B: Monotherapy (n=2621; 30%) C: Dual therapy (n=1044; 12%) D: Triple therapy: ART, non-PI (n=1781; 20%) E: Triple therapy: ART, PI (n=782; 9%) Total N=8,793 | <37 weeks | Mean 37 weeks (range 26-42) | 1.21 (1.04 to 1.48), p-value NR |
| Townsend et al, 2007 ⁸² | A: ART (n=3384; 69%) B: Mono/dual therapy (n= 1061; 21%) C: Untreated; not included in analyses (n= 494; 10%) Total N=4,939 | <37 weeks | <37 weeks 14.1%† <35 weeks 7.8% <32 weeks 1.4% | <37 weeks: 1.39 (1.05 to 1.83), p=0.02 <35 weeks: 2.02 (1.35 to 3.04), p=0.001 <32 weeks: 2.63 (1.3 to 5.33), p=0.007 |
| Grosch-Warner et al, 2008 ⁷⁷ | A: Monotherapy (n=76; 42%) B: Dual therapy (n=32; 17%) C: ART without PI (n=54; 30%) D: ART with PI (n=21; 11%) Total N=183 | <36 weeks | <36 weeks 34%† (crude rate) | ART (-) PI: 0.89 (0.38 to 2.12), p=0.8 ART (+) PI: 3.40 (1.13 to 10.2), p=0.03 |
| Powis et al, 2011 ⁷² | A: PI group, KAL/CBV (lopinavir/ritonavir/ zidovudine/ lamudivine) (n=275; 49%) B: NRTI group, TZV (abacavir/zidovudine/lamidvudine)(n=285; 51%) Total N=560 | <37 weeks | <37 weeks 11.8%† Triple NRTI; 21.4% PI based <32 weeks 2.6% (n=12); 8/12 associated with ART + PI; 4/12 triple NRTI | ART (-) PI (NRTI-based): 1.0 ART (+) PI: 2.02 (1.25 to 3.27), p=0.004 |

*Studies that adjusted for confounders.

†Percent of study population.

ART = antiretroviral therapy; GA = gestational age; NR = not reported; NRTI = nucleoside/nucleotide reverse transcriptase inhibitors; NS = not significant; PI = protease inhibitor.

Table 5. Summary of Evidence

| Main findings from 2005 USPSTF review | Number and type of studies identified for update <i>Overall quality*</i> | Limitations | Consistency | Applicability | Updated findings |
|---|---|--|--------------------|---|---|
| Key Question 1. What are the benefits of HIV screening vs. no screening in asymptomatic pregnant women on maternal or child morbidity, mortality, or quality of life or rates of mother-to-child transmission? | | | | | |
| No studies | No studies | No studies | No studies | No studies | No study directly compared clinical outcomes (including risk of perinatal transmission) between pregnant women screened and not screened for HIV infection. |
| Key Question 2a. What is the yield of repeat HIV screening in asymptomatic pregnant women? | | | | | |
| No studies | No studies | No studies | No studies | No studies | No study evaluated the yield of repeat prenatal HIV screening compared to one-time screening, or compared the yield of different strategies for repeat screening. |
| Key Question 2b. What are the adverse effects (including false-positive results and anxiety) of rapid vs. standard HIV testing in asymptomatic pregnant women? | | | | | |
| 1 observational study reported false-alarm rate of 10% with rapid testing during labor | 2 observational studies† <i>Overall quality: Fair</i> | Few studies; small numbers of HIV-infected women | Consistent | No issues | One large (n=7,753), fair-quality prospective study of women presenting in labor with unknown HIV status (prevalence 0.7%) found the positive predictive value for the rapid test was higher (90% [52/58]) than for the standard test (74% [52/70]). One other, smaller study reported consistent results, but only five HIV cases were identified. No study evaluated adverse clinical consequences of interventions given as a result of false-positive results. |
| Key Question 3a. What is the effectiveness of newer antiretroviral regimens for reducing mother-to-child transmission? | | | | | |
| 4 cohort studies found full-course combination antiretroviral therapy associated with substantially lower risk of transmission compared to no antiretrovirals or regimens with fewer drugs (absolute risk 1%-2%) | 4 cohort studies and 6 RCTs <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy in nonresource-poor settings | Consistent | RCTs evaluated shorter-course antiretroviral regimens in primarily breastfeeding women in resource-poor countries | Three cohort studies of antiretroviral therapy conducted in nonbreastfeeding women in the U.S. and Europe confirm the findings from the 2005 USPSTF review that full-course combination antiretroviral therapy is highly effective at reducing risk of mother-to-child transmission (<1% to 2.4% with combination antiretroviral therapy compared to 9% to 22% with no antiretroviral therapy). Shorter courses of antiretroviral therapy are not as effective as full-course regimens, but also reduce risk of mother-to-child transmission. |
| Key Question 3b. What are the effects of antiretroviral regimens in pregnant, HIV-positive women on long-term maternal morbidity, mortality, or quality of life? | | | | | |
| 1 study of women originally enrolled in an RCT of zidovudine monotherapy found no adverse maternal outcomes after 4 years | No studies | No studies | No studies | No studies | No new studies evaluated effects of prenatal antiretroviral therapy on long-term maternal clinical outcomes. |
| Key Question 3c. What are the effects of antiretroviral regimens in pregnant, HIV-positive women on long-term maternal morbidity, mortality, or quality of life? | | | | | |
| <i>Pregnancy outcomes</i> | | | | | |
| 1 meta-analysis and one large cohort study found no clear association between combination antiretroviral therapy use and low birth weight, and mixed evidence on premature delivery | 1 RCT and 10 cohort studies <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy | Some inconsistency | No issues | One RCT and four prospective cohort studies that adjusted for confounders found some antiretroviral regimens associated with increased risk of preterm delivery. Four studies that did not adjust for confounders reported inconsistent results. Cohort studies found no association between antiretroviral therapy use and low birth weight. |

Table 5. Summary of Evidence

| Main findings from 2005 USPSTF review | Number and type of studies identified for update <i>Overall quality*</i> | Limitations | Consistency | Applicability | Updated findings |
|--|---|---|-------------|---------------|---|
| Mitochondrial dysfunction | | | | | |
| 3 cohort studies found in utero antiretroviral exposure associated with laboratory mitochondrial dysfunction, but did not assess clinical effects | 3 cohort studies <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy; studies did not assess clinical outcomes | Consistent | No issues | Three studies evaluated risk of mitochondrial dysfunction following in utero exposure to antiretroviral therapy, but none evaluated clinical outcomes associated with mitochondrial dysfunction. |
| Congenital abnormalities | | | | | |
| 1 prospective cohort study found no association between in utero antiretroviral exposure and congenital abnormalities | 4 cohort studies <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy | Consistent | No issues | Four studies found no association between in utero exposure to antiretroviral drugs and risk of congenital abnormalities |
| Neurodevelopment | | | | | |
| 1 prospective cohort study found no effect of in utero antiretroviral exposure on neurodevelopment | 2 cohort studies <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy | Consistent | No issues | Two studies found no association between in utero exposure to antiretroviral drugs and neurodevelopment through ages 2 to 3 years. |
| Other harms of in utero exposure | | | | | |
| 1 cohort study found no association between in utero exposure to zidovudine and echocardiographic abnormalities | 5 cohort studies <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy; studies of mitochondrial dysfunction and echocardiography abnormalities did not assess clinical outcomes | Consistent | No issues | Four cohort studies found an association between exposure to perinatal antiretroviral therapy and increased risk during infancy of hematological abnormalities and echocardiographic markers of impaired myocardial growth, but the clinical significance of these findings was unclear. One cohort study found no association between exposure to perinatal antiretroviral therapy and increased risk of childhood cancer. |
| Maternal harms | | | | | |
| 1 meta-analysis found no association between perinatal zidovudine monotherapy and maternal deaths or long-term harms. 1 study found antiretroviral therapy associated with gestational diabetes. 1 trial found continuous nevirapine associated with serious hepatic or cutaneous toxicity in women with CD4 counts >0.250 x 10 ⁹ cells/L | 2 cohort studies <i>Overall quality: Fair</i> | No RCTs of full-course combination antiretroviral therapy; not clear if gestational diabetes diagnosed prior to initiation of antiretroviral therapy | Consistent | No issues | 2 cohort studies found an association between antiretroviral therapy during pregnancy and gestational diabetes, but causality was unclear or estimates were not statistically significant. |

* "Overall quality" is based on new evidence identified for this update plus previously reviewed evidence.

† One of the observational studies reports longer-term followup from a study included in the prior review.

Appendix A1. Search Strategies

All Key Questions

Database: EBM Reviews - Cochrane Database of Systematic Reviews

- 1 hiv.ti.
- 2 limit 1 to full systematic reviews
- 3 antiretroviral.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 4 haart.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 5 3 or 4
- 6 2 and 5
- 7 screen\$.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 8 2 and 7
- 9 test\$.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 10 2 and 9
- 11 6 or 8 or 10
- 12 limit 11 to last 8 years
- 13 pregnan\$.mp. [mp=title, short title, abstract, full text, keywords, caption text]
- 14 12 and 13

Key Questions 1, 2a, and 2b

Database: Ovid MEDLINE(R) without Revisions

- 1 exp AIDS Serodiagnosis/
- 2 exp HIV Seronegativity/
- 3 exp HIV Antigens/
- 4 exp HIV/
- 5 exp HIV Seroprevalence/
- 6 exp HIV Seropositivity/
- 7 exp HIV Antibodies/
- 8 or/2-7
- 9 exp Mass Screening/
- 10 8 and 9
- 11 1 or 10
- 12 (hiv adj1 screen\$).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]
- 13 11 or 12
- 14 13 and (200406\$ or 200407\$ or 200408\$ or 200409\$ or 20041\$ or 2005\$ or 2006\$ or 2007\$ or 2008\$ or 2009\$ or 2010\$ or 2011\$).ed.
- 15 limit 14 to English language
- 16 limit 14 to abstracts
- 17 15 or 16
- 18 limit 17 to humans
- 19 Pregnancy/
- 20 pregnan\$.mp.
- 21 19 or 20
- 22 18 and 21

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 exp AIDS Serodiagnosis/

Appendix A1. Search Strategies

- 2 exp HIV Seronegativity/
- 3 exp HIV Antigens/
- 4 exp HIV/
- 5 exp HIV Seroprevalence/
- 6 exp HIV Seropositivity/
- 7 exp HIV Antibodies/
- 8 or/2-7
- 9 exp Mass Screening/
- 10 8 and 9
- 11 1 or 10
- 12 (hiv adj1 screen\$).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]
- 13 11 or 12
- 14 limit 13 to yr="2004 -Current"
- 15 Pregnancy/
- 16 14 and 15

Key Question 3a

Database: Ovid MEDLINE(R) without Revisions

- 1 Antiretroviral Therapy, Highly Active/
- 2 haart.mp.
- 3 1 or 2
- 4 Anti-HIV Agents/
- 5 3 or 4
- 6 Infectious Disease Transmission, Vertical/
- 7 HIV Infections/tm [Transmission]
- 8 6 or 7
- 9 5 and 8
- 10 Pregnancy/
- 11 9 and 10
- 12 limit 11 to English language
- 13 limit 11 to abstracts
- 14 12 or 13
- 15 limit 14 to yr="2004 -Current"

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

- 1 Antiretroviral Therapy, Highly Active/
- 2 haart.mp.
- 3 1 or 2
- 4 Anti-HIV Agents/
- 5 3 or 4
- 6 Infectious Disease Transmission, Vertical/
- 7 HIV Infections/tm [Transmission]
- 8 6 or 7
- 9 5 and 8
- 10 Pregnancy/
- 11 9 and 10

Appendix A1. Search Strategies

12 limit 11 to yr="2004 -Current"

Key Question 3b and 3c

Database: Ovid MEDLINE(R) without Revisions

1 Antiretroviral Therapy, Highly Active/

2 Anti-HIV Agents/

3 haart.mp.

4 or/1-3

5 Pregnancy/

6 4 and 5

7 limit 6 to yr="2004 - Current"

8 limit 7 to English language

9 limit 7 to abstracts

10 8 or 9

11 10 not (letter or editorial or comment or case reports).pt.

Database: EBM Reviews - Cochrane Central Register of Controlled Trials

1 Antiretroviral Therapy, Highly Active/

2 Anti-HIV Agents/

3 haart.mp.

4 or/1-3

5 Pregnancy/

6 4 and 5

7 limit 6 to yr="2004 -Current"


Appendix A2. Inclusion and Exclusion Criteria per Key Question

| | Include | Exclude |
|---|---|--|
| All Key Questions | | |
| Settings | Primary care or other settings generalizable to primary care (e.g., family planning clinics, school-based health clinics), other health care settings in which screening is commonly performed (e.g., emergency room or urgent care). Focus on studies conducted in the United States and other developed countries, except for randomized trials of antiretroviral therapies (Africa). | Developing countries, unless fair- or good-quality trials and studies in the United States are lacking |
| Key Question 1: What are the benefits of HIV screening vs. no screening in asymptomatic pregnant women on maternal or child morbidity, mortality, or quality of life or rates of mother-to-child transmission? | | |
| Populations | Asymptomatic pregnant women; neonates, infants, and children who were exposed to ART in utero | Known HIV infection, on dialysis, post-transplant, occupational exposure |
| Interventions | Rapid or standard HIV testing | |
| Comparisons | HIV screening versus no screening | |
| Outcomes | Mother-to-child transmission rates of HIV, mortality related to HIV infection, and quality of life for mothers and their newborns | Pharmacokinetics |
| Study designs | Randomized, controlled trials and controlled observational studies | Modeling studies |
| Key Question 2a: What is the yield of repeat HIV screening in asymptomatic pregnant women? | | |
| Populations | Asymptomatic pregnant women | Known HIV infection, on dialysis, post-transplant, occupational exposure |
| Interventions | Rapid or standard HIV testing | |
| Comparisons | Repeat HIV screening during pregnancy versus one-time screening, or screening at one interval versus another interval | |
| Outcomes | Number of positive test results | |
| Study designs | Randomized, controlled trials and controlled observational studies | Modeling studies |
| Key Question 2b: What are the adverse effects (including false-positive results and anxiety) of rapid vs. standard HIV testing in asymptomatic pregnant women? | | |
| Populations | Asymptomatic pregnant women | Known HIV infection, on dialysis, post-transplant, occupational exposure |
| Interventions | Rapid or standard HIV testing | |
| Comparisons | Rapid versus standard HIV testing | |
| Outcomes | False-positive results, anxiety, and effects of labeling; partner discord, abuse, or violence | |
| Study designs | Randomized, controlled trials and comparative observational studies | Modeling studies |
| Key Question 3a: What is the effectiveness of newer antiretroviral regimens for reducing mother-to-child transmission? | | |
| Populations | Pregnant women with HIV; neonates and infants who were exposed to antiretroviral regimens in utero | Women already or previously on ART prior to pregnancy; acute HIV or HIV subtypes |
| Interventions | Newer antiretroviral regimens | Discontinuing ART during pregnancy; treatment interruption |
| Comparisons | Newer antiretroviral regimens versus placebo, older antiretroviral regimens, or one another | |
| Outcomes | Mother-to-child transmission rates of HIV | |
| Study designs | Randomized, controlled trials and controlled observational studies | Modeling studies |
| Key Question 3b: What are the effects of antiretroviral regimens in pregnant, HIV-positive women on long-term maternal morbidity, mortality, or quality of life? | | |
| Populations | Women who were on antiretroviral regimens while pregnant | Women already or previously on ART prior to pregnancy; acute HIV or HIV subtypes |
| Interventions | Newer antiretroviral regimens | Discontinuing ART during pregnancy; treatment interruption |
| Comparisons | Newer antiretroviral regimens versus placebo, older antiretroviral regimens, or one another | |
| Outcomes | Long-term maternal morbidity, mortality, or quality of life | Pharmacokinetics |
| Study designs | Any | |
| Timing | One or more years after giving birth | Less than 1 year after giving birth |

Appendix A2. Inclusion and Exclusion Criteria per Key Question

| | Include | Exclude |
|--|--|---|
| Key Question 3c: What are the harms (including longer-term harms) to the mother or child associated with antiretroviral therapy during pregnancy? | | |
| Populations | Women who were on antiretroviral regimens while pregnant; neonates, infants, and children who were exposed to antiretroviral therapy in utero | Women already or previously on antiretroviral therapy prior to pregnancy; acute HIV or HIV subtypes |
| Interventions | Newer antiretroviral regimens | Discontinuing antiretroviral therapy during pregnancy; treatment interruption |
| Comparisons | Newer antiretroviral regimens versus placebo, older antiretroviral regimens, or one another | |
| Outcomes | Harmful effects on pregnancy outcomes, neonatal outcomes, or effects on exposed children; long-term cardiovascular and metabolic maternal outcomes | Pharmacokinetics |
| Study designs | Any | |
| Timing | Any | |

Appendix A3. Literature Flow Diagram



*Cochrane databases include the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.

†Other sources include reference lists, suggestions from peer reviewers.

‡ Some articles are included for more than one key question.

Appendix A4. Excluded Studies List

Wrong Population

Alrajhi A, Edathodu J, Halim M, Dahham M. Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia. *Ann Saudi Med.* 2010;30:15-7 PMID: 20103953.

Aluisio A, Richardson BA, Bosire R, John-Stewart G, Mbori-Ngacha D, Farquhar C. Male antenatal attendance and HIV testing are associated with decreased infant HIV infection and increased HIV-free survival. *J Acquir Immune Defic Syndr.* 2011;56(1):76-82 PMID: 21084999

Asavapiriyant S, Kasiwat S. Prevalence of low birthweight infants in HIV-infected women delivered in Rajavithi Hospital. *J Med Assoc Thai.* 2011;94 Suppl 2:S66-70 PMID: 21717881.

Azcoaga-Lorenzo A, Ferreyra C, Alvarez A, Palma PP, Velilla E, del Amo J. Effectiveness of a PMTCT programme in rural Western Kenya. *AIDS Care.* 2011;23(3):274-80 PMID: 21347890.

Becker S, Mlay R, Schwandt HM, Lyamuya E. Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial. *AIDS Behav.* 2010;14(3):558-66 PMID: 19763813.

Betancourt TS, Abrams EJ, McBain R, Fawzi MC. Family-centred approaches to the prevention of mother to child transmission of HIV. *J Int AIDS Soc.* 2010;13(2) PMID: 20573284

Black V, Hoffman RM, Sugar CA, Menon P, Venter F, Currier JS, et al. Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. *J Acquir Immune Defic Syndr.* 2008;49(3):276-81 PMID: 18845949

Black V, von Mollendorf CE, Moyes JA, Scott LE, Puren A, Stevens WS. Poor sensitivity of field rapid HIV testing: implications for mother-to-child transmission programme. *BJOG.* 2009;116(13):1805-8 PMID: 19781042

Boer K, Nellen JF, Patel D, Timmermans S, Tempelman C, Wibaut M, et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. *BJOG.* 2007;114(2):148-55 PMID: 17305888.

Bracher L, Valerius NH, Rosenfeldt V, Herlin T, Fisker N, Nielsen H, et al. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark. *Scand J Infect Dis.* 2007;39(9):799-804 PMID: 17701719.

Briand N, Le Coeur S, Traisathit P, Karnchanamayul V, Hansudewechakul R, Ngampiyasakul C, et al. Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission. *Pediatr Infect Dis J.* 2006;25(4):325-32 PMID: 16567984.

Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. *J Acquir Immune Defic Syndr.* 2007;45(3):269-73 PMID: 17450102.

Casula M, Bosboom-Dobbelaer I, Smolders K, Otto S, Bakker M, de Baar MP, et al. Infection with HIV-1 induces a decrease in mtDNA. *J Infect Dis.* 2005;191(9):1468-71 PMID: 15809905.

Appendix A4. Excluded Studies List

Casula M, Weverling GJ, Wit FW, Timmermans EC, Stek M, Lange JM, et al. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. *J Infect Dis*. 2005;192(10):1794-800 PMID: 16235179.

Chama C, Gashau W, Oguche S. The value of highly active antiretroviral therapy in the prevention of mother-to-child transmission of HIV. *J Obstet Gynaecol*. 2007;27(2):134-7 PMID: 17454457.

Chatterjee A, Bosch RJ, Kupka R, Hunter DJ, Msamanga GI, Fawzi WW. Predictors and consequences of anaemia among antiretroviral-naive HIV-infected and HIV-uninfected children in Tanzania. *Public Health Nutr*. 2010;13(2):289-96 PMID: 19650963.

Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. *AIDS*. 2007;21(8):957-64 PMID: 17457089.

Ching N, Deville JG, Nielsen KA, Ank B, Wei LS, Sim MS, et al. Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). *Eur J Pediatr*. 2007;166(1):51-6 PMID: 16868780.

Ciaranello AL, Perez F, Maruva M, Chu J, Engelsmann B, Keatinge J, et al. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. *PLoS One*. 2011;6(6):e20224 PMID: 21655097.

Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression. *JAMA*. 2010;304(10):1082-90 PMID: 20823434.

Coovadia HM, Brown ER, Fowler MG, Chipato T, Moodley D, Manji K, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2012;379(9812):221-8. PMID: 22196945

Dabis F, Elenga N, Meda N, Leroy V, Viho I, Manigart O, et al. 18-Month mortality and perinatal exposure to zidovudine in West Africa. *AIDS*. 2001;15(6):771-9 PMID: 11371692.

Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. *J Acquir Immune Defic Syndr*. 2006;42(1):29-35 PMID: 16763490

Darin N, Oldfors A, Moslemi A-R, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: Clinical features and morphological, biochemical, and DNA abnormalities. *Ann Neurol*. 2001;49(3):377-83 PMID: 11261513.

Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration. *J Acquir Immune Defic Syndr*. 2011;56(3):270-8 PMID: 21107266.

Appendix A4. Excluded Studies List

- Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. *J Acquir Immune Defic Syndr*. 2011;56(5):428-36 PMID: 21266910.
- Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. *AIDS*. 2008;22(14):1815-20 PMID: 18753864.
- Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. *J Acquir Immune Defic Syndr*. 2011;56(2):183-7 PMID: 21084995.
- Farquhar C, Kiarie JN, Richardson BA, Kabura MN, John FN, Nduati RW, et al. Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. *J Acquir Immune Defic Syndr*. 2004;37(5):1620-6 PMID: 15577420.
- Geddes R, Giddy J, Butler LM, Van Wyk E, Crankshaw T, Esterhuizen TM, et al. Dual and triple therapy to prevent mother-to-child transmission of HIV in a resource-limited setting--lessons from a South African programme. *S Afr Med J*. 2011;101(9):651-4 PMID: 21920158.
- Gumbo FZ, Kandawasvika GQ, Duri K, Masingure MP, Kurewa NE, Nathoo K, et al. Reduced HIV transmission at subsequent pregnancy in a resource-poor setting. *Trop Doct*. 2011;41(3):132-5 PMID: 21576348.
- Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. *Int J STD AIDS*. 2001;12(9):555-64 PMID: 11516363.
- Hernandez S, Moren C, Lopez M, Coll O, Cardellach F, Gratacos E, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. *AIDS*. 2012;26(4):419-28. PMID: 22156962
- Hughes CA, Zuk D, Foisy M, Robinson J, Singh AE, Houston S. Prenatal screening and perinatal HIV transmission in Northern Alberta, 1999-2006. *Am J Public Health*. 2009;99(2) PMID: 19372528.
- Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. *Lancet*. 2003;362(9387):859-68 PMID: 13678973.
- Jao J, Palmer D, Leus I, Tih P, Baweja M, Klotman M, et al. Prevalence and predictors of proteinuria in HIV-infected and uninfected pregnant women in Cameroon. *Nephrol Dial Transplant*. 2011;26(9):3051-3 PMID: 21719713.
- Joseph O, Biodun O, Michael E. Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection. *J Coll Physicians Surg Pak*. 2011;21(6):356-9 PMID: 21711992.
- Jungmann EM, Mercey D, DeRuiter A, Edwards S, Donoghue S, Booth T, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? *Sex Transm Infect*. 2001;77(6):441-3 PMID: 11714944.
- Khalsa A, Karim R, Mack W, Minkoff H, Cohen M, Young M, et al. Hypertension in HIV-infected Women Related to HAART: Women's Interagency HIV Study 11th

Appendix A4. Excluded Studies List

Conference on Retroviruses and Opportunistic Infections. 2004:Abstract 741 PMID: N/A.

Kiarie JN, Kreiss JK, Richardson BA, John-Stewart GC. Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. *AIDS*. 2003;17(1):65-71 PMID: 12478070.

Leroy V, Karon JM, Alioum A, Ekpini ER, van de Perre P, Greenberg AE, et al. Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa. *AIDS*. 2003;17(10):1493-501 PMID: 12824787.

Lindsey JC, Malee KM, Brouwers P, Hughes MD. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. *Pediatrics*. 2007;119(3):e681-93 PMID: 17296781.

Lopez-Vilchez MA, Guxens Junyent M, Mur Mila E, Mur Sierra A. HIV-mother-to-child transmission in a tertiary hospital in the era of generalization of preventive interventions [Spanish]. *Med Clin (Barc)*. 2009;132(13):487-94 PMID: 19345962.

Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. *Sex Transm Infect*. 2009;85:82-7 PMID: 18987014.

Matida LH, Santos NJS, Ramos AN, Jr., Gianna MC, da Silva MH, Domingues CSB, et al. Eliminating vertical transmission of HIV in Sao Paulo, Brazil: progress and challenges. *J Acquir Immune Defic Syndr*. 2011;57 Suppl 3:S164-70 PMID: 21857313.

Miura T, Goto M, Hosoya N, Odawara T, Kitamura Y, Nakamura T, et al. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. *J Med Virol*. 2003;70(4):497-505 PMID: 12794710.

Moodley D, Esterhuizen TM, Pather T, Chetty V, Ngaleka L. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. *AIDS*. 2009;23(10):1255-9 PMID: 19455017.

Myers JJ, Modica C, Dufour MS, Bernstein C, McNamara K. Routine rapid HIV screening in six community health centers serving populations at risk. *J Gen Intern Med*. 2009;24(12):1269-74 PMID: 19655204.

Ndirangu J, Newell ML, Tanser F, Herbst AJ, Bland R. Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact? *AIDS*. 2010 24(4):593-602 PMID: 20071975.

Onyeador N, Patel D, Lyall H. Renal tubular dysfunction associated with tenofovir-based HAART in perinatally acquired HIV: the need for paediatric formulations and pharmacokinetic studies. *HIV Med*. 2008;9(Supplement 1):26 (P61) PMID: N/A

Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, et al. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. *AIDS*. 2009 23(18):2425-30 PMID: 19617813.

Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *N Engl J Med*. 2010;363(16):1510-20 PMID: 20942667.

Appendix A4. Excluded Studies List

Parekh N, Ribaud H, Souda S, Chen J, Mmalane M, Powis K, et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-age infants among HIV-exposed and HIV-unexposed infants in Botswana. *Int J Gynaecol Obstet.* 2011;115(1):20-5 PMID: 21767835.

Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR, 3rd, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. *AIDS.* 2009;23(14):1893-901 PMID: 19644348.

Peixoto MF, Pilotto JH, Stoszek SK, Kreitchmann R, Mussi-Pinhata MM, Melo VH, et al. Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities. *Braz J Infect Dis.* 2011;15(3):253-61 PMID: 21670927.

Phanuphak N, Apornpong T, Intarasuk S, Teeratakulpisarn S, Phanuphak P. Toxicities from nevirapine in HIV-infected males and females, including pregnant females with various CD4 cell counts. 12th Conference on Retroviruses and Opportunistic Infections. 2005:Abstract 21 PMID: N/A.

Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, van Widenfelt E, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. *J Acquir Immune Defic Syndr.* 2011;56(2):131-8 PMID: 21124227.

Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. *AIDS.* 2011;25(10):1299-303 PMID: 21516029.

Semrau K, Kuhn L, Vwalika C, Kasonde P, Sinkala M, Kankasa C, et al. Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events. *AIDS.* 2005;19(6):603-9 PMID: 15802979.

Singh HK, Gupte N, Kinikar A, Bharadwaj R, Sastry J, Suryavanshi N, et al. High rates of all-cause and gastroenteritis-related hospitalization morbidity and mortality among HIV-exposed Indian infants. *BMC Infect Dis.* 2011;11:193 PMID: 21762502.

Szyld E, Warley E, Freimanis L, Gonin R, Cahn P, Calvet GA, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. *AIDS.* 2006;20:2345-53 PMID: 17117021.

Theron GB, Shapiro DE, Van Dyke R, Cababasay MP, Louw J, Watts DH, et al. Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa. *Int J Gynaecol Obstet.* 2011;113(1):44-9 PMID: 21251654.

Uusimaa J, Remes AM, Rantala H, Vainionpaa L, Herva R, Vuopala K, et al. Childhood encephalopathies and myopathies: a prospective study in a defined population to assess the frequency of mitochondrial disorders. *Pediatrics.* 2000;105(3):598-603 PMID: 10699115.

van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. *J Int AIDS Soc.* 2011;14:42 PMID: 21843356.

van Lettow M, Bedell R, Landes M, Gawa L, Gatto S, Mayuni I, et al. Uptake and outcomes of a prevention-of-mother-to-child transmission (PMTCT) program in Zomba

Appendix A4. Excluded Studies List

district, Malawi. *BMC Public Health*. 2011;11:426 PMID: 21639873.

Viani RM, Hubbard P, Ruiz-Calderon J, Araneta MR, Lopez G, Chacon-Cruz E, et al. Performance of rapid HIV testing using Determine HIV-1/2 for the diagnosis of HIV infection during pregnancy in Tijuana, Baja California, Mexico. *Int J STD AIDS*. 2007;18(2):101-4 PMID: 17331281.

Vyankandondera J, Luchters S, Hassink E, Pakker N, Mmiro F, Okong P, et al. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA study). 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. 2003:Abstract LB7 PMID: N/A.

Wood SM, Shah SS, Steenhoff AP, Rutstein RM. The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. *AIDS*. 2009;23(14):1859-65 PMID: 19584705.

Wrong Intervention

Almario CV, Moskowitz EJ, Koran J, Berman B, Pracilio VP, Crawford A, et al. Examining the effectiveness of an opt-in approach to prenatal human immunodeficiency virus screening. *Am J Obstet Gynecol*. 2010;202(2):159.e1-6 PMID: 19846053

Arrive E, Chaix ML, Nerrienet E. The TEmAA ANRS 12109 phase II trial, step 1: tolerance and viral resistance after single dose nevirapine and short course of tenofovir disoproxil fumarate and emtricitabine to prevent mother-to-child transmission of HIV-1. 15th Conference on Retroviruses and Opportunistic Infections. 2008:Abstract 45b PMID: N/A.

Bae WH, Wester C, Smeaton LM, Shapiro RL, Lockman S, Onyait K, et al. Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. *AIDS*. 2008;22(13):1633-40 PMID: 18670224.

Baroncelli S, Pinnetti C, Genovese O, Tamburrini E, Florida M. Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine. *J Med Virol*. 2011;83(3):551-6 PMID: 21264878.

Boer K, Smit C, van der Flier M, de Wolf F, group Acs. The comparison of the performance of two screening strategies identifying newly-diagnosed HIV during pregnancy. *Eur J Public Health*. 2011;21(5):632-7 PMID: 21051473.

Chi BH, Wang L, Read JS, Sheriff M, Fiscus S, Brown ER, et al. Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024. *AIDS*. 2005;19(16):1857-64 PMID: 16227794.

Chibwesa CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, et al. Optimal time on HAART for prevention of mother-to-child transmission of HIV. *J Acquir Immune Defic Syndr*. 2011;58(2):224-8 PMID: 21709566.

Chintu N, Giganti MJ, Putta NB, Sinkala M, Sadoki E, Stringer EM, et al. Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months. *Trop Med Int Health*. 2010;15(7):842-7 PMID: 20487418.

Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, et al. Field efficacy of zidovudine, lamivudine and single-dose

Appendix A4. Excluded Studies List

nevirapine to prevent peripartum HIV transmission. *AIDS*. 2005;19(3):309-18 PMID: 15718842.

Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. *JAMA*. 2002;288(2):189-98 PMID: 12095383.

European Collaborative Study, Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. *Antivir Ther*. 2011;16(6):895-903 PMID: 21900722.

Forsyth BWC, Barringer SR, Walls TA, Landry ML, Ferguson D, Tinghitella TJ, et al. Rapid HIV testing of women in labor: too long a delay. *J Acquir Immune Defic Syndr*. 2004;35(2):151-4 PMID: 14722447.

Galegov GA. Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women [Russian]. *Antibiot Khimioter*. 2009;54(3-4):58-60 PMID: 19711853.

Giaquinto C, Rampon O, De Rossi A. Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine. *Clin Drug Investig*. 2006;26(11):611-27 PMID: 17163296.

Ivanova ES, Shmagel NG, Vorob'eva NN. Nikavir in chemoprevention regimens for vertical HIV infection transmission [Russian]. *Vopr Virusol*. 2010;55(2):31-4 PMID: 20455469.

Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort

study. *Pharmacoepidemiol Drug Saf*. 2009;18(7):589-94 PMID: 19402031.

Kuhn L, Aldrovandi GM, Sinkala M, Kankasa C, Semrau K, Mwiya M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. *N Engl J Med*. 2008;359(2):130-41 PMID: 18525036.

Kuhn L, Sinkala M, Semrau K, Kankasa C, Kasonde P, Mwiya M, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-Infected mothers. *Clin Infect Dis*. 2010;50(3):437-44 PMID: 20047479.

Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened Zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. *N Engl J Med*. 2000;343(14):982-91 PMID: 11018164.

Limpongsanurak S, Thaithumyanon P, Chaithongwongwatthana S, Thisyakorn U, Ruxrungtham K, Kongsin P, et al. Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trial. *J Med Assoc Thai*. 2001;84(Suppl 1):S338-45 PMID: 11529355.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. *HIV Med*. 2006;7(5):338-44 PMID: 16945080.

Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1

Appendix A4. Excluded Studies List

correlates with favorable pregnancy outcomes. *AIDS*. 2011 24;25(13):1611-8 PMID: 21673553.

McIntyre JA, Martinson N, Gray GE, Hopley M, Kimura T, Robinson P, et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. The 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005;Abstract no. TuFo0204 PMID: N/A.

McIntyre JA, Martinson N, Grey GE, Team TI. Single-dose nevirapine combined with a short course of combivir for prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and infant resistant virus. *Antivir Ther*. 2005;10(Suppl 1):S4 PMID: N/A.

Money DM, Khoo D, MacDonald G. A comparison of toxicity in nevirapine vs protease inhibitor-containing HAART regimens in pregnant women. 12th Conference on Retroviruses and Opportunistic Infections. 2005;Abstract 784 PMID: N/A.

Omer SB, Six Week Extended Dose Nevirapine Study T. Twelve-month follow-up of six week extended dose nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count. *AIDS*. 2011;25(6):767-76 PMID: 21330912.

Onen NF, Nurutdinova D, Sungkanuparph S, Gase D, Mondy K, Overton ET. Effect of postpartum HIV treatment discontinuation on long-term maternal outcome. *J Int Assoc Physicians AIDS Care*. 2008;7(5):245-51 PMID: 18812593.

Padua E, Almeida C, Nunes B, Cortes Martins H, Castela J, Neves C, et al. Assessment of mother-to-child HIV-1 and HIV-2 transmission: an AIDS reference laboratory collaborative study. *HIV Med*. 2009;10(3):182-90 PMID: 19207600.

Pilotto JH, Velasque LS, Friedman RK, Moreira RI, Veloso VG, Grinsztejn B, et al. Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil. *Antivir Ther*. 2011;16(3):349-56 PMID: 21555817.

Stringer JS, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, et al. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. *AIDS*. 2003;17(11):1659-65 PMID: 12853748.

Taha TE, Kumwenda N, Gibbons A, Hoover D, Lema V, Fiscus S, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. *AIDS*. 2002;16(6):851-8 PMID: 11919486.

Webber MP, Demas P, Enriquez E, Shanker R, Oleszko W, Beatrice ST, et al. Pilot study of expedited HIV-1 testing of women in labor at an inner-city hospital in New York City. *Am J Perinatol*. 2001;18(1):49-57 PMID: 11321245.

Wrong Outcome

Aaron E, Levine AB, Monahan K, Biondo CP. A rapid HIV testing program for labor and delivery in an inner-city teaching hospital. *AIDS Read*. 2006;16(1):22-4 PMID: 16433470.

Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2007. 2007 PMID: N/A.

Appendix A4. Excluded Studies List

Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al. Adherence to antiretrovirals among US women during and after pregnancy. *J Acquir Immune Defic Syndr.* 2008;48(4):408-17 PMID: 18614923.

Bedikou G, Viho I, Tonwe-Gold B, Coffie JP, Amani-Bosse C, Allou G, et al. 6-month immunological response with HAART containing nevirapine in HIV-infected women post exposure to single doses of nevirapine for PMTCT. The MTCT-PLUS initiative in Abidjan, Côte D'ivoire (2003-2005). 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 2005:Abstract No. MoOa0203 PMID: N/A.

Beitune PE, Duarte G, Foss MC, Montenegro RM, Spara P, Quintana SM, et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. *Diabetes Metab Res Rev.* 2006;22(1):59-63 PMID: 16021650

Bhadrakom C, Simonds RJ, Mei JV, Asavapiriyant S, Sangtaweessin V, Vanprapar N, et al. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. *AIDS.* 2000;14(5):509-16 PMID: 10780713.

Borges-Almeida E, Milanez HM, Vilela MM, Cunha FG, Abramczuk BM, Reis-Alves SC, et al. The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. *BMC Infect Dis.* 2011;11:38 PMID: 21291536.

Bryson Y, Stek A, Mirochnick M, Mofenson L, Connor J, Watts H, et al. Pharmacokinetics, Antiviral Activity, and Safety of Nelfinavir (NFV) with ZDV/3TC in Pregnant HIV-Infected Women and Their Infants: PACTG 353 Cohort 2. 9th Conf

Retrovir Oppor Infect. 2002:abstract no. 795-W PMID: N/A.

Castejon OC, Lopez AJ, Perez Ybarra LM, Castejon OC. Placental villous lesions in HIV-1 infection treated with zidovudine [Spanish]. *Ginecol Obstet Mex.* 2011;79(5):269-79 PMID: 21966815.

Cédric A, Olivier T. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. *Drugs.* 2005;65:633-59 PMID: 15748098.

Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. *Pharmacogenomics.* 2010;11(1):23-31 PMID: 20017669.

Clarke SM, Mulcahy F, Healy CM, Condon S, Butler KM. The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome. *Int J STD AIDS.* 2000;11(4):220-3 PMID: 10772084.

Coovadia A, Marais B, Abrams E, Sherman G, Barry G, Hammer S, et al. Virologic Response to NNRTI Treatment among Women Who Took Single-dose Nevirapine 18 to 36 Months Earlier. 13th Conference on Retroviruses and Opportunistic Infections. 2006 PMID: N/A.

Cunningham CK, Chaix M-L, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. *J Infect Dis.* 2002;186(2):181-8 PMID: 12134253.

Appendix A4. Excluded Studies List

Dabis F, Ekouevi DK, Bequet L, Rouet F, Horo A, Fassinou P, et al. A Short Course of Zidovudine + Peripartum Nevirapine is Highly Efficacious in Preventing Mother-to-Child Transmission of HIV-1: The ANRS 1201 DITRAME-plus Study, Abidjan, Cote d'Ivoire. 10th Conference on Retroviruses and Opportunistic Infections. 2003:Abstract 854 PMID: N/A.

D'Costa G F, Khadke K, Patil YV. Pathology of placenta in HIV infection. *Indian J Pathol Microbiol.* 2007;50(3):515-9 PMID: 17883121.

Ekouevi DK, Touré R, Becquet R, Viho I, Sakarovich C, Rouet F, et al. Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 Study, Abidjan, Ivory Coast. *Pediatrics.* 2006;118(4):e1071-e7 PMID: 16950945.

El Beitune P, Duarte G. Antiretroviral agents during pregnancy: Consequences on hematologic parameters in HIV-exposed, uninfected newborn infant. *Eur J Obstet Gynecol Reprod Biol.* 2006;128:59-63 PMID: 16876310.

El Beitune P, Duarte G, Campbell O, Quintana SM, Rodrigues LC. Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants. *Braz J Infect Dis.* 2007;11(3):314-7 PMID: 17684631.

El-Beitune P, Duarte G, de Morais EN, Campbell O, Spara-Gadelha P, Mauad-Filho F, et al. Antiretroviral agents and acid-base balance at delivery of the neonate. *Braz J Med Biol Res.* 2007;40(7):957-61 PMID: 17653449.

Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, et

al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6–8 weeks after single-dose NVP prophylaxis: HIVNET 012. *AIDS Res Hum Retroviruses.* 2004;20(6):595-9 PMID: 15242535.

Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. *AIDS Rev.* 2002;4(2):59-63 PMID: 12152519.

Feiterna-Sperling C, Weizsaecker K, Buhrer C, Casteleyn S, Loui A, Schmitz T, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. *J Acquir Immune Defic Syndr.*;45(1):43-51 PMID: 17356471.

Fiore S, Thorne C, Newell ML. European participation in an international perinatal trial. *Med Wieku Rozwoj.* 2003;7(4 Pt 1):449-58 PMID: 15010555.

Gingelmaier A, Eberle J, Kost BP, Bogner JR, Hofmann J, Weissenbacher T, et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. *Clin Infect Dis.* 2010;50(6):890-4 PMID: 20166821.

Griner R, Williams PL, Read JS, Seage GR, 3rd, Crain M, Yogev R, et al. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. *AIDS Patient Care STDS.* 2011;25(7):385-94 PMID: 21992592.

Hankin C, Thorne C, Newell ML. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? *J Acquir Immune Defic Syndr.* 2005;40(3):364-70 PMID: 16249713.

Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): the first powered, prospective trial of

Appendix A4. Excluded Studies List

pharmacogenetic screening to reduce drug adverse events. *Pharm Stat*. 2008;7(2):121-9 PMID: 17534855.

Ibieta MF, Cano JM, Amador JT, Gonzalez-Tome MI, Martin SG, Gomez MN, et al. Growth of uninfected infants exposed to antiretrovirals born to HIV-infected woman [Spanish]. *An Pediatr (Barc)*. 2009;71(4):299-309 PMID: 19660998.

Katz IT, Shapiro R, Li D, Govindarajulu U, Thompson B, Watts DH, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. *J Acquir Immune Defic Syndr*. 2010;54(1):27-34 PMID: 20065861.

Keiser O, Gayet-Ageron A, Rudin C, Brinkhof MW, Gremlich E, Wunder D, et al. Antiretroviral treatment during pregnancy. *AIDS*. 2008;22(17):2323-30 PMID: 18981771.

Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, Ghosh M, et al. Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. *J Pediatr*. 2006;149(5):611-6 PMID: 17095329.

Kuhn LP, Trabattoni DB, Kankasa CM, Semrau KM, Kasonde PM, Lissoni FM, et al. [alpha]-Defensins in the prevention of HIV transmission among breastfed infants. *J Acquir Immune Defic Syndr*. 2005;39(2):138-42 PMID: 15905728.

Kully C, Yerly S, Erb P, Kind C, Krauthaim A, Perrin L, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. *J Infect Dis*. 1999;179(3):705-8 PMID: 9952382.

Lahoz R, Noguera A, Rovira N, Catala A, Sanchez E, Jimenez R, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. *Pediatr Infect Dis J*. 2010;29(4):376-9 PMID: 19949355.

Lallemant M, Jourdain G, Le Coeur S, Mary JY, McIntosh K, Ngo-Giang Huong N, et al. Multicenter, randomized RCT, assessing the safety and efficacy of nevirapine in addition to zidovudine for the prevention of prenatal HIV in Thailand: PHPT-2 update. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. 2003:Abstract 62 PMID: N/A.

Lallemant M, Ngo-Giang-Huong N, Jourdain G, Traisaitit P, Cressey TR, Collins IJ, et al. Efficacy and safety of one-month postpartum zidovudine and didanosine to prevent HIV-resistance mutations following intrapartum single-dose nevirapine. *Clin Infect Dis*. 2010;50(6):898-908 PMID: 20158398.

Lehman DA, Chung MH, Mabuka JM, John-Stewart GC, Kiarie J, Kinuthia J, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. *J Acquir Immune Defic Syndr*. 2009;51(5):522-9 PMID: 19502990.

Lehtovirta P, Skogberg K, Salo E, Ammala P, Ristola M, Suni J, et al. Pregnancy outcome among HIV-infected women in the Helsinki metropolitan area. *Acta Obstet Gynecol Scand*. 2005;84(10):945-50 PMID: 16167909.

Livingston EG, Cohn SE, Yang Y, Watts HD, Bardeguez AD, Jones TB, et al. Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy. *Obstet*

Appendix A4. Excluded Studies List

Gynecol. 2007;110(2, Part 1):391-7 PMID: 17666616.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. *N Engl J Med.* 2010 363(16):1499-509 PMID: 20942666.

Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. *N Engl J Med.* 2007;356(2):135-47 PMID: 17215531.

Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. *AIDS.* 2005;19(1):63-7 PMID: 15627034.

Magder LS, Mofenson L, Paul ME, Zorrilla CD, Blattner WA, Tuomala RE, et al. Risk factors for in utero and intrapartum transmission of HIV. *J Acquir Immune Defic Syndr.* 2005;38(1):87-95 PMID: 15608531.

Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. *Eur J Obstet Gynecol Reprod Biol.* 2011;157(1):18-21 PMID: 21492993.

Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. *J Acquir Immune Defic Syndr.* 2004;35(5):492-502 PMID: 15021314.

Martin F, Navaratne L, Khan W, Sarner L, Mercey D, Anderson J, et al. Pregnant women with HIV infection can expect

healthy survival: three-year follow-up. *J Acquir Immune Defic Syndr.* 2006;43(2):186-92 PMID: 16940856.

Martinson NA, Ekouevi DK, Dabis F, Morris L, Lupodwana P, Tonwe-Gold B, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. *J Acquir Immune Defic Syndr.* 2007 ;45(2):206-9 PMID: 17438480.

Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, Ledwaba J, et al. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. *AIDS.* 2009 ;23(7):809-16 PMID: 19287298.

Mbori-Ngacha D, Nduati R, John G, Reilly M, Richardson B, Mwatha A, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women. *JAMA.* 2001;286(19):2413-20 PMID: 11712936.

McConnell M, Bakaki P, Eure C, Mubiru M, Bagenda D, Downing R, et al. Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. *J Acquir Immune Defic Syndr.* 2007;46(3):291-6 PMID: 18167645.

Minkoff H, Ahdieh L, Watts H, Greenblatt RM, Schmidt J, Schneider M, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. *Am J Obstet Gynecol.* 2001;184(6):1221-7 PMID: 11349192.

Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association

Appendix A4. Excluded Studies List

with timing of maternal intrapartum nevirapine dose. *J Acquir Immune Defic Syndr*. 2003;33(2):153-6 PMID: 12794547.

Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. *Pediatr Infect Dis J*. 2002;21(9):835-8 PMID: 12352805.

Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandia J, Hitti J, et al. Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. *HIV Med*. 2007;8(7):451-6 PMID: 17760737.

Mmiro FA, Aizire J, Mwatha AK, Eshleman SH, Donnell D, Fowler MG, et al. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. *J Acquir Immune Defic Syndr*. 2009;52(1):32-9 PMID: 19617849.

Nachman SA, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage GR 3rd, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. *Arch Pediatr Adolesc Med*. 2009;163(2):164-71 PMID: 19188649.

Nasi M, Pinti M, Chiesa E, Fiore S, Manzini S, Del Giovane C, et al. Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery. *Antivir Ther*. 2011;16(3):365-72 PMID: 21555819.

Noguera A, Fortuny C, Munoz-Almagro C, Sanchez E, Vilaseca MA, Artuch R, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants

who are exposed to antiretrovirals. *Pediatrics*. 2004;114(5) PMID: 15492359.

Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. *Ann Pharmacother*. 2008;42(11):1581-5 PMID: 18957630.

Nyandiko WM, Otieno-Nyunya B, Musick B, Bucher-Yiannoutsos S, Akhaabi P, Lane K, et al. Outcomes of HIV-exposed children in western Kenya: efficacy of prevention of mother to child transmission in a resource-constrained setting. *J Acquir Immune Defic Syndr*. 2010;54(1):42-50 PMID: 20224420.

Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangelaviraj S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. *HIV Med*. 2007;8(6):357-66 PMID: 17661843.

Phanuphak N, Teeratakulpisarn S, Apornpong T, Phanuphak P, et al. Comparison of hepatic and cutaneous toxicities in pregnant women with baseline CD4 ≤ 250 cells/mm³ versus those with CD4 > 250 cells/mm³ receiving nevirapine (NVP)-containing highly active anti-retroviral therapy (HAART) for the prevention of mother-to-child transmission (PMTCT) in Thailand. Seventh International Congress on Drug Therapy in HIV Infection. 2004:P322 PMID: N/A.

Pinnetti C, Baroncelli S, Molinari A, Nardini G, Genovese O, Ricerca BM, et al. Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimens. *J Infect*. 2011;63(2):144-50 PMID: 21683094.

Pornprasert S, Faye A, Mary JY, Dolcini G, Leechanachai P, Chaouat G, et al. Down

Appendix A4. Excluded Studies List

modulation of TNF-alpha mRNA placental expression by AZT used for the prevention of HIV-1 mother-to-child transmission. *Placenta*. 2006;27(9-10):989-95 PMID: 16359728.

Rahangdale L, Sarnquist C, Maldonado Y, Cohan D. Patient acceptance of and satisfaction with rapid HIV testing in a labor and delivery setting. *J Womens Health (Larchmt)*. 2008;17(3):465-71 PMID: 18373491.

Rajegowda BK, Das BB, Lala R, Rao S, Mc Neeley DF. Expedited human immunodeficiency virus testing of mothers and new-borns with unknown HIV status at time of labor and delivery. *J Perinat Med*. 2000;28(6):458-63 PMID: 11155432.

Raymond EG, Taylor D, Cates W Jr, Tolley EE, Borasky D, CANCEL A, et al. Pregnancy in effectiveness trials of HIV prevention agents. *Sex Transm Infect*. 2007;34(12):1035-9 PMID: 17621249.

Schlosser R, Linde R, Dunsch D, Reitter A, Haberl A, Bauer K. Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants [German]. *Z Geburtshilfe Neonatol*. 2007;211(6):230-5 PMID: 18176903.

Solis Villamarzo I, Munoz Galligo E, Ramos Amador JT, Gonzalez Tome MI, Rojano Luque X, Almeda Ortega J, et al. Maternal characteristics of a cohort of pregnant women with HIV-1 infection [Spanish]. *Med Clin (Barc)*. 2006;127(4):121-5 PMID: 16831391.

Stuart GS, Castano PM, Sheffield JS, McElwee B, McIntire DD, Wendel GD. Postpartum sterilization choices made by HIV-infected women. *Infect Dis Obstet Gynecol*. 2005;13(4):217-22 PMID: 1784575.

Study EC, Newell ML, Dunn D, Peckham CS, Ades AE, Pardi G, et al. Risk factors for mother-to-child transmission of HIV-1. *Lancet*. 1992;339(8800):1007 PMID: 1349050.

Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME. Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects [Dutch]. *Ned Tijdschr Geneesk*. 2004;148(41):2021-5 PMID: 15553999.

Tepper NK, Farr SL, Danner SP, Maupin R, Nesheim SR, Cohen MH, et al. Rapid human immunodeficiency virus testing in obstetric outpatient settings: the MIRIAD study. *Am J Obstet Gynecol*. 2009;201(1) PMID: 19398094.

Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, et al. Nelfinavir and nevirapine side effects during pregnancy. *AIDS*. 2005;19(8):795-9 PMID: 15867493.

van der Lugt J, Autar S, Ubolyam S, Cooper D, Lamge J, Phanuphak P, et al. Pharmacokinetics and Pharmacodynamics of Double Boosted PI Regimen of Saquinavir and Lopinavir/Ritonavir in Treatment Naive HIV-1 Infected Adults. 14th Conference on Retroviruses and Opportunistic Infections. 2007:Abstract 578 PMID: N/A.

Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. *J Infect Dis*. 2004;190(12):2167-74 PMID: 15551216.

Wagner TA, Kress CM, Beck I, Techapornroong M, Wittayapraparat P, Tansuphasawasdikul S, et al. Detection of

Appendix A4. Excluded Studies List

HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. *J Clin Microbiol.* 2010;48(5):1555-61 PMID: 20181911.

Walter J, Kuhn L, Kankasa C, Semrau K, Sinkala M, Thea DM, et al. Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. *BMC Infect Dis.* 2008;8(172) PMID: 19116004.

Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, Livingston E, et al. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. *Environ Mol Mutagen.* 2007;48(3-4):322-9 PMID: 17358032.

Yang SC, Lu CY, Lee CY, Hung CC, Chen MY, Chuang CY, et al. Clinical course of children of human immunodeficiency virus-infected mothers in Taiwan. *J Microbiol Immunol Infect.* 2004;37(4):225-30 PMID: 15340650.

Zorrilla C, Van Dyke R, Bardeguet A. Clinical Response, Safety and Tolerability of Saquinavir-SGC With Low Dose Ritonavir Boosting in Combination With Zidovudine and Lamibudine in HIV-Infected Pregnant Women: Preliminary Results of PACTG 386. 10th Conference on Retroviruses and Opportunistic Infections. 2003 PMID: N/A.

Wrong Study Design for Key Question

Arrive E, Dabis F, Newell ML. Frequency of nevirapine resistance (NVPR) after single dose nevirapine (SD-NVP) use to prevent HIV-1 vertical transmission: a meta-

analysis. Proceedings of the 3rd IAS Conference. 2005:Abstract TuPe5.2P15 PMID: N/A.

Brindley NM. Antiretroviral agents mimicking functional neonatal bowel obstruction: a case report. *Eur J Pediatr Surg.* 2006;16(4):276-8 PMID: 16981095.

Chi BH, Sinkala M, Levy J. Maternal immune response and clinical outcomes on NNRTI-based antiretroviral therapy (ART) following exposure to single dose nevirapine (NVP) for prevention of mother to child transmission (PMTCT). XVI International AIDS Conference. 2006:Abstract WEAB0104 PMID: N/A.

Coulter-Smith S, Lambert JS, Butler K, Brennan M, Cafferkey M. HIV testing and treatment in the antenatal care setting. *Ir Med J.* 2010;103(1):14-7 PMID: 20222387.

De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional exposure to efavirenz and neural tube defects. *Arch Intern Med.* 2002;162(3):355- PMID: 11822930.

Force PH. Safety and toxicity of individual antiretroviral agents in pregnancy. 2010 PMID: N/A.

Fregonese F, Maleesatharn A, Ratanakosol J, Yuthavisuthi P, Ariyadej S, Chalermpanmetagul S, et al. Six months follow up of highly active antiretroviral therapy (HAART) initiated during pregnancy in Thailand. International Conference on AIDS. 2004:Abstract no. ThPeB7088 PMID: N/A.

Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV

Appendix A4. Excluded Studies List

resistance. *AIDS*. 2009;23(3):434-5 PMID: 19188762.

Ghosn J, De Montgolfier I, Cornelie C, Dominguez S, Perot C, Peytavin G, et al. Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy. *Antimicrob Agents Chemother*. 2008;52(4):1542-4 PMID: 18250187.

Gonzalez-Tome MI, Ramos J, Solis I, Muñoz E, Guillen S, Almeda J, et al. Gestational Diabetes and ART in Pregnant HIV-1 Infected Women. 12th Conference on Retroviruses and Opportunistic Infections. 2005:Abstract 68 PMID: N/A.

Hankin C, Lyall H, Willey B, Peckham C, Masters J, Tookey P. In utero exposure to antiretroviral therapy: feasibility of long-term follow-up. *AIDS Care*. 2009;21(7):809-16 PMID: 19504373.

Hill JB, Sheffield JS, Zeeman GG, Wendel GDJ. Hepatotoxicity with antiretroviral treatment of pregnant women. *Obstet Gynecol*. 2001;98(5, Part 2):909-11 PMID: 11704198.

Hillis SD, Rakhmanova A, Vinogradova E, Voronin E, Yakovlev A, Khaldeeva N, et al. Rapid HIV testing, pregnancy, antiretroviral prophylaxis and infant abandonment in St Petersburg. *Int J STD AIDS*. 2007;18(2):120-2 PMID: 17331286.

Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. *Antivir Ther*. 2010;15(4):677-80 PMID: 20587860.

Kassis N, Heard A, Sprawka N, Cu-Uvin S, Anderson B. Antiretroviral-induced

hepatotoxicity presenting as nonreassuring fetal testing. *Obstet Gynecol*. 2010;2:515-7 PMID: 20664438.

Kramer F, Stek A, Du WB, Kovacs A. Nevirapine Tolerability in HIV-infected Women in Pregnancy. *Conf Retrovir Oppor Infect*. 2004;11(Abtract # 923) PMID: N/A.

Lopriore E, Rozendaal L, Gelinck LB, Bokenkamp R, Boelen CC, Walther FJ. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. *AIDS*. 2007;21(18):2564-5 PMID: 18025905.

Loubeyre-Unique C, Gautier A, Vauzelle-Gardier C, Champart AM, Bavoux F. Antiretroviral agents and pregnancy: mitochondrial dysfunction and nucleoside analogs [French]. *Therapie* 2001;56(3):261-6 PMID: 11475805.

Martinson N, Morris L, Gray G, Moodley D, Lupondwana P, Chezzi C, et al. HIV Resistance and Transmission Following Single-Dose Nevirapine in a PMTCT Cohort. 11th Conference on Retroviruses and Opportunistic Infections. 2004;abstract no. 38. PMID: N/A.

Myers SA, Torrente S, Hinthorn D, Clark PL. Life-threatening maternal and fetal macrocytic anemia from antiretroviral therapy. *Obstet Gynecol*. 2005;106(5 Pt 2):1189-91 PMID: 16260567.

Namukwaya Z, Mudiope P, Kekitiinwa A, Musoke P, Matovu J, Kayma S, et al. The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago National Referral Hospital in Kampala, Uganda, January 2007 to May 2009. *J Acquir Immune Defic Syndr*. 2011;56(1):69-75 PMID: 21099692

Appendix A4. Excluded Studies List

Overton ET, Sungkanuparph S, Nurutdinova D, Powderly WG. Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. *AIDS*. 2005;19(13):1439-40 PMID: 16103781.

Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, et al. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. *The J Infect Dis*. 2009;200(10):1490-7 PMID: 19832114.

Theron G, Nellensteijn M, Theron A, Louw J. HIV transmission from mother to child--HAART compared with dual therapy. *S Afr Med J* 2009;99(10) PMID: 20128268.

Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial. *PLoS Med*. 2011;8(3):e1001015 PMID: 21468300.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. *PLoS Med*. 2007;4(8) PMID: 17713983.

Tovo PA, Chiapello N, Gabiano C, Zeviani M, Spada M. Zidovudine administration during pregnancy and mitochondrial disease in the offspring. *Antivir Ther*. 2005;10(6):697-9 PMID: 16218167.

Velinov M, Dolzhanskaya N, Mendez H. Mitochondrial T9098C sequence change in the MTATP6 gene and development of severe mitochondrial disease after in utero antiretroviral prophylaxis. *Pharmacotherapy*. 2009;29(12) PMID: 19947808.

Wensing AM, Boucher CA, van Kasteren M, van Dijken PJ, Geelen SP, Juttmann JR. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. *AIDS*. 2006;20(10):1465-7 PMID: 16791028.

No Original Data

Mother-to-child transmission of HIV infection and its prevention. *Curr HIV Res*. 2003;1:447-62 PMID: 15049430.

Abarzua F, Hubinont C, Yombi JC, Bernard P, Debieve F, Goubau P, et al. Highly Active Antiretroviral Therapy (HAART) in Pregnant HIV-Infected Women. Efficacy and Safety for the Mothers and Infants. 9th European AIDS Conference (EACS). 2003:Abstract 14.2/1 PMID: N/A.

Abarzua F, Nunez F, Hubinont C, Bernard P, Yombi JC, Vandercam B. Human immunodeficiency virus (HIV) infection in pregnancy: antiretroviral treatment (ART) and mode of delivery [Spanish]. *Rev Chilena Infectol*. 2005;22(4):327-37 PMID: 16341354.

Ammann AJ. Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies. *J Acquir Immune Defic Syndr*. 2009;51(5):509-12 PMID: 19521253

Anastos K. Good news for women living with HIV. *J Infect Dis*. 2007;196(7):971-3 PMID: 17763315

Anderson JR. XV International AIDS Conference: women and HIV in the spotlight. *Hopkins HIV Rep*. 2004;16(5):7-9 PMID: 15529456.

Anderson JR. HIV and pregnancy at the 12 CROI. *Hopkins HIV Rep*. 2005;17(2):6-7, 9 PMID: 16419317

Appendix A4. Excluded Studies List

- Anderson JR. 3rd IAS Conference: pregnancy issues. *Hopkins HIV Rep.* 2005;17(5):6-7 PMID: 16419302.
- Anonymous. Who publishes new guidelines on preventing mother to child transmission of HIV. *Cent Eur J Public Health.* 2004;12(4):223 PMID: 15672499
- Anonymous. Preventing mother to child transmission of HIV. *J Adv Nurs.* 2004;48(4) PMID: 15543657.
- Anonymous. Testing: no damages for woman, baby over false-positive HIV test. *AIDS Policy Law.* 2007 7;22(17):8 PMID: 18228625
- Anonymous. Treatment: study findings show HAART drugs benefit pregnant women. *AIDS Policy & Law.* 2007;22(19):2 PMID: 18210649.
- Anonymous. Treatment: study could revolutionize HIV policies for pregnant women. *AIDS Policy Law.* 2007;22(19):2 PMID: 18203398
- Anonymous. Birth defect rates unchanged by antiretrovirals. *AIDS Patient Care STDS.* 2007;21(6) PMID: 17594253
- Bateman C. Finally--PMTCT dual therapy. *S Afr Med J.* 2008;98(3) PMID: 18350215
- Baylor M, Truffa M, Gibbs N. Hepatic Toxicity of Antiretrovirals in HIV-infected Pregnant Women: A Review of the FDA's Adverse Event Reporting System. *Conf Retrovir Oppor Infect* 2004;11th (no. 944) PMID: N/A.
- Becquet R, Ekouevi DK. Breastfeeding, triple ARV prophylaxis, and MTCT prevention. *Lancet Infect Dis.* 2011;11(3):154-5 PMID: 21237717.
- Bersoff-Matcha SJ, Rourke D, Blank J. Evaluation of the safety of nevirapine therapy during pregnancy. *J Acquir Immune Defic Syndr.* 2010 15;54(5):560-2 PMID: 20647826
- Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. *AIDS.* 1998;12(14):1735-44 PMID: 9792373.
- Brogly S, Williams P, Seage GR, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the Pediatric AIDS Clinical Trials Group 219 and 219C cohorts. *J Acquir Immune Defic Syndr.* 2006;41(4):535-6 PMID: 16652068.
- Buchholz B, Beichert M, Marcus U, Grubert T, Gingelmaier A, Haberl A, et al. German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. *Eur J Med Res.* 2009;14(11):461-79 PMID: 19948442.
- Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. *Semin Fetal Neonatal Med.* 2005;10(2):161-75 PMID: 15701581.
- Carosi G, Nasta P, Fiore S, Matteelli A, Cauda R, Ferrazzi E, et al. Women facing HIV: key question on women with HIV infection: Italian consensus workshop. *Infection.* 2009;37(2):168-78 PMID: 19308320.
- Catherine M W. Perinatal HIV transmission--a global problem: controversy and protection of the next generation. *Semin Pediatr Infect Dis.* 1998;9(4):339-44 PMID: N/A.
- Centers for Disease Control and Prevention. Rapid HIV antibody testing during labor and delivery for women of unknown HIV status. 2004 Available at:

Appendix A4. Excluded Studies List

http://www.cdc.gov/hiv/rapid_testing/materials/Labor&DeliveryRapidTesting.pdf.
PMID: N/A

Clayden P. Pregnancy outcomes in the DART trial. *GMHC Treat Issues*. 2006;20(8-12):14-5 PMID: 17569165.

Coll O, Suy A, Martinez E, Lonca M, Lazzari E, Pisa S, et al. Increased Risk of Pre-eclampsia and Fetal Death in HIV-infected Pregnant Women Receiving Highly Active Antiretroviral Therapy. 11th Conference on Retroviruses and Opportunistic Infections. 2004:Abstract 921 PMID: 16327320.

Cooper E. HIVNET 012 and Petra. *Lancet*. 2004;363(9404):245-6 PMID: 14738806.

Coovadia H. Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS. *N Engl J Med*. 2004 15;351(3):289-92 PMID: 15247337.

Cossarizza A, Moyle Ga. Antiretroviral nucleoside and nucleotide analogues and mitochondria. *AIDS*. 2004;18(2):137-51 PMID: 15075530.

Delva W, Temmerman M. The efficacy-effectiveness gap in PMTCT. *S Afr Med J*. 2004;94(10) PMID: 15532743.

Dunable D. News from the 11th conference on retroviruses and opportunistic infections. *Surviv News (Atlanta Ga)*. 2004;15(2):9-10 PMID: 15124572.

El Beitune P, Duarte G, Quintana SM, Figueiro-Filho EA, Marcolin AC, Abduch R. Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children. *Braz J Infect Dis*. 2004;8(2):140-50 PMID: 15361992.

Fellay J, Cavassini M. HIV-AIDS: answers to new questions [French]. *Rev Med Suisse*. 2006;2(60):912-7 PMID: 16673722.

Fernandez AD, McNeeley DF. Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts. *Am J Perinatol*. 2000;17(08):429-36 PMID: 11142394.

Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. *AIDS*. 2011 25(18):2301-4 PMID: 21918421.

Foster C, Lyall H. HIV and mitochondrial toxicity in children. *J Antimicrob Chemother*. 2008;61(1):8-12 PMID: 17999978.

Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? *HIV Med*. 2009;10(7):397-406 PMID: 19459986.

Foster CJ, Lyall EG. HIV in pregnancy: evolution of clinical practice in the UK. *Int J STD AIDS*. 2006;17(10):660-7 PMID: 17059634.

Fowler MG. Prevention of perinatal HIV infection: what do we know? Where should future research go? *Ann N Y Acad Sci*. 2000;918:45-52 PMID: 11131733.

Funk MJ, Belinson SE, Pimenta JM, Morsheimer M, Gibbons DC. Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy. *Drug Saf*. 2007;30(10):1-12 PMID: 17867723.

Goldschmidt RH, Fogler JA. Opportunities to prevent HIV transmission to newborns. *Pediatrics*. 2006;117(1):208-9 PMID: 16396878.

Appendix A4. Excluded Studies List

- Goldschmidt RH, Poage RE. Preventing HIV--a primary care imperative. *Am Fam Physician*. 2004 70(2):15 PMID: 15291083.
- Gonzalez Garcia A, Fernandez MI, Cotter AM. Nevirapine toxicity in the obstetrical population when used in combination with other antiretrovirals. 15th International AIDS conference. 2007:Abstract WePeB5918 PMID: N/A.
- Hankin C, Lyall H, Peckham C, Tookey P. Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. *AIDS*. 2007;21(7):867-9 PMID: 17415042.
- Harris C. Testing pregnant patients. *N J Med*. 1998;95(3) PMID: 16013140.
- Hudson CP. HIVNET 012 and Petra. *Lancet*. 2004;363(9404):17 PMID: 14738804.
- Hudson CP. Zidovudine monotherapy and the prevention of mother-to-child HIV-1 transmission. *Lancet Infect Dis*. 2005;5(2) PMID: 15680770.
- Hughes V. Extra drugs and slower weaning lowers HIV risk for newborns. *Nat Med*. 2008;14(7) PMID: 18607354.
- Jackson B, Mmiro F, HIVNET 102 Study Team. HIVNET 012 and Petra. *Lancet*. 2004 363(9404):245-6 PMID: 14738808.
- Jourdain G, Ngo-Giang-Huong N, Tungyai P, Kummee A, Bowonwatanuwong C, Kantipong P, et al. Exposure to Intrapartum Single-dose Nevirapine and Subsequent Maternal 6-Month Response to NNRTI-based Regimens. 11th Conference on Retroviruses and Opportunistic Infections. 2004:Abstract 41LB PMID: N/A.
- Karakousis PC, Page KR, Bishai WR. From the Infectious Diseases Society of America (IDSA) meeting--important new findings in HIV treatment and pathogenesis, 2003. *Hopkins HIV Rep*. 2004;16(1):2-3 PMID: 14989191.
- Katzenstein TL, Gerstoft J. Zidovudine monotherapy in pregnancy: is it state of the art? *HIV Med*. 2008;9(7):445-7 PMID: 18840149.
- Koenig LJ, Nesheim S, Abramowitz S. Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors. *Curr Opin Obstet Gynecol*. 2011;23(5):321-7 PMID: 21836510.
- Kourtis AP, Fowler MG. Antiretroviral use during pregnancy and risk of preterm delivery: more questions than answers. *J Infect Dis*. 2011 ;204(4):493-4 PMID: 21791648.
- Kreitchmann R, Cinti I, Gomes da Silva MM, Barcelos N, Fuchs SC. Discussing the effectiveness of short-term zidovudine prophylaxis on detection of HIV-1 subtype E in human placenta and vertical transmission. *J Acquir Immune Defic Syndr*. 2006 15;42(5):649-50 PMID: 16837870.
- Kresge KJ. Women and HIV: women's research roundup. *BETA*. 2005;17(4):30-3 PMID: 16124120.
- Kriebs JM. Changing the paradigm: HIV in pregnancy. *J Perinat Neonatal Nurs*. 2006;20(1):71-3 PMID: 16508466.
- Lallemant M, Jourdain G. Preventing mother-to-child transmission of HIV--protecting this generation and the next. *N Engl J Med*. 2010;363(16):1570-2 PMID: 20942674
- Lane HC, Folkers GK, Fauci AS. Reports on nevirapine threaten public health. *Nat Med*. 2005;11(3) PMID: 15746930.

Appendix A4. Excluded Studies List

Laurence J. Fighting a flexible virus with flexible drugs. *AIDS Read.* 2004;14(7):345-6 PMID: 15281169.

Lavigne JE, Shearer WT, Thompson B, Orav EJ, Starc TJ, Colan SD, et al. Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study. *Cardiovasc Toxicol.* 2004;4(2):187-97 PMID: 15371634.

Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. *Nat Med.* 1995;1(5):417-22 PMID: 7585087.

Mascolini M. Prevention, planning, resistance, toxicity. IAPAC sessions--USA. May 20-21, 2004, Chicago. IAPAC Mon. 2004;10(6):196-215 PMID: 15484372.

Mascolini M, Kort R. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice--biomedical prevention. *J Int AIDS Soc.* 2010;13(1) PMID: 20519025.

McConnell MS, Stringer JS, Kourtis AP, Weidle PJ, Eshleman SH. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? *Am J Obstet Gynecol.* 2007;197(3 Suppl) PMID: 17825651.

McIntosh K. Mitochondrial toxicity of perinatally administered zidovudine. *Conf Retrovir Oppor Infect.* 2000;7th PMID: 11712936.

McIntyre J. Prevention of mother-to-child transmission of HIV: treatment options. *Expert Rev Anti Infect Ther.* 2005;3(6):971-80 PMID: 16307509.

McIntyre J. Strategies to prevent mother-to-child transmission of HIV. *Curr Opin Infect Dis.* 2006;19(1):33-8 PMID: 16374215.

McIntyre JA. Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. *Expert Opin Pharmacother.* 2006;7(6):677-85 PMID: 16556085.

Morris L, Martinson N, Pillay C. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. 15th International AIDS Conference. 2004 PMID: N/A.

Musoke P. Recent advances in prevention of mother to child (PMTCT) of HIV. *Afr Health Sci.* 2004;4(3):144-5 PMID: 15687065.

Myer L. Initiating antiretroviral therapy in pregnancy: the importance of timing. *J Acquir Immune Defic Syndr.* 2011 58(2):125-6 PMID: 21799436.

Nagy GS. Report from the 12th Retrovirus Conference. Perinatal transmission. *AIDS Clin Care.* 2005;17(4):41-2 PMID: 15884152.

Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. *Antivir Ther.* 2004;9:849-63 PMID: 15651744.

Oleske JM. Long-term outcomes in infants born to HIV-infected women. *J Acquir Immune Defic Syndr.* 2003;32(4):353 PMID: 12640190.

World Health Organization. New data on the prevention of mother-to-child transmission of HIV and their policy implications: conclusions and recommendations. 2001 PMID: N/A

Appendix A4. Excluded Studies List

Orio M, Pena JM, Rives MT, Sanz M, Bates I, Madero R, et al. Changes in vertical HIV transmission: comparison between 1994 and 2004 [Spanish]. *Med Clin (Barc)*. 2007;128(9):321-4 PMID: 17376357.

Patel AK, Patel KK, Sharma R, Ranjan RR, Shukla RK, Patel JA. Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India. *J Acquir Immune Defic Syndr*. 2009;50(2):231-3 PMID: 19155769.

Rahangdale L, Sarnquist C, Feakins C, Nassos P, Haller B, Cohan D. Rapid HIV testing on labor and delivery: lessons from the field. *J Acquir Immune Defic Syndr*. 2007;46(3):376-8 PMID: 18090304.

Rakhmanina NY, van den Anker JN, Soldin SJ. Safety and pharmacokinetics of antiretroviral therapy during pregnancy. *Ther Drug Monit*. 2004;26(2):110-5 PMID: 15228149.

Sabin M, Lo YR. Progress in providing HIV testing and counseling in health facilities: WHO/UNAIDS guidance. *JAMA*. 2010;304(3):342-3 PMID: 20639569.

Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. *AIDS Rev*. 2011;13(4):198-213 PMID: 21975356.

Shapiro RL, Ribaud H, Powis K, Chen J, Parekh N. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. *AIDS*. 2012;26(1):120-1. PMID: 22126816

Smith CB, Battin MP, Francis LP, Jacobson JA. Should rapid tests for HIV infection now

be mandatory during pregnancy? Global differences in scarcity and a dilemma of technological advance. *Dev World Bioeth*. 2007;7(2):86-103 PMID: 17614994.

Smith DM. The controversies of nevirapine for preventing mother-to-child HIV transmission. *AIDS*. 2006;20(2):281-3 PMID: 16511423.

Stek AM. Antiretroviral medications during pregnancy for therapy or prophylaxis. *Curr HIV/AIDS Rep*. 2009;6(2):68-76 PMID: 19358777.

Study EC. Pregnancy-related changes in the longer-term management of HIV-infected women in Europe. *Euro J Obstet Gynecol Reprod Biol*. 2003;111(1):3-8 PMID: 14557003.

Sturt AS, Read JS. Antiretroviral use during pregnancy for treatment or prophylaxis. *Expert Opin Pharmacother*. 2011;12(12):1875-85 PMID: 21534886.

Surjushe A, Maniar J. Prevention of mother-to-child transmission. *Indian J Dermatol Venereol Leprol*. 2008;74(3):200-7 PMID: 18583783.

Talaie H, Nava-Ocampo AA, Koren G. Antiretroviral treatment of maternal HIV infection. *Can Fam Physician*. 2004;50:865-8 PMID: 15233367.

Tardieu M. The risk of very long-term brain dysfunction in treated adolescents with perinatally acquired HIV-1 infection. *AIDS*. 2009;23(14):1891-2 PMID: 19574881.

The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. *J Acquir Immune*

Appendix A4. Excluded Studies List

Defic Syndr. 2000;25(3):261-8 PMID: 11115957.

Thorne C, Newell ML. Prevention of mother-to-child transmission of HIV infection. *Curr Opin Infect Dis*. 2004;17(3):247-52 PMID: 15166829.

Thorne C, Newell ML. Treatment options for the prevention of mother-to-child transmission of HIV. *Curr Opin Investig Drugs*. 2005;6(8):804-11 PMID: 16121687.

Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? *Drug Saf*. 2007;30(3):203-13 PMID: 17343429.

Townsend CL, Tookey PA, Cortina-Borja M, Peckham CS. Antiretroviral therapy and congenital abnormalities in infants born to HIV-1-infected women in the United Kingdom and Ireland, 1990 to 2003. *J Acquir Immune Defic Syndr*. 2006;42(1):91-4 PMID: 16763496.

Venhoff N, Walker UA. Mitochondrial disease in the offspring as a result of antiretroviral therapy. *Expert Opin Drug Saf*. 2006;5(3):373-81 PMID: 16610967.

Vigano A, Cerini C, Pattarino G, Fasan S, Zuccotti GV. Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients. *Expert Opin Drug Saf*. 2010;9(3):431-45 PMID: 20078250.

Volmink J. HIV: mother to child transmission. *Clin Evid*. 2003;9:785-94 PMID: 12967392.

Volmink J. HIV: mother to child transmission. *Clin Evid*. 2004;11:902-12 PMID: 15652045.

Waters L, John L, Nelson M. Non-nucleoside reverse transcriptase inhibitors: a

review. *Int J Clin Pract*. 2007;61(1):105-18 PMID: 17229185.

Watts DH. Treating HIV during pregnancy: an update on safety issues. *Drug Saf*. 2006;29(6):467-90 PMID: 16752931.

Wilfert CM. Perinatal HIV transmission--a global problem: controversy and protection of the next generation. *Semin Pediatr Infect Dis*. 1998;9(4):339-44 PMID: N/A.

Wunder D, Evison JM. Antiretroviral therapy and pregnancy [German]. *Ther Umsch*. 2005;62(1):37-42 PMID: 15702705.

Zijenah L, Kadzirange G, Rusakaniko S, Kupfa T, Tobaiwa O, Moyo S, et al. Community-based generic antiretroviral therapy following single-dose nevirapine or short-course AZT in Zimbabwe. 12th Conference on Retroviruses and Opportunistic Infections. 2005:abstract 632 PMID: N/A.

Out of Scope

Barker PM, Mphatswe W, Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems' performance on mother-to-child transmission of HIV. *J Acquir Immune Defic Syndr*. 2011;56(2):e45-8 PMID: 21084998.

Ciaranello AL, Seage GR 3rd, Freedberg KA, Weinstein MC, Lockman S, Walensky RP. Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. *AIDS*. 2009;23(17):2359-69 PMID: 18981776.

Dennis RL, Negron TJ, Lindsay M, Nesheim SR, Lee FK, Jamieson DJ. Rapid human immunodeficiency virus testing in labor and delivery: a comparison of implementation models between 2 hospitals.

Appendix A4. Excluded Studies List

J Perinat Neonatal Nurs. 2007;21(4):298-306 PMID: 18004167.

Koulinska IN, Villamor E, Chaplin B, Msamanga G, Fawzi W, Renjifo B, et al. Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr. 2006;41(1):93-9 PMID: 16340480.

Newell ML, Borja MC, Peckham C; European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111(1):e52-e60 PMID: 12509595.

Palumbo P, Holland B, Dobbs T, Pau CP, Luo CC, Abrams EJ, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis. 2001;184(9):1120-6 PMID: 11598834.

Patterson KB, Leone PA, Fiscus SA, Kuruc J, McCoy SI, Wolf L, et al. Frequent detection of acute HIV infection in pregnant women. AIDS. 2007;21(17):2303-8 PMID: 18090278.

Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. BJOG. 2008;115(9):1078-86 PMID: 18503577.

Townsend CL, Tookey PA, Newell ML, Cortina-Borja M. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission. Antivir Ther. 2010;15(5):775-83 PMID: 20710059.

Udeh B, Udeh C, Graves N. Perinatal HIV transmission and the cost-effectiveness of

screening at 14 weeks gestation, at the onset of labour and the rapid testing of infants. BMC Infect Dis. 2008;8(174) PMID: 19117527.

Sample Size Too Small

Brogly SB, DiMauro S, Van Dyke RB, Williams PL, Naini A, Libutti DE, et al. Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. AIDS Res Hum Retroviruses. 2011;27(7):777-83 PMID: 21142587.

Giaquinto C, De Romeo A, Giacomet V, Rampon O, Ruga E, Burlina A, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS. 2001;15(8):1074-5 PMID: 11399997.

Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS. 1998;12(18):F241-F7 PMID: 9875571.

Martin AM, Hammond E, Nolan D, Pace C, Den Boer M, Taylor L, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet. 2003;72(3):549-60 PMID: 12587093.

Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinti M, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr. 2003;32(4):370-4 PMID: 12640193.

Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, Thom SA, Hughes AD, et al. Pre-eclampsia, antiretroviral therapy, and

Appendix A4. Excluded Studies List

immune reconstitution. *Lancet*. 2002;360(9340):1152-4 PMID: 12387967.

Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, et al. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. *Antimicrob Agents Chemother*. 2008;51(6):2208-10 PMID: 17420209.

Systematic Review, Not Directly Used

Chigwedere P, Seage GR, Lee TH, Essex M. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. *AIDS Res Hum Retroviruses*. 2008;24(6):827-37 PMID: 18544018.

Kourtis AP, Schmid CH, Jamieson D, Lau B. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. *AIDS*. 2007;21:607-15 PMID: 17314523.

McKoy JM, Bennett CL, Scheetz MH, Differding V, Chandler KL, Scarsi KK, et al. Hepatotoxicity associated with long-versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug Events and Reports (RADAR) project. *Drug Saf*. 2009;32(2):147-58 PMID: 19236121.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. *Cochrane Database Syst Rev*. 2010(8) PMID: 21735394.

Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. *J Clin Pharm Ther*. 2007;32(3):293-311 PMID: 17489882.

Diagnostic Accuracy Studies

Criteria:

- Screening test relevant, available for primary care, adequately described
- Study uses a credible reference standard, performed regardless of test results
- Reference standard interpreted independently of screening test
- Handles indeterminate results in a reasonable manner
- Spectrum of patients included in study
- Sample size
- Administration of reliable screening test
- Random or consecutive selection of patients
- Screening cutoff pre-determined
- All patients undergo the reference standard

Definition of ratings based on above criteria:

- Good:** Evaluates relevant available screening test; uses a credible reference standard; interprets reference standard independently of screening test; reliability of test assessed; has few or handles indeterminate results in a reasonable manner; includes large number (more than 100) broad-spectrum patients with and without disease; study attempts to enroll a random or consecutive sample of patients who meet inclusion criteria screening cutoffs pre-stated.
- Fair:** Evaluates relevant available screening test; uses reasonable although not best standard; interprets reference standard independent of screening test; moderate sample size (50 to 100 subjects) and a “medium” spectrum of patients (i.e. applicable to most screening settings).
- Poor:** Has important limitation such as: uses inappropriate reference standard; screening test improperly administered; biased ascertainment of reference standard; very small sample size of very narrow selected spectrum of patients.

Randomized Controlled Trials (RCTs) and Cohort Studies

Criteria:

- Initial assembly of comparable groups: RCTs—adequate randomization, including concealment and whether potential confounders were distributed equally among groups; cohort studies—consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements: equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered
- Analysis: adjustment for potential confounders for cohort studies, or intention-to-treat analysis for RCTs; for cluster RCTs, correction for correlation coefficient

Appendix A5. U.S. Preventive Services Task Force Quality Rating Criteria

Definition of ratings based on above criteria:

- Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (followup at least 80 percent); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention to confounders in analysis.
- Fair:** Studies will be graded “fair” if any or all of the following problems occur, without the important limitations noted in the “poor” category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for.
- Poor:** Studies will be graded “poor” if any of the following major limitations exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessment); and key confounders are given little or no attention.

Source: Harris R, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001;20(3S):21-35.

Appendix A6. Expert Reviewers of the Draft Report

Marc Bulterys, MD, MPH, PhD

Director, Centers for Disease Control and Prevention, Global AIDS Program - China

Timothy Dondero, MD

Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention

Laurie Zephyrin, MD

National Director for Reproductive Health, Department of Veterans Affairs

Appendix B1. Key Question 2b: Quality Ratings of Diagnostic Accuracy Studies

| Study, year | Representative spectrum | Random or consecutive sample | Screening test adequately described | Screening cutoffs predefined | Credible reference standard | Reference standard applied to all screened patients | Same reference standard applied to all patients | Reference standard and screening examination interpreted independently | High rate of uninterpretable results or noncompliance with screening test | Analysis includes patients with uninterpretable results or noncompliance | Quality rating |
|---|-------------------------|------------------------------|-------------------------------------|------------------------------|-----------------------------|---|---|--|---|--|----------------|
| Jamieson, 2007 ³⁹ See also Bulterys, 2004 ²⁸ | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Not applicable | No | No | Fair |
| Tung, 2010 ⁴⁰ | Limited | Yes | Yes | Yes | Yes | No; only those testing positive | Yes | Yes | No | No | Fair |

Appendix B2. Key Question 3a: Evidence Table of Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Type of study/location/setting/ high or low prevalence population (based on 0.1% prevalence rate) | Study dates/ duration of followup | Comparison groups | Baseline population characteristics for mother/baby | Eligibility criteria |
|---|---|--|---|--|--|
| Garcia-Tejedor, 2009 ⁵⁸ | Cohort Maternity hospital Spain Prevalence not reported | 1984-2006 Details not reported | ART during pregnancy: A: no treatment n=214 B: mono/dual therapy n=116 C: ART n=159 | Age, race, CD4 count, HIV stage not reported Before 1997, 27% of women received ART (mono/dual therapy) After 1997, 91% of women received ART (77% with ART, 23% with mono/dual therapy) After 2002, ART was only therapy administered; 96% of women receiving treatment during pregnancy also received ART during delivery | HIV-infected pregnant women with attendance for prenatal care at least once at study obstetric clinic and/or delivery in maternity department between Jan 1984-Dec 2006 |
| Harris, 2007 ⁵⁷ | Cohort United States surveillance data from areas that reported ≥60 HIV-positive women giving birth per year but prevalence not reported (sites represented 89% of all perinatal AIDS cases reported in 2003) | Births from 1999-2001 Infants followed up by health department every 6 months until HIV status determined Analysis of surveillance data over study period | Prenatal ART regimes: A: no treatment n=292 B: neonatal ART only n=359 C: intrapartum ART and neonatal ART n=322 D: prenatal ART and neonatal ART n=316 E: prenatal ART and intrapartum ART and neonatal ART n=6029 | Age at delivery (years): 13-19: n=509 20-29: n=3641 30-39: n=2652 >40: n=195 Race: White n=826 Black n=4887 Hispanic n=1224 Other n=60 CD4 count and HIV stage not reported | HIV-infected mothers and HIV-exposed infants born in 1999, 2000, 2001. Women known to be HIV-infected in pregnancy (tested before or at delivery), women not known to be HIV-infected in pregnancy but whose child tested positive for HIVAll infants born in or receiving care in project site |
| Tariq, 2011 ⁵⁹ See also Townsend, 2008 ⁵⁶ , European Collaborative Study, 2005 ⁹³ | Cohort Population surveillance data from the European Collaborative Study and the National Study of HIV in Pregnancy and Childhood United Kingdom, Ireland, Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, Sweden Prevalence not reported (rates of mother to child transmission in Europe and the UK declined from 20% in 1990s to <2% in "recent" years) | 2000-2009 Followup testing schedule not reported Analyses of data over study period | Only antepartum treatment considered: A: ZDV-containing ART n=6374 B: ZDV-sparing ART n=1199 About 30% of women were on ART at conception | Maternal age at delivery, years (n=7547); A vs. B, p<0.001: <25; n=1072 (16.9%) vs. n=110 (9.2%) 25-29; n=1979 (31.2%) vs. n=257 (21.6%) 30-34; n=2006 (31.6%) vs. n=738 (61.7%) ≥35; n=1293 (20.4%) vs. n=92 (7.7%) Ethnicity (n=7550); A vs. B, p<0.001: Black n=4974 (78.3%) vs. n=882 (73.8%) White n=1086 (17.1%) vs. n=269 (22.5%) Asian/other n=294 (4.6%) vs. n=45 (3.8%) Baseline CD4 count, cells/mm ³ (n=6993); A vs. B, p=0.14: ≥500; n=1520 (25.9%) vs. n=316 (28.4%) 200-499; n=3427 (58.3%) vs. n=636 (57.2%) <200; n=934 (15.9%) vs. n=160 (14.4%) HIV stage: Not reported | All reported live singleton births to women who received ART for at least 14 days before delivery between 2000-2009 |
| Townsend, 2008 ⁵⁶ | Cohort Population surveillance data from the NSHPC UK, Ireland Prevalence not reported (mother to child transmission rates in UK, Ireland fell from 20% to 2% between 1993 and 1998) | Births from 2000-2006 to women diagnosed before delivery and reported by June 2007 Followup testing schedule not reported Analyses of data over study period | Only antepartum treatment considered: Number at baseline/number in analysis A: ART therapy n=4726/4120 B: Dual therapy n=136/126 C: Monotherapy n=712/638 D: None n=186/14324 1% (1075/4469) started ART before pregnancy | Age at delivery, median (years): 29.8 (IQR 26.2-33.6) Race: White n=775 (13.2%) Black African n=4630 (78.8%) Other n=470 (8.0%) CD4 count:At least 0.500 x 10 ⁹ cells/L n=1595 (35.1%) 350-499 cells/mL n=1158 (25.5%) 0.200-0.349 x 10 ⁹ cells/L n=1241 (27.3%) <0.200 x 10 ⁹ cells/L n=545 (12.0%) Clinical status: Asymptomatic n=4606 (89.7%) AIDS or HIV-related symptoms n=528 (10.3%) | Singleton births between 2000 and 2006 to women diagnosed with HIV infection before delivery and reported to the NSHPC by June 2007 |

Appendix B2. Key Question 3a: Evidence Table of Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Exclusion criteria | Number screened/ eligible/enrolled/ withdrawals/% analyzed | Breastfeeding rate/duration | Cesarean rate | Adjusted variables for statistical analysis |
|---|---|---|--|---|---|
| Garcia-Tejedor, 2009 ⁵⁸ | Children with unknown serological status | 500 HIV-infected women (495 singleton births, five twins); 505 children delivered; 489 mother-child pairs analyzed (1 miscarriage, 11 stillborns, 2 perinatal deaths, 2 lost to followup) | Breastfeeding suppressed in all cases | Elective; n = 139/489 Emergency; n = 109/489 | Clinical outcomes of interest not adjusted |
| Harris, 2007 ⁵⁷ | None reported a priori for population Inadequate ART data excluded from analysis, missing data for other variables of interest excluded cases as appropriate for logistic regression models of interest | 8530 eligible; 7344 births with ART data (further excluded as per logistic regression models and outcomes of interest resulting in n=6997 and n=6974 for analyses) | Not reported | n=3678/6997 (elective or emergency not reported) | AOR=maternal age, race, prenatal care, timing of maternal HIV test, delivery type, site AOR2=year of birth, maternal age, race, delivery type, site |
| Tariq, 2011 ⁵⁹ See also Townsend, 2008 ⁵⁶ ; European Collaborative Study, 2005 ⁹³ | Mother-child pairs lacking information on all 3 outcomes of interest ECS excluded data from centers in the Ukraine (limited antenatal ART) and UK (to avoid duplication of cases reported to the NSHPC) | 7573 mother-child pairs analyzed (n=1263 from ECS, n=6310 from NSHPC) | Not reported | n=7488 with data Elective; A vs B: n=3564 (56.5%) vs n=634 (54.0%) Emergency; A vs B: n=1151 (18.2%) vs n=243 (20.7%) | AOR=OR adjusted for duration of ART, study, mode of delivery |
| Townsend, 2008 ⁵⁶ | Multiple births excluded Children with unreported infection status excluded from analysis. Analysis performed using likely infection status to check for potential bias from excluding this group Only antepartum treatment considered in analysis | 5930 singleton births; 5151 mother-child pairs with infection status reported; 5027 with ART data for analysis | Breastfeeding reported in 0.6% (29/4399) of infants (although not recommended in UK or Ireland). 3 infants infected, all born to untreated women | Elective; n=3368/5901 (57.1%) Emergency; n=1223/5901 (20.7%) | AOR=OR adjusted for ART, mode of delivery, sex (gestational age was not a significant risk factor for transmission in women on ART and was excluded from analyses) AOR2=OR adjusted for mode of delivery, gestational age, sex, viral load |

AIDS = acquired immune deficiency syndrome; AOR = adjusted odds ratio; ART = antiretroviral therapy; CD4 = cluster of differentiation 4; CDC = Centers for Disease Control and Prevention; CI = confidence interval; ECS = European Collaborative Study; IQR = interquartile range; MTCT = mother-to-child transmission; NNRTI = nonnucleoside reverse transcriptase inhibitor; NSHPC = National Study of HIV in Pregnancy and Childhood; OR = odds ratio; PI = protease inhibitor; ZDV = Zidovudine.

Appendix B3. Key Question 3a: Quality Ratings of Cohort Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)? | Were the groups comparable at baseline on key prognostic factors (e.g., by restriction or matching)? | Did the study maintain comparable groups through the study period? | Did the study use accurate methods for ascertaining exposures and potential confounders? | Were outcome assessors and/or data analysts blinded to the exposure being studied? | Did the article report attrition? | Did the study perform appropriate statistical analyses on potential confounders? | Is there important differential loss to followup or overall high loss to followup? | Were outcomes prespecified and defined, and ascertained using accurate methods? | Quality rating |
|------------------------------------|---|--|--|--|--|-----------------------------------|--|--|---|----------------|
| Garcia-Tejedor, 2009 ⁵⁸ | Yes | Unclear; baseline characteristics are not reported | Unclear | Unclear | Unclear | Yes | No; only univariate results available for outcome of interest | No | Yes | Fair |
| Harris, 2007 ⁵⁷ | Yes; included study sites meeting prespecified criteria (represented 89% of all perinatal AIDS cases reported in 2003) | Unclear; not reported by ART groups | Yes | Yes | Unclear | Yes | Yes | No | Yes | Fair |
| Tariq, 2011 ⁵⁹ | Yes | No; significant between ART group differences on several variables | Unclear | Yes | Unclear | Yes | Yes | No/Yes | Yes | Fair |
| Townsend, 2008 ⁵⁶ | Yes | Unclear; not reported by ART groups | Unclear | Yes | Unclear | Yes | Yes | No | Yes | Fair |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Location/setting/high or low prevalence population (based on 0.1% prevalence rate) | Study dates/ duration of followup | Treatment groups | Baseline population characteristics for mother/baby |
|--|--|--|--|---|
| Chi, 2008 ⁶¹ See also Chi, 2007 ⁶⁶ | Zambia; public health clinics; prevalence not reported | Women randomized between March 16 2005 and February 13 2007; followup until infant is 6 weeks old | A: maternal TDF 300mg/FTC 200mg at delivery B: maternal ZDV 300mg BD starting at 32 weeks, NVP 200mg in labor, infant NVP 2mg/kg at birth, and discharged with 7 day course of ZDV 4mg/kg (standard of care) | Original cohort (as per Chi 2007): Intervention vs. Control Median age (interquartile range): 26 y (22-29) vs. 24 y (22-29) Race: Not reported Mean CD4 (SD): 464 (208) vs. 490 (200) cells/mL WHO stage III: 3 (2%) vs. 3 (2%) |
| de Vincenzi, 2011 ⁶⁰ See also Kesho Bora Study Group, 2010 ⁶⁷ | Burkina Faso, Kenya, South Africa; antenatal clinics; prevalence not reported | June 2005 to August 2008; followup until infant is 12 months old | From 34-36 weeks gestation: A: Maternal ZDV + 3TC + ABT-378 + RTV until cessation of breastfeeding (maximum 6.5 months postpartum) B: Maternal ZDV until delivery, ZDV + sdNVP at labor onset (protocol change from December 2006, prophylaxis started at 28 weeks gestation and women given 3TC + ZDV for 1 week postpartum) Infants received NVP within 72 hours of birth, co-trimoxazole from age 6 weeks to 12 months, unless not HIV infected after cessation of breastfeeding (protocol change from December 2006, infants received 1 week of ZDV from birth) | A: median age (IQR) 27 years (24-31), median CD4 count (IQR) at enrollment 0.336 x 10 ⁹ cells/L (0.282-0.408 x 10 ⁹ cells/L), median maternal viral load (IQR) at enrollment 4.23 log ₁₀ copies/mL (3.66-4.75) B: median age (IQR) 27 years (23-31), median CD4 count (IQR) at enrollment 339 cells/mL (267-408), median maternal viral load (IQR) at enrollment 4.21 log ₁₀ copies/mL (3.58-4.74) |
| Gray, 2006 ⁶² | South Africa; prevalence not reported | Open label, randomized 4-arm single-center study from May 1999 to May 2000; maternal followup until 6 weeks postpartum. Infant followup until 24 weeks of age. | From 34 weeks gestation: A: d4T 40mg BD B: ddl 200mg BD C: d4T 40 mg + ddl 200mg BD D: ZDV 300mg BD Infants received same ART regime as mother within 36 hours of birth until 6 weeks of age. | <u>ALL groups, n = 373</u> Age, mean (SD): 28.3 (5.8) Race: Black = 372/373 (100) Est. week of gestation: mean: 34.7 (0.8), median: 34.7, range: 31-39 CD4 count (cells/L): mean: 0.4308 x 10 ⁹ cells/L (225), median: 0.3920 x 10 ⁹ cells/L, range: 0.027-1.286 x 10 ⁹ cells/L |
| Shapiro, 2010 ⁶³ | Botswana; study clinics; 27% of pregnant women screened at antenatal clinics had HIV | Enrolled July 2006 to May 2008; followup until 6 months postpartum | Randomization groups (women with CD4 count ≥200 cells/mm ³): From 26-34 weeks gestation through weaning or 6 months postpartum, whichever first: A: maternal ABC + ZDV + 3TC B: maternal ABT-378 + RTV + ZDV + 3TC Observational group (women with CD4 count <200 cells/mm ³ or with AIDS defining illness): From 18-34 weeks to continue indefinitely: C: maternal NVP, ZDV, 3TC Infants received sdNVP at birth and ZDV from birth to 4 weeks. | A: median age at enrollment 26 years, median CD4 count (IQR) 0.393 x 10 ⁹ cells/L (0.305-0.514 x 10 ⁹ cells/L), median HIV-1 RNA (IQR) 13,300 copies/mL (2,340-50,900), median (IQR) gestational age at delivery 39.3 years (37.9-40.3), median (IQR) infant birthweight 3.0 kg (2.7-3.3) B: median age at enrollment 25 years, median CD4 count (IQR) 403 (297-514), median HIV-1 RNA (IQR) 9,100 copies/mL (2,210-39,900), median (IQR) gestational age at delivery 39.0 years (37.4-40.0), median (IQR) infant birthweight 2.9 kg (2.6-3.2) C: median age at enrollment 29 years, median CD4 count (IQR) 147 (115-183), median HIV-1 RNA (IQR) 51,700 copies/mL (14,400-179,000), median (IQR) gestational age at delivery 39.4 years (38.4-40.3), median (IQR) infant birthweight 2.9 kg (2.6-3.2) Median duration of ART before delivery was 11 weeks in randomized groups, 13 weeks in observational group |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Location/setting/high or low prevalence population (based on 0.1% prevalence rate) | Study dates/ duration of followup | Treatment groups | Baseline population characteristics for mother/baby |
|-----------------------------|--|--|--|--|
| Shapiro, 2006 ⁶⁴ | Botswana; study sites at district hospitals; 37% of pregnant women test HIV positive at surveillance sites in Botswana | Enrolled June 2002 to October 2003; followup until infant is 1 month old | A: maternal sdNVP during labor B: maternal placebo during labor All mothers received ZDV from 34 weeks gestation until delivery and all infants received sdNVP and ZDV from birth to 1 month of age ART was offered to women with CD4 counts <200 or AIDS defining illness at any point in study participation. If women started ART before delivery, they did not receive NVP or placebo at labor onset. Infants confirmed HIV infected were also given ART. | A: median age 27.6 years, median CD4 count (IQR) 0.356 x 10 ⁹ cells/L (0.218-0.519 x 10 ⁹ cells/L), median length of gestation at delivery (IQR) 40 weeks (38-40), median infant birthweight (IQR) 3.0 kg (2.8-3.4) B: median age 27.1 years, median CD4 count (IQR) 363 (250-536) cells/μl, median length of gestation at delivery (IQR) 40 weeks (39-40), median infant birthweight (IQR) 3.1 kg (2.9-3.4) Race: Not reported HIV stage: Not reported |
| Thistle, 2007 ⁶⁵ | Zimbabwe; hospital; 21.6% at study site | 2002 to 2004 (terminated secondary to fertility) | A: maternal ultra short course ZDV (given during labor), sdNVP in labor, infant ZDV for 72 hours after delivery and NVP therapy within 72 hours of delivery B: maternal sdNVP therapy in labor, infant NVP therapy within 72 hours of delivery | Age, mean years ± SD: A: 25.7 ± 5.6 B: 25.6 ± 5.7 |

| Author, Year | Eligibility criteria | Exclusion criteria | Number screened/ eligible/enrolled/ withdrawals/% analyzed | Breastfeeding rate/duration |
|--|--|--|--|---|
| Chi, 2008 ⁶¹ See also Chi, 2007 ⁶⁶ | HIV-infected women seeking care at 2 public sector primary health facilities who tested positive for HIV and who were between 28 and 38 weeks gestation. All women were offered short course ZDV from 32 weeks onward and intrapartum NVP for perinatal prophylaxis prior to recruitment as part of routine care. All HIV-exposed infants were given NVP syrup before discharge and week long supply of ZDV. | Women who qualified for ART based on WHO criteria for health, and women with any previous use of ART. Enrolled women who had given consent and who presented to study facility in labour were assessed by staff. Only women who reported self-administration of single-dose NVP before arrival or who were seen to ingest the dose after admission, who were in active labor, and had no clinical indications for transfer to tertiary care facility, were randomized. | 627 enrolled; 397 randomized; 355 (89%) mother-infant pairs analyzed (n=3 [1%] stillbirths, n=9 [2%] infant deaths before 6 weeks of age, n=30 [8%] mother-child pairs lost to followup) A: n=180 (51%) B: n=175 (49%) | Intervention vs. Control Infant breastfeeding at 6 weeks n = 166 (92%) vs. 161 (92%) (as per Chi 2007 Table 1) |
| de Vincenzi, 2011 ⁶⁰ See also Kesho Bora Study Group, 2010 ⁶⁷ | ART naive pregnant women infected with HIV-1 visiting antenatal clinics at 5 study sites, less than 32 weeks gestation, WHO stage 1, 2, or 3 HIV infection, CD4 count 0.200-0.500 x 10 ⁹ cells/L | Women with contraindications to rapid initiation of ART (i.e., allergy to ART or benzodiazepines), those on drugs that interact with ART, or those with severe anemia, neutropenia, liver or renal failure First, liveborn infants used for analysis | 882 enrolled; 824 randomized (412 to group A, 412 to group B); 401 livebirths in group A, 404 livebirths in group B | A: 307/401 (77%) ever breastfed, median duration of breastfeeding (IQR) 21.4 weeks (8.6-25.4), exclusive breastfeeding up to last available visit before 3 months 135/298 (45%) B: 317/404 (78%) ever breastfed, median duration of breastfeeding (IQR) 19.0 weeks (9.0-25.7), exclusive breastfeeding up to last available visit before 3 months 134/304 (44%) P values = 0.55, 0.95, 0.80 |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Eligibility criteria | Exclusion criteria | Number screened/ eligible/enrolled/ withdrawals/% analyzed | Breastfeeding rate/duration |
|-----------------------------|---|---|--|---|
| Gray, 2006 ⁶² | HIV-1 infected, antiretroviral-naive pregnant women >18 years old, 34-36 weeks of gestation; prepared to formula feed infants; willing to have infants followed for 6 months | Presence of severe fetal abnormalities, presence of 3 or more fetuses, occurrence of a newly diagnosed HIV-related opportunistic infection, malignancy, condition requiring acute therapy, active drug abuse, history of pancreatitis, past or present symptoms of grade 2 or greater bilateral peripheral neuropathy | 373 women randomized: A: 93 to d4T B: 95 to ddl C: 95 to d4T + ddl D: 92 to ZDV 13 women began study treatment earlier or later than 34-36 weeks gestation 372 infants born to 369 women (3 sets of twins) 11 mother-infant pairs unevaluable | None |
| Shapiro, 2010 ⁶³ | Pregnancy of 26-34 weeks gestation for randomized groups or 18-34 weeks gestation for observational group, had positive HIV-1 ELISA on 2 separate samples, were ≥18 years old, had hemoglobin ≥8 g/dL, absolute neutrophil count ≥1000 cells/mm ³ , alanine amino transferase and aspartate amino transferase no more than 2.5 times upper limit of normal range | Women who preferred to exclusively formula feed their infants | 15,414 screened; 4209 tested positive; 1248 referred to study clinics; 730 enrolled; 560 randomized and 170 observed (709 liveborn infants) A: n=285 assigned, 274 had live born infants (n=283 liveborn infants) B: n=275 assigned, 269 had live born infants (n=270 liveborn infants) C: n=170 assigned, 156 had live born infants (n=156 liveborn infants) | All women asked to exclusively breast-feed and wean 3 days before 6 month study visit; 97% of all women with live-born infants breastfed and 71% continued for at least 5 months (70% in group A, 73% in group B, 71% in group C) A: n=264 (96%) initiated breastfeeding while receiving ART, n=71 (27%) weaned ≤5 months before stopping ART, n=2 (1%) weaned ≤5 months after stopping ART, n=5 (2%) lost to followup but breastfed to last contact, n=186 (70%) breastfed for >5 months while receiving ART B: n=263 (98%) initiated breastfeeding while receiving ART, n=66 (25%) weaned <5 months before stopping ART, n=4 (2%) weaned <5 months after stopping ART, n=3 (1%) stopped ART before weaning >5 months, n=5 (2%) lost to followup but breastfed to last contact, n=185 (70%) breastfed for >5 months while receiving ART C: n=150 (96%) initiated breastfeeding while receiving ART, n=39 (26%) weaned <5 months while continuing ART, n=1 (1%) lost to followup but breastfed to last contact, n=1 (1%) died <5 months, n=109 (72%) breastfed for >5 months while receiving ART |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Eligibility criteria | Exclusion criteria | Number screened/ eligible/enrolled/ withdrawals/% analyzed | Breastfeeding rate/duration |
|-----------------------------|--|--|---|---|
| Shapiro, 2006 ⁶⁴ | HIV positive pregnant women who were between 33 and 35 weeks gestation, had positive HIV-1 ELISA on 2 separate samples, were ≥18 years old, had hemoglobin ≥8 g/dL, absolute neutrophil count ≥1000 cells/μl, alanine amino transferase and aspartate amino transferase ≤10 times the upper limit of normal, creatinine ≤1.5 mg/dL, did not have intolerance to zidovudine or nevirapine and provided written informed consent | Did not plan to remain in study area, presented after 34 weeks gestation, laboratory ineligibility Only first born, liveborn infants included in analysis | 9031 screened; 709 enrolled A: n=354 randomized, n=345 live births, n=40 started ART prior to delivery, n=327 infants with HIV status known at 1 month B: n=355 randomized, n=349 live births, n=31 started ART prior to delivery, n=329 infants with HIV status known at 1 month | C: n=150 (96%) initiated breastfeeding while receiving ART, n=39 (26%) weaned <5 months while continuing ART, n=1 (1%) lost to followup but breastfed to last contact, n=1 (1%) died <5 months, n=109 (72%) breastfed for >5 months while receiving ART |
| Thistle, 2007 ⁶⁵ | HIV positive pregnant women with positive test results on both dipstick HIV 1, 2 and recombinant test kit, able to give informed consent, willing to have infants involved | Inability to give or refusal to give informed consent, clinical evidence of significant hepatic disease, receipt of previous ART Only data from firstborn infant included if multiple birth | Overall: 7467 screened; 1610 eligible; 1140 randomized A: n = 569 randomized B: n = 571 randomized A: n=440 births B: n=434 births n=609 infants with data at 6 weeks A: n=312 B: n=297 | A: 89.4% breastfeeding at 6 weeks, 0.4% mixed feeding at 6 weeks B: 91.1% breastfeeding at 6 weeks, 0 mixed feeding at 6 weeks |

| Author, Year | Cesarean rate | Transmission rates |
|---|---------------|---|
| Chi, 2008 ⁶¹ See also Chi, 2007 ⁶⁶ | Not reported | Transmission according to actual use ART regimens for perinatal HIV prevention: Intrauterine With antenatal ZDV NVP+TDF/FTC: 3/126 (2.4%) NVP alone: 8/117 (6.8%) Without antenatal ZDV NVP+TDF/FTC: 3/22 (13.6%) NVP alone: 1/27 (3.7%) Other ZDV + TDF/FTC: 1/23 (4.3%) ZDV only: 0/22 TDF/FTC only: 1/5 (20.0%) No drug: 0/6 Missing NVP cord plasma: 1/7 (14.3%) Total: 18/355 (5.1%) Intrapartum/Early transmission With antenatal ZDV NVP+TDF/FTC: 2/123 (1.6%) NVP alone: 3/109 (2.8%) p=0.67 Without antenatal ZDV NVP+TDF/FTC: 0/19 NVP alone: 1/26 (3.4%) Other ZDV + TDF/FTC: 0/22 |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Cesarean rate | Transmission rates |
|--|---|--|
| | | <p>ZDV only: 0/22 TDF/FTC only: 0/4 No drug: 0/6 Missing NVP cord plasma: 0/6 Total: 6/337 (1.8%) Overall With antenatal ZDV NVP+TDF/FTC: 5/126 (4.0%) NVP alone: 11/117 (9.4%) p=0.12 Without antenatal ZDV NVP+TDF/FTC: 3/22 (13.6%) NVP alone: 2/27 (7.4%)p=0.65 Other ZDV + TDF/FTC: 1/23 (4.3%) ZDV only: 0/22 TDF/FTC only: 1/5 (20.0%) No drug: 0/6 Missing NVP cord plasma: 1/7 (14.3%) Total: 24/355 (6.8%) **Intrapartum/early transmission = baby tested negative at birth but positive at 6 weeks (IMP: these women are breastfeeding), so this transmission rate seems not applicable to nonbreastfeeding groups Overall, 24/355 (7%) infants were infected with HIV by 6 weeks. Most transmissions occurred during intrauterine period (n=18) compared to intrapartum/early postpartum (n=6). Transmission rates were similar between intervention and control arms for intrauterine (4% vs. 6%, p=0.63), intrapartum/early postpartum (1% vs. 2%, p=0.44), or overall (6% vs. 8%, p=0.40) transmission. Mother-to-child HIV transmission according to drug regimen: ZDV use during antenatal period None: AOR=1.0 <30 days: AOR=0.7 (95% CI 0.3-2.1) >30 days: AOR=0.4 (95% CI 0.1-1.3)</p> |
| <p>de Vincenzi, 2011⁶⁰ See also Kesho Bora Study Group, 2010⁶⁷</p> | <p>A: Cesarean before labor, rupture of membranes, or both n=19 (5%), Cesarean after labor, rupture of membranes, or both n=25 (6%) B: Cesarean before labor, rupture of membranes, or both n=13 (3%), Cesarean after labor, rupture of membranes, or both n=38 (9%)</p> | <p>Comparing infection rates and events among infants: Birth A: 7/394, 1.8%, 95% CI 0.9-3.7% B: 10/402, 2.5%, 95% CI 1.3-4.6% RR reduction 28% p=0.52 6 weeks A: 13/375, 3.3%, 95% CI 1.9-5.6% B: 20/374, 5.0%, 95% CI 3.3-7.7% RR reduction 34% p=0.24 6 months A: 19/349, 4.9%, 95% CI 3.1-7.6% B: 33/339, 8.4%, 95% CI 6.0-11.6% RR reduction 42% 12 months A: 21/333, 5.4%, 95% CI 3.6-8.1% B: 37/305, 9.5%, 95% CI 7.0-12.9% RR reduction 43% p=0.029 *p value stratified by center, intention to breastfeed</p> |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Cesarean rate | Transmission rates |
|-----------------------------|---|--|
| Gray, 2006 ⁶² | 37% (137/372) 5 stillbirths | <p>Mother to child transmission rates by treatment group: Cumulative positive HIV-1 DNA (MTCT rate*)</p> <p>Birth</p> <p>A: 3/91 (3.3%) B: 2/94 (2.1%) C: 2/88 (2.3%) D: 4/89 (4.5%) All groups: 11/362 (3.0%)</p> <p>Week 6</p> <p>A: 9/91 (9.9%) B: 6/94 (6.4%) C: 3/88 (3.4%) D: 4/89 (4.5%) All groups: 22/362 (6.1%)</p> <p>Week 12</p> <p>A: 10/91 (11.0%) B: 9/94 (9.6%) C: 4/88 (4.6%) D: 4/89 (4.5%) All groups: 27/362 (7.5%)</p> <p>Week 24</p> <p>A: 11/91 (12.1%, 95% CI 6.2-20.6) B: 10/94 (10.6%, 95% CI 5.2-18.7) C: 4/88 (4.6%, 95% CI 1.3-11.2) D: 5/89 (5.6%, 95% CI 1.9-12.6) All groups: 30/362 (8.3%, 95% CI 5.7-11.6)</p> <p>* number with positive HIV-1 DNA divided by the number of evaluable mother-infant pairs</p> |
| Shapiro, 2010 ⁶³ | Not reported | <p>Overall 8/709 (1.1%, 95% CI 0.5-2.2) infants were infected by 6 months of age: 6 infants infected in utero; A: n=4, B: n=1, C: n=1 (includes one infant that died without confirmed AIDS defining cause after positive PCR result at birth) 2 infants in group A infected through late breastfeeding transmission</p> <p>Infections between randomized groups (study not powered for between randomized group comparisons of transmission rates):</p> <p>A: 6/283 (2.1%) liveborn infants infected B: 1/270 (0.4%) liveborn infants infected percentage point difference, 1.7, 95% CI -2.0 to 7.1</p> <p>In utero transmission = confirmed positive HIV PCR assay of DNA from blood sample obtained from infants less than 4 days old Late breastfeeding transmission = negative test at one month and first confirmed positive test thereafter Intrapartum/early breastfeeding transmission = negative result at birth and first confirmed positive test at one month of age</p> |
| Shapiro, 2006 ⁶⁴ | Emergency or elective A: Median 8.8% B: Median 9.9% | <p>A: n=345 live births, n=345 deliveries with HIV PCR test results, n=13 (3.8%) HIV+ at birth, n=15 [4.3%±2.3 (2SD)] HIV+ at one month of age B: n=349 live births, n=346 deliveries with HIV PCR test results, n=8 (2.3%) HIV+ at birth, n=13 [3.7%±2.2 (2SD)] HIV+ at one month of age 95% CI for difference between infant groups at one month with HIV infection, -2.4 to 3.8%, met equivalence Rate of HIV infection at birth is number of first positive HIV PCR results by 15 days of age divided by number of live births Rate of HIV infection by one month is number of first positive HIV PCR results by 45 days divided by number of live births Excluding liveborn infants whose mothers received ART before delivery, 14/305 (4.6%) in maternal NVP arms were</p> |

Appendix B4. Key Question 3a: Evidence Table of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Cesarean rate | Transmission rates |
|-----------------------------|--------------------|--|
| | | HIV infected by one month vs. 12/319 (3.8%) in maternal placebo arm (p=0.69, 95% CI for difference -2.4 to 4.2%, met equivalence) No transmission difference in infants who became infected between birth and one month between groups (2 infections in maternal NVP arm vs. 5 in placebo arm, p=0.45) |
| Thistle, 2007 ⁶⁵ | A: 8.2% B: 6.1% | Outcomes at 6 weeks postpartum in infants whose mothers were randomized: A: n=312 infants with data at 6 weeks postpartum; n=45 (14.4%) of infants positive for HIV, n=23 (7.4%) of infants were dead, n=68 (21.8%) of infants met primary outcome (death or HIV infection) B: n=297 infants with data at 6 weeks postpartum; n=49 (16.5%) of infants positive for HIV, n=21 (7.1%) of infants were dead, n=70 (23.6%) of infants met primary outcome p=0.06, percentage difference 1.8%, 95% CI -4.9 to 8.4% for primary outcome, AOR = 1.28 (95% CI 0.75-2.19) *AOR = age, gestational age, marital status, premature rupture of membranes, mode of delivery, maternal opportunistic infection, sexually transmitted infection |

3TC = lamivudine; ABC = abacavir; ABT-378 = lopinavir; AIDS = acquired immunodeficiency syndrome; AOR = adjusted odds ratio; ART = antiretroviral therapy; BD = twice daily; CD4 = cluster of differentiation 4; CDC = Centers for Disease Control and Prevention; CI = confidence interval; CIDA = Canadian International Development Agency; D4T = stavudine; DDL = didanosine; DNA = deoxyribonucleic acid; ELISA = enzyme-linked immunosorbent assay; FTC = emtricitabine; IQR = interquartile range; MTCT = mother-to-child transmission; NVP = nevirapine; PCR = polymerase chain reaction; PROM = premature rupture of membranes; RNA = ribonucleic acid; RR = relative risk; RTV = ritonavir; SD = standard deviation; sdNVP = single-dose nevirapine; TDF = tenofovir; UNDP = United Nations Development Programme; UNFPA = United Nations Population Fund; WHO = World Health Organization; ZDV = zidovudine.

Appendix B5. Key Question 3a: Quality Ratings of African-Based Randomized, Controlled Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

| Author, Year | Randomization adequate? | Allocation concealment adequate? | Groups similar at baseline? | Eligibility criteria specified? | Outcome assessors masked? | Care provider masked? | Patient masked? | Attrition and withdrawals reported? | Loss to followup differential/high? | Intention-to-treat analysis? | Quality rating | Funding |
|---------------------------------|-------------------------|----------------------------------|-----------------------------|---------------------------------|---------------------------|---|-----------------|-------------------------------------|-------------------------------------|------------------------------|----------------|---|
| Chi 2008 ⁶¹ | Yes | Yes | Yes | Yes | Unclear | Unclear | Unclear | Yes | No | No | Fair | Elizabeth Glaser Pediatric AIDS Foundation |
| de Vincenzi, 2011 ⁶⁰ | Yes | Yes | Yes | Yes | Unclear | No | No | Yes | No | Yes | Good | Agence Nationale de Recherches sur le SIDA et les Hepatites Virales, Department of Int'l Development, European and Developing Countries Clinical Trials Partnership, Thrasher Research Fund, Belgian Directorate General for Int'l Cooperation, CDC, Eunice Kennedy Shriver National Insitute of Child Health and Human Development, UNDP/ NFPA/World Bank/WHO Special Programme of Research, Development and Research Training in Human Reproduction |
| Gray, 2006 ⁶² | Unclear | No; open trial | Yes | Yes | No | No | No | Yes | No | No | Fair | Not reported |
| Shapiro, 2010 ⁶³ | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | Yes | No | Unclear | Fair | National Institute of Allergy and Infectious Diseases, Fogarty International Center, GlaxoSmithKline, Abbott Pharmaceuticals |
| Shapiro, 2006 ⁶⁴ | Yes | Unclear | Yes | Yes | Unclear | Unclear | Unclear | Yes | No | Yes | Fair | National Institutes of Health , Boehringer Ingelheim, GlaxoSmithKline, Fogarty International Center |
| Thistle, 2007 ⁶⁵ | Yes | Unclear | Yes | Yes | Unclear | Unclear; physician blinded to study allocation determined infant admission to at-risk nursery but no comment on other providers | Yes | Yes | No/Yes | Unclear | Fair | Ministry of Health and Child Welfare, Zimbabwe; CIDA; Ve'ahavta: Canadian Jewish Humanitarian and Relief Committee; Salvation Army of Zimbabwe; MAC AIDS; GlaxoSmithKlein Canada, Rotary club of Whitby, Canada; Department of Family and Community Medicine, St.Michaels' Hospital, Toronto, Canada |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Type of harm | Type of study/location/setting/high or low prevalence population (based on 0.1% prevalence rate) | Study dates/duration of followup | Comparison groups |
|--------------------------------|------------------------|--|--|---|
| Aldrovandi, 2009 ⁹⁰ | PBMC mtDNA | Retrospective cohort US Samples from WITS and p1009 observational cross-sectional study | Study dates unclear Followup: up to 5 years post-delivery | Uninfected infants born to HIV-infected women who received: A. No ARV therapy n=71 B. ZDV monotherapy n=71 C. ZDV/Lamivudine cARV therapy n=71 D. Healthy children aged birth to 18 years born to HIV-uninfected women n=411 |
| Alimenti, 2006 ⁹⁶ | Neuro-development | Prospective, cross-sectional British Columbia, Canada Hospital based | June 2003 to December 2004 | A: ART exposed group of HIV-uninfected children born to HIV positive women, n=39 B: Unexposed children, n=24 BSID-I (Bayley Scales of Infant Development) used to assess cognitive, language, psychomotor functioning to identify developmental delay); results provide MDI and PDI scores (Mental Development and Psychomotor Development Index) |
| Benhammou, 2008 ¹⁰³ | Other harms | Cohort France Multicenter NR French Perinatal Cohort | September 24, 1984 to May 1, 2007 Followup 24 months | A: Peri or postpartum exposure only (n=274) B: Zidovudine monotherapy (n=2147) C: zidovudine + lamivudine + other NRTIs except didanosine (n=4752) D: didanosine + lamivudine + other NRTIs (n=365) Other NRTI combinations (n=715) Prospective multicenter study following HIV infected pregnant women and their children |
| Briand, 2009 ⁷³ | Low birth weight, INGR | Prospective cohort France | Infants born from January 1990 through 2006 | A. Monotherapy 1999-2004 n=4270, ART widespread B. ART 2005-2006 n=1239 C. 1990-1993, n=846, no ART during pregnancy D. 1994-1996, n=906, ZDV monotherapy as standard E. 1997-1998, n=931, dual nucleoside therapy trial and 1st availability of ART |
| Brogly, 2007 ⁹¹ | Mitochondrial toxicity | Cohort US, Puerto Rico NR PACTG 219, 219C Study Group | May 1993 to August 2000 | A: Cases (n=20) B: Noncases (n=1017) |
| Bunders, 2005 ¹⁰⁰ | Hematologic | Observational Single center Europe NR European Collaborative Study | February 1997 to October 2002 | 75 children matched for gestational age, gender, ethnicity, prematurity, race |
| Carceller, 2009 ⁷⁴ | Premature birth | Retrospective cohort Canada | 1997 through 2005 Infant followup: 2 year minimum 5 year median, range 2-10 years | A. ART with protease inhibitors n=176 B. ART without protease inhibitors n=30 C. Control: infants born to non-HIV infected mothers (not exposed to ART) n=206 |
| Cote, 2008 ⁹² | Mitochondrial toxicity | Prospective cohort Canada | July 2003 to June 2006 Infants followed birth to 8 months | A: ART exposed infants; majority exposed to ADV + 3TC, with a protease inhibitor (n=41), a non-NRT (n=20) or both (n=4) All infants born to HIV+ mothers received ZDV prophylaxis B: Infants born to HIV uninfected mothers |
| Cotter, 2006 ⁷⁵ | Premature birth | Prospective cohort US | Women who gave birth 1990 through 2002 | Antiretroviral therapy A. None n=338 (25%) B. Monotherapy n=492 (37%) C. Combination therapy with PIs n=373 (28%) D. Combination therapy without PIs n=134 (10%) |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Type of harm | Type of study/location/setting/high or low prevalence population (based on 0.1% prevalence rate) | Study dates/duration of followup | Comparison groups |
|------------------------------------|-----------------------------------|--|--|--|
| El Beitune, 2005 ⁷⁶ | Premature birth | Prospective cohort Brazil | September 2001 to March 2003 | A. HIV infected pregnant women taking zidovudine (CD4>500 and viral load <1,000 copies/mL) n=20 B. HIV infected pregnant women taking triple ARV (zidovudine + lamivudine + nelfinavir), (CD4 <500) n=25 C. Non-HIV infected pregnant women with normal clinical and lab data n=12 |
| Grosch-Woerner, 2008 ⁷⁷ | Birth outcomes (prematurity, LBW) | Observational Germany, Austria | 1995-2001 18 month followup | A: Monotherapy B: Dual therapy C: ART without PID: ART with PI |
| Lipschultz, 2011 ⁹⁹ | Infant harms: cardiac | Cohort US NR | June 2003 to January 2006 | A: CHAART-1 infants exposed to ART; n = 166 B: P ² C ² HIV infants not exposed to ART n = 216 CHAART = cardiovascular status of HAART therapy in HIV exposed infants and children P ² C ² = pediatric pulmonary and cardiac complications of vertically transmitted HIV |
| Marti, 2007 ¹⁰⁹ | Maternal toxicity | Prospective cohort Spain | Women who delivered between January 1, 1997 and December 31, 2003 Infants were followed for at least 2 years after delivery | A: Women who did not receive ART during pregnancy n=15 (9%) B: Monotherapy with zidovudine n=23 (14%) C: Dual NRTIs were used with or without a 3rd NRTI or NNRTI n=35 (21%) D: Triple ART used along with a protease inhibitor n=94 (56%) |
| Morris, 2005 ⁷⁸ | Premature birth | Retrospective cohort US, Puerto Rico | Women treated between December 1997 and December 2001 | Treatment with single PIs: 96.5% Ritonavir-boosted regimen: 3.4% Nelfinavir as part of the regimen: 92% Regimen included dual nucleoside combination of zidovudine and lamivudine: 93% |
| Mussi-Pinhata, 2007 ¹⁰¹ | Hepatotoxicity | Observational Latin America, Caribbean Hospital NR | September 2002 to March 1, 2005 6 month followup | A: 1 or 2 NRTIs B: 2 NRTIs + NNRTI (ART/NNRTI) C: 2 NRTIs + 1 PI (ART/PI) D: other |
| Pacheco, 2006 ¹⁰² | Hematologic | Observational Multicenter US, Puerto Rico | 1989-2004 | 2171 infants: A: No ARV drugs, n=351 B: Any ARV drugs, n=1820 C: Monotherapy, n=803 (91% zidovudine) D: Combination therapy, n=1017 |
| Patel, 2005 ⁹³ | Congenital/birth defects | Cohort European Collaborative Study Includes low and high prevalence areas | Enrolled 1986 to December 2003 | A: NRTI only B: NRTI + protease inhibitor C: NRTI + NNRTID: NRTI + NNRTI + PI |
| Paul, 2005 ⁷⁹ | Low birth weight, INGR | Prospective and retrospective cohort US, Puerto Rico | Children born to women enrolled in WITS January 1990 to October 1999 Children followed through age 2 | A. HIV-infected children n=163 A-1. No maternal ARV n=78 (49%) A-2. Maternal monotherapy n=72 (46%) A-3. Maternal ART/combo n=8 (5%) B. HIV-uninfected children n=955 B-1. No maternal ARV n=139 (15%) B-2. Maternal monotherapy n=487 (51%) B-3. Maternal ART/combo n=328 (34%) |
| Powis, 2011 ⁷² | Premature birth | Randomized, controlled trial Botswana NR | July 2006 and May 2008 Women evaluated before ART and monthly through postpartum | A: PI group (lopinavir/ritonavir/zidovudine/lamivudine) - KAL/CBV; n=275 B: NRTI group (abacavir/zidovudine/lamivudine) - TZV; n=285 |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Type of harm | Type of study/location/setting/high or low prevalence population (based on 0.1% prevalence rate) | Study dates/duration of followup | Comparison groups |
|---|-----------------------------------|---|---|---|
| Rudin, 2011 ⁸⁰ | Premature birth | Cohort Switzerland Low MoCHiV = Swiss Mother & Child HIV Study SHCS = Swiss HIV Cohort Study | 1990-1998 | A: no ART, n=624 B: mono or dual ART, n=147 C: cART (combined) (84% PI based), n=409 |
| Schulte, 2007 ⁸¹ | Premature birth | Retrospective cohort US | Infants born in 1989 through 2004 | Antiretroviral therapy A. None n=2565 (29%) B. 1 drug n=2621 (30%) C. 2 drugs n=1044 (12%) D. 3 drugs: ART, non-PI n=1781 (20%) E. 3 drugs: ART, PI n=782 (9%) |
| Tariq, 2011 ⁵⁹ See also Townsend, 2008 ⁵⁶ , European Collaborative Study, 2005 ⁹³ | Congenital | Cohort/ Population surveillance data from ECS and NSHPC/UK, Ireland, Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, Sweden Prevalence NR | 2000-2009 Followup testing schedule not reported; analyses of data over study period | Only antepartum treatment considered: A: ZDV-containing ART n=6374 B: ZDV-sparing ART n=1199 Note: About 30% of women were on ART at conception |
| Townsend, 2007 ⁵² | Birth outcomes (prematurity, LBW) | Cohort study UK, Ireland Low | 1990-2005 N/A | A: ART therapy n = 3384 B: Mono/dual therapy n = 1061 C: Untreated n = 494 (this group not included in analyses) |
| Townsend, 2009 ⁹⁴ | Congenital/birth defects | Cohort UK, Ireland National Study of HIV in Pregnancy and Childhood Low | January 1990 to December 2007 Median age of infants at last report was 6 months (interquartile range 3 to 15 months) | Timing of antiretroviral therapy exposure A: None B: Late (2nd, 3rd trimester) C: Early (1st trimester) |
| Tuomala, 2005 ¹⁰⁸ | Maternal toxicity | Prospective cohort US | Pregnancies that ended between January 1990 and February 2002 Followup duration: to delivery | A: Cohort 1, ART use before March 1994; n = 794 B: Cohort 2, ART use March 1994 through July 1996; n = 556 C: Cohort 3, ART use August 1996 through February 2002; n = 1190 Timing of ART use: Early: use recorded at enrollment and/or at 18- and/or 25-week visit Late: use recorded at 32-week visit and/or delivery visit Classes of ART: ZDV monotherapy and combination therapy including ZDV; NRTI other than ZDV; any PI; any NNRTI |
| Watts, 2011 ⁹⁵ | Congenital defects | Cohort of RCT participants US, Brazil, Bahamas, Europe Pediatric AIDS Clinical Trial Group 316 (PACTG 316) Prevalence NR | May 1997 to June 2000 Maternal followup until 6 weeks postpartum; infant followup until 6 months of age | A: First trimester ARV exposure (first 12 weeks of pregnancy) B: Second/third trimester ARV exposure (after 12 weeks gestation) PACTG 316 randomization groups Standard ART plus one of the following: A: maternal single dose NVP in active labor and single dose NVP to infant between 48 to 72 hours of birth B: maternal placebo in active labor and placebo to infant between 48 to 72 hours of birth |
| Williams, 2010 ⁹⁷ | Neuro-development | Prospective, multicenter cohort US | 1993-2006 | A: ARV exposed in utero B: non-ARV exposed in utero MDI = mental developmental index PDI = psychomotor developmental index |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|--------------------------------|--|--|--|
| Aldrovandi, 2009 ⁹⁰ | <p>Mean age at delivery</p> <p>A: 28.02 B: 26.08 C: 29.18</p> <p>Race</p> <p>White</p> <p>A: 6 (9%) B: 7 (10%) C: 8 (11%)</p> <p>Black</p> <p>A: 39 (55%) B: 30 (42%) C: 30 (42%)</p> <p>Hispanic</p> <p>A: 23 (32%) B: 30 (42%) C: 29 (41%)</p> <p>Other</p> <p>A: 3 (4%) B: 4 (6%) C: 4 (6%)</p> <p>Mean CD4 count at delivery</p> <p>A: 625.92 B: 479.47 C: 530.65</p> <p>Mean HIV RNA at delivery</p> <p>A: 3.70 B: 3.69 C: 3.11</p> <p>Infant birth weight <2.5 kg</p> <p>A: 8.95% B: 14.49% C: 7.14%</p> <p>Prematurity <37 week gestation</p> <p>A: 14.8% B: 8.45% C: 8.45%</p> | <p>HIV-positive women and their uninfected infants were selected from those who participated in WITS. Infection status was determined by WITS protocol and reflected differential use of ARVs during pregnancy. From among subject pairs who met the selection criteria and had sufficient stored material available, efforts were made to balance, within each time period, the degree of ARV exposure.</p> <p>Samples from healthy children born to HIV-uninfected women were obtained from an observational, cross-sectional study (P1009) of lymphocyte subsets at sites that included all of the WITS centers.</p> | Not reported |
| Alimenti, 2006 ⁹⁶ | <p>Maternal age at delivery:</p> <p>A:28.5 B:30.1</p> <p>Maternal ethnicity: A, B</p> <p>White: 22 (56%), 21 (91); p=0.030</p> <p>Aboriginal: 10 (26), 1 (4)</p> <p>Black: 4 (10), 0</p> <p>other: 3 (8), 1 (4)</p> | <p>Cases: born to HIV positive mothers, exposed to at least 3 antiretroviral drugs in utero for a minimum of 1 week and to zidovudine during delivery and the neonatal period, HIV-uninfected at 18 and 36 weeks, at least 2 nonreactive HIV pcr tests between 1 and 6 months of age and seroreverted HIV-1 serologic testing.</p> <p>Controls: from a cohort of children followed in a hepatitis C vertical transmission study; born to HIV negative, HCV-infected mothers with a high proportion (49.5%) of IVDU history. Attempted to match the ART exposed group in terms of socioeconomic background and substance abuse during pregnancy</p> | Sibling participation; non-English speaking, developmental delay due to other factor |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|--------------------------------|--|---|---|
| Benhammou, 2008 ¹⁰³ | Risk factors for tumor in the subgroup of NRTI exposed children (n=8853) Mother's geographical origin Metropolitan France = 2556 Sub-Saharan Africa = 5051 Other =1158 Mmother's CD4 count, absolute number >0.350 x 10 ⁹ cells/L n=5641 0.200-0.350 x 10 ⁹ cells/L n=1850 <0.200 x 10 ⁹ cells/L n=880 | Uninfected children born to HIV infected mothers followed from birth until 2 years | 541 HIV infected children, 521 questionnaires not completed or validated, 53 missing data for treatment exposure, 1852 not exposed to treatment, 274 exposed during only the peri and postpartum phases |
| Briand, 2009 ⁷³ | Maternal age <25 A: 736 (17%) B: 141 (11%) 25-34 A: 2640 (62%) B: 766 (62%) >35 A: 881 (21%) B: 331 (27%) Sub-Saharan African maternal geographic origin A. 2474 (60%) B: 914 (74%) Mean maternal CD4 at delivery A. 0.499 x 10 ⁹ cells/L (SD 0.312 x 10 ⁹ cells/L) B. 0.508 x 10 ⁹ cells/L (SD 0.274 x 10 ⁹ cells/L) | All live-born neonates born to HIV-infected mothers from January 1990 through 2006 enrolled in the French Perinatal Cohort (EPF CO-01) if they did not have the risk factors listed in exclusion criteria | Mothers who used illicit drugs during pregnancy, had no prenatal care before the 3rd trimester, twins and stillbirths. HIV-infected neonates diagnosed on site on 2 separate samples or if anti-HIV-1 antibodies persisted after 18 months of age |
| Brogly, 2007 ⁹¹ | Characteristics of the 1037 children in the primary analysis: Cases, Noncases; n (%) Sex Male: 15 (75), 476 (47) Female: 5 (25), 541 (53) Race Black: 12 (63), 535 (54) Hispanic: 4 (21), 329 (33) White: 3 (15), 132 (13) Other/unknown: 1, 21 Premature birth Yes: 2 (24), 139 (18) No: 13 (77), 654 (83) Unknown: 3, 224 | 1220 HIV-uninfected children who enrolled in PACTG 219 or 219c prior to 2 years of age and had completed 1 year of followup as of 31 August 2003 | 512 not included: did not complete 1 year of followup Children whose presentation could be explained by an etiology other than mitochondrial dysfunction (MD) or who did not meet the case definition of possible MD; children whose only sign of MD was cognitive developmental delay |
| Bunders, 2005 ¹⁰⁰ | 109 HIV-1/ART exposed infants: Gender (n, male/female) 64/45 Ethnicity (n, black, non) 78/31 Gestation, median week 38.4 (37-41) Delivery (n, vaginal/cesarean) 54/47 | All neonates born to HIV-1 infected mothers enrolled (109) | 17 children excluded because of HIV-infection, perinatal mortality, lack of ART exposure in utero, or insufficient data on in utero ART exposure |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|-------------------------------|--|---|---|
| Carceller, 2009 ⁷⁴ | Data not available for all mothers Age: <20 A: none reported B: 2/28 (7%) 21-30 A: 83/168 (49%) B: 12/28 (43%) 31-40 A: 76/168 (45%) B: 13/28 (46%) >40 A: 4/168 (2%) B: 1/28 (4%) Race: African A: 78/168 (46%) B: 11 (37%) Caucasian A: 49/168 (29%) B: 11 (37%) Haitian A:40/168 (24%) B: 8 (27%) | HIV-infected pregnant women treated with ART between 1997 and 2005 who were followed during pregnancy and delivered at CHU Sainte-Justine, Montreal, as well as their infants | Mothers infected with HIV and not treated, those who received antiretroviral monotherapy, or received only 2 antiretroviral agents during pregnancy or at the time of delivery. |
| Cote, 2008 ⁹² | All infants: A: ART exposed, n=73 B: control, n=81 Gestation time, weeks: A: 38 (38-40) B: 39 (37-40) Birth Weight (kg) A: 3.1 (2.7-3.4) B: 3.2 (2.7-3.6) Maternal Ethnicity: A(%), B(%) Aboriginal: 8 (11), 0 (0) White: 18 (25), 44 (54) Black-African Canadian: 34 (47), 0 (0) Hispanic: 4 (5.5), 5 (6) Asian: 6 (8), 6 (7) South, East, West Asian: 6 (8), 6 (7) Other: 2 (3), 13 (16) | ART-exposed infants: 1) born to an HIV infected woman who received ART during pregnancy and intravenous ZDV during labor; 2) received oral ZDV prophylaxis during the first 6 weeks of life starting within ~12hrs of birth. Control infants: born to HIV uninfected mothers and enrolled from 3 sources: 1) 1 to 6 month old infants having bloodwork done prior to elective minor pediatric surgery, 2) neonates (0-3 days old) born at Children's and Women's Health Center of British Columbia, 3) infants 1 day to 8months old) having bloodwork done for various minor medical reasons | Known mitochondrial disorder or serious and/or febrile illness |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|--------------------------------|---|---|---|
| Cotter, 2006 ⁷⁵ | <p>Age at delivery</p> <p><34</p> <p>A: 88%</p> <p>B: 86%</p> <p>C: 75%</p> <p>D: 84%</p> <p>≥34</p> <p>A: 12%</p> <p>B: 18%</p> <p>C: 25%</p> <p>D: 16%</p> <p>Race</p> <p>Black</p> <p>A: 59%</p> <p>B: 44%</p> <p>C: 37%</p> <p>D: 47%</p> <p>White</p> <p>A: 6%</p> <p>B: 4%</p> <p>C: 6%</p> <p>D: 4%</p> <p>Hispanic</p> <p>A: 10%</p> <p>B: 15%</p> <p>C: 26%</p> <p>D: 11%</p> <p>Haitian:</p> <p>A: 20%</p> <p>B: 30%</p> <p>C: 26%</p> <p>D: 31%</p> <p>Lowest CD4 count >0.500 x 10⁹ cells/L:</p> <p>A: 52%</p> <p>B: 33%</p> <p>C: 19%</p> <p>D: 19%</p> | <p>Women determined to be HIV positive before or during pregnancy who sought care at the prenatal clinic and gave birth at the University of Miami/Jackson Memorial Medical Center from January 1990 to December 2002. Singleton pregnancy, attendance at >1 prenatal visit at obstetric clinic dedicated to the care of HIV positive patients</p> | <p>Not reported</p> |
| El Beitune, 2005 ⁷⁶ | <p>Median maternal age</p> <p>A: 24, interquartile variation of 7 years</p> <p>B: 27, interquartile variation of 6 years</p> <p>C: 22.5, interquartile variation of 6 years</p> <p>Race"</p> <p>Race distribution was uniform in the 3 groups, P=0.14, chi-square test = NR</p> | <p>Not clearly specified.</p> <p>Implied: pregnant women aged 16 to 43 with singleton gestations. 45 women infected with HIV; 12 were not. Only HIV-infected patients who had not been treated previously with antiretroviral drugs were selected for the study.</p> | <p>Renal and hepatic insufficiency, personal or 1st degree relative with history of diabetes, initial BMI >30 kg/m, predictors of recurrent gestational diabetes (spontaneous abortion, major congenital malformation, stillbirth or macrosomia in prior pregnancies), noncompliance with use of antiretroviral drugs, use of medication with known diabetogenic effect.</p> |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|------------------------------------|--|--|---|
| Grosch-Woerner, 2008 ⁷⁷ | <p>Maternal and delivery characteristics in mother-infant pairs exposed to antiretrovirals; A (%), B (%), C+D (%)</p> <p>Race</p> <p>White: 41 (54), 13 (41), 35 (57)</p> <p>Black: 28 (37), 11 (34), 27 (36)</p> <p>Other: 7 (9), 8 (25), 12 (16)</p> <p>Unknown: 0, 0, 1</p> <p>Maternal age at delivery:</p> <p><25: 20 (26), 13 (41), 26 (34)</p> <p>26-34: 45 (59), 17 (53), 37 (49)</p> <p>>35: 11 (14), 2 (6), 12 (16)</p> <p>Median age: 28 (18-41), 27 (19-40), 28 (17-41)</p> <p>CD4 count at delivery</p> <p>>0.500 x 10⁹ cells/L: 42 (56), 12 (39), 21 (29)</p> <p>0.200-0.500 x 10⁹ cells/L: 33 (44), 18 (58), 43 (59)</p> <p><0.200 x 10⁹ cells/L: 0, 1 (3), 9 (12)</p> | <p>All mother-child pairs with information on ART, exposure during pregnancy identified before or during pregnancy in one center in Berlin or 12 centers in Germany and Austria.</p> | <p>7 women: no information on ART exposure during pregnancy; 2 with late presentation; 1 refused to participate</p> |
| Lipschultz, 2011 ⁹⁹ | <p>Age at delivery:</p> <p><30</p> <p>A: 84 (62%)</p> <p>B: 153 (71%)</p> <p>>30</p> <p>A: 52 (38%)</p> <p>B: 63 (39%)</p> <p>Race:</p> <p>Black</p> <p>A: 83 (61%)</p> <p>B: 120 (56%)</p> <p>White</p> <p>A: 10 (7%)</p> <p>B: 29 (13%)</p> <p>Hispanic</p> <p>A: 43 (32%)</p> <p>B: 67 (31%)</p> <p>Birthweight:</p> <p><2500 g</p> <p>A: 12 (9%)</p> <p>B: 32 (15%)</p> <p>>2500 g</p> <p>A: 124 (91%)</p> <p>B: 182 (84%)</p> <p>Unknown</p> <p>A: 0</p> <p>B: 2 (1%)</p> <p>Maternal CD4 count during pregnancy:</p> <p>A: 0.5322 x 10⁹ cells/L (0.491-0.572 x 10⁹ cells/L)</p> <p>B: 0.5862 x 10⁹ cells/L (0.517-0.655 x 10⁹ cells/L)</p> | <p>Patients enrolled in Women and Infants Transmission Study (WITS), age 2 years or less, followed until loss to followup, child withdrew, December 2006, or whichever came first.</p> | <p>Maternal: diabetes, phenylketonuria, chromosomal or Mendelian defect, heart defect requiring medication or surgery, pregnancy exposures to chemotherapy, radiation, drugs associated with heart disease in offspring</p> |
| Martí, 2007 ¹⁰⁹ | <p>Maternal age: median 30.9, range 18-42</p> <p>Nadir lymphocytes CD4 cell count <0.200 x 10⁹ cells/L: n=40 (27%)</p> <p>CD4 cell count 1st trimester: mean 0.445 x 10⁹ cells/L, SD: 0.214 x 10⁹ cells/L</p> | <p>All HIV-infected women who delivered between January 1, 1997 and December 31, 2003 at a tertiary center hospital in Madrid.</p> | <p>Cases of prematurely interrupted pregnancy or early prenatal death of the fetus.</p> |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|------------------------------------|---|---|---|
| Morris, 2005 ⁷⁸ | <p>Median age: 27 years (1-43)</p> <p>Race:</p> <p>Latina: 47%</p> <p>African American: 31%</p> <p>White: 15%</p> <p>Other: 7%</p> <p>Asymptomatic HIV: 73%</p> <p>Symptomatic HIV but not AIDS: 7%</p> <p>AIDS based on CD4 cell counts $<0.200 \times 10^9$ cells/L or history of AIDS indicator condition: 13%</p> | Medical records of all women treated with PIs during pregnancy at 5 sites in the US and Puerto Rico between December 1997 and December 2001 | Not reported |
| Mussi-Pinhata, 2007 ¹⁰¹ | <p>Maternal characteristics (n=503, 100%)</p> <p>Race:</p> <p>Hispanic/Latino: 197, 39.2%</p> <p>White: 163, 32.4%</p> <p>Black/ African: 102, 20.3%</p> <p>Other: 41, 8.2%</p> <p>CD4+ count at enrollment</p> <p>$<0.200 \times 10^9$ cells/L: 80, 16%</p> <p>$0.200-0.499 \times 10^9$ cells/L: 297, 59%</p> <p>$>0.500 \times 10^9$ cells/L: 53, 10.5%</p> | Term, HIV-1 uninfected infants who were the products of the first pregnancy on study of HIV-1 infected women enrolled before March 1, 2005 and were discharged from the hospital within the first 6 days of life; followed through 6 months of life; mothers received ARVs for >28 days during the third trimester of pregnancy | Not reported |
| Pacheco, 2006 ¹⁰² | <p>Mothers:</p> <p>Age at delivery, mean</p> <p>A: 27.8 (41.5-45.1)</p> <p>B: 27.6 (15.1-44.3)</p> <p>CD4 count at delivery</p> <p>A: 0.6709×10^9 cells/L (0.050-0.260×10^9 cells/L)</p> <p>B: 0.5114×10^9 cells/L (0-2.709×10^9 cells/L)</p> <p>$<0.200 \times 10^9$ cells/L</p> <p>A: 13 (4.6%)</p> <p>B: 210 (14.2%)</p> <p>Race/ethnicity: A/B</p> <p>White/nonHispanic: 44 (12.7%)/190 (10.7%)</p> <p>Black/nonHispanic: 161 (46.5%)/885 (49.6%)</p> <p>Hispanic: 11 (3.2%)/80 (4.5%)</p> <p>Other: 5/37</p> <p>Mode of delivery (%): A/B</p> <p>Scheduled Cesarean: 14 (4.2)/223 (15.6)</p> <p>Nonscheduled Cesarean: 41 (12.2)/193 (13.6)</p> <p>Vaginal: 280 (83.6)/1000 (70/6)</p> <p>NA: 16/404</p> | 2171 HIV infected mothers with singleton pregnancies and their HIV exposed, uninfected infants | Infants with no laboratory values obtained |
| Patel, 2005 ⁹³ | <p>Age at delivery, mean = 28 (10-45)</p> <p>Race</p> <p>White: 72% (2700/3740)</p> <p>Black: 21% (781/3740; mainly from sub-saharan Africa)</p> <p>Other: 7% (493/3740)</p> <p>CD4 count at delivery, mean = 0.420×10^9 cells/L (0-2.350×10^9 cells/L)</p> <p>Median gestational age at delivery = 38 weeks (22-43)</p> | HIV infected women identified during pregnancy | Reported elsewhere (see European Collaborative Study) |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|-----------------------------|---|--|--|
| Paul, 2005 ⁷⁹ | Child race/ethnicity White A: 23 (15%) B: 104 (11%) Black A: 66 (42%) B: 489 (52%) Hispanic A: 55 (35%) B: 309 (33%) Other A: 13 (8%) B: 39 (4%) Child ARV for perinatal prophylaxis None A: 104 (64%) B: 167 (18%) Monotherapy A: 52 (32%) B: 754 (79%) ART/combo A: 7 (4%) B: 34 (4%) | Children enrolled in WITS as of October 1999, born from 1st on-study pregnancy for a woman enrolled in WITS, HIV status was known, and complete clinical classification information was available | Not reported |
| Powis, 2011 ⁷² | Median age: A: 25 B: 26 CD4 count at enrollment A: 403 (297-514) B: 393 (305-514) Gestational age at enrollment (weeks) A: 27.1 (26.4-29.0) B: 27.1 (26.4-29.9) | HIV infected women identified during pregnancy enrolled in the randomized aspect of the Mma Bana Study. Eligibility included pregnancy of 26-34 weeks gestation, HIV-1 infection confirmed by two blood samples positive on ELISA, >8 years old, Hgb 8.0g/dL, an absolute neutrophil count of 1000 c/mm ³ | Exclusively formula fed infants |
| Rudin, 2011 ⁸⁰ | Gestational age A: 39 (38-40) B: 39 (37-39) C: 39 (37-38) Birthweight (kg) A: 3.1 B: 2.9 C: 2.9 Premature birth A: 14.9% B: 20.4% C: 24.2% | HIV-1 positive women with a history of at least one pregnancy that was completed to live birth | Multiple (twin) pregnancies; elective Cesarean <37 weeks duration; not started cART before or during pregnancy; not under study followup; no viral load during pregnancy |
| Schulte, 2007 ⁸¹ | Infants Race Black 62% Mean birth weight 2890 g Mean gestational age 37.3 weeks | White nonHispanic, black nonHispanic and Hispanic infants born in 1989 through 2004 for whom available data included birth weight and gestational age, and whose HIV testing was first conducted during the first 30 days of life. | Not reported |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|--|---|--|--|
| Tariq, 2011 ³⁹ See also Townsend, 2008 ⁵⁶ ; European Collaborative Study, 2005 ⁹³ | Maternal age at delivery, years (n=7547); A vs B: <25; n=1072 (16.9%) vs n=110 (9.2%) 25-29; n=1979 (31.2%) vs n=257 (21.6%) 30-34; n=2006 (31.6%) vs n=738 (61.7%) >35; n=1293 (20.4%) vs n=92 (7.7%) p<0.001 Ethnicity (n=7550); A vs B: Black n=4974 (78.3%) vs n=882 (73.8%) White n=1086 (17.1%) vs n=269 (22.5%) Asian/other n=294 (4.6%) vs n=45 (3.8%) p<0.001 Baseline CD4 count, cells/mm ³ (n=6993); A vs B: >500; n=1520 (25.9%) vs n=316 (28.4%) 200-499; n=3427 (58.3%) vs n=636 (57.2%) <200; n=934 (15.9%) vs n=160 (14.4%)p=0.14 HIV stage: not reported | All reported live singleton births to women who received ART for at least 14 days before delivery between 2000-2009 | Mother-child pairs lacking information on all outcomes of interest, ECS excluded data from centers in the Ukraine (limited antenatal ART) and the UK (to avoid duplication of cases reported to the NSHPC) |
| Townsend, 2007 ⁸² | Age at delivery; #, % (A, B, C) 14-24 yrs: 572, 17%; 239, 23%; 124, 25% 25-34: 2161, 36.9; 681, 64.2; 334, 67.7 35-46: 651, 19.2; 140, 13.2; 35, 7.1 Ethnic origin White: 439, 13; 211, 19.9; 164, 33.7 Black African: 2647, 78.2; 763, 72; 303, 62.3 Other: 297, 8.8; 86, 8.1; 19, 3.9 CD4 count >0.500 x 10 ⁹ cells/L: 895, 30.1; 387, 47.9; 63, 30.9 0.200-0.499 x 10 ⁹ cells/L: 1628, 54.7; 372, 46; 110, 53.9; <0.200 x 10 ⁹ cells/L: 454, 15.3; 49, 6.1; 31, 15.2 HIV stage/AIDS defining illness Major differences in baseline characteristics | Pregnancies resulting in singleton livebirth, stillbirth; between 1990-2005;diagnosis of HIV before delivery; reported to National Study of HIV in Pregnancy and Childbirth by March 2006 | Inadequate information on ART |
| Townsend, 2009 ⁹⁴ | Maternal ethnicity: n, % (n=8171) White: 1285, 15.7 Black African: 6244, 76.4 Black other: 326, 4.0 Other: 316, 3.9 Age at delivery (n=8184) <25: 1471, 18% 25-34: 5154, 63 >35: 1559, 19 Clinical status (n=7235) No HIV related symptoms: 6451, 89.2 HIV related symptoms/AIDS: 784, 10.8 | All infants born between 1990-2007 in the UK and Ireland to women diagnosed with HIV before delivery, and reported by June 2008 | Inadequate information on ART |
| Tuomala, 2005 ¹⁰⁸ | Early ART Age range: 27.34 to 28.82 Ethnicity: White 12% to 15% Black: 40% to 59% Latina: 29% to 46% CD4 mean: 24% to 29% Late ART Age range: 27.19 to 28.04 | Enrollment in WITS study of HIV-infected pregnant women and their infants. For maternal toxicities: All singleton pregnancies that ended between January 1990 and February 2002. For obstetric outcomes: all singleton pregnancies resulting in delivery at more than 20 weeks of gestation. | Not reported in this publication |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Baseline population characteristics for mother/baby | Eligibility criteria | Exclusion criteria |
|------------------------------|---|---|--|
| | Ethnicity: White 10% to 15% Black 47% to 58% Latina 32% to 38% CD4 mean: 26% to 29% | | |
| Watts, 2011 ⁹⁵ | Age, mean (years): 28.2 Race/ethnicity: Caucasian, nonHispanic n=317 (22%) Black, nonHispanic n=827 (58%) Hispanic n=253 (18%) Other n=17 (1%) CD4 count: >400 cells/μL n=790 (56%) 200-399 cells/μL n=450 (32%) <200 cells/μL n=173 (12%) | Women aged 13 years or older, receiving a stable ARV regimen not including a nonnucleoside reverse transcriptase inhibitor, able and willing to sign informed consent, enrolled after 20 weeks gestation | Women already enrolled in other treatment trials, women with elevated alanine aminotransferase levels, hypersensitivity to benzodiazepines, women who had received nonnucleoside ARV drugs in the past, or had a fetus with an anomaly incompatible with life in the current pregnancy |
| Williams, 2010 ⁹⁷ | Age at test, median = 1.8 (1-2) Race/ethnicity, n (%) White nonHispanic + other = 242 (13) Black nonHispanic = 1016 (55) Hispanic = 582 (32) Maternal viral load, n (%) copies/mL <400 = 362 (39) 401-5000 = 272 (29) 5000-50,000 = 235 (25) >50,000 = 67 (7) Unknown = 904 | Children perinatally HIV exposed, uninfected enrolled in the clinical trial group between 1993-2006; had at least 1 neurodevelopmental functioning test by using the Bayley Scales of Infant Development (BSID) | Invalid BSID scores, missing ARV exposure information |

| Author, Year | Number screened/eligible/enrolled/withdrawals/% analyzed | Adjusted variables for statistical analysis |
|--------------------------------|---|--|
| Aldrovandi, 2009 ⁹⁰ | 213 uninfected infants born to HIV-infected women 411 healthy children born to HIV-uninfected women | For infant mDNA levels: mixed model analysis of variance controlled for: ARV exposure, maternal alcohol use, maternal cocaine/crack use, maternal hard drug use, maternal predelivery CD4 count, maternal predelivery plasma HIV RNA, maternal delivery CD4 count, maternal delivery CD4 %, maternal delivery HIV RNA level, infant birth weight, and infant age. |
| Alimenti, 2006 ⁹⁶ | 64 children born to mothers in ART; 25 children unavailable or not eligible; 11 did not return phone calls; 8 declined participation; 3 language barrier; 3 excluded because of sibling participation | Analysis of covariance used to allow for control of specific variables and on frequencies by using chi-square tests |
| Benhammou, 2008 ¹⁰³ | 12,074 live born infants; 11,553 HIV uninfected; 9127 exposed to at least one NRTI during one or more of the pre-, peri-, or postpartum phases; 8853 children exposed to NRTIs in utero | Multivariate and univariate analyses performed. |
| Briand, 2009 ⁷³ | 8192 mother-infant pairs 317 excluded due to illicit drug use 396 excluded due to twin pregnancies 439 HIV-infected neonates excluded | SGA studied using univariate and multivariate regression analysis; association with birthweight Z-scores used univariate and multivariate linear regression models fitted to obtain regression coefficients. Models adjusted for maternal geographic origin, maternal age, parity, and gestational age at booking. Birth weight Z-score adjusted for gestational age and sex lower than -2 SD. Similar analysis for head circumference and height. |
| Brogly, 2007 ⁹¹ | 1732 enrolled through August 2003; 1220 enrolled prior to 2 years of age and had completed 1 year of followup. 512 not included, enrolled earlier, followed longer before 3 years of age | Sex, race/ethnicity, year of birth, premature birth, neonatal ARV prophylaxis, peak maternal HIV RNA copy number during 3rd trimester or delivery, in utero psychoactive drug exposure |
| Bunders, 2005 ¹⁰⁰ | 109 eligible; 93 with followup more than 2 years; 17 excluded | Multivariate model allowing for birthweight, gestational age |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Number screened/eligible/enrolled/withdrawals/% analyzed | Adjusted variables for statistical analysis |
|------------------------------------|---|--|
| Carceller, 2009 ⁷⁴ | 347 pregnant women with HIV screened 248 ART-exposed mother infant pairs eligible, 42 excluded due to insufficient data 206 ART-exposed mother-infant pairs included Control: 206 randomly selected infants of non-HIV-infected mothers % analyzed: A: 97%-99% B: 93%-97% C: 82% | Logistic regression analysis to examine effect of protease inhibitors on prematurity and SGA |
| Cote, 2008 ⁹² | 73 ART-exposed infants and 81 control infants born between July 2003 and June 2006 eligible. 87 controls initially, but 6 excluded due to febrile illness or abnormal lab values. For analysis of mtRNA level, 32 study and 62 control infants were ultimately analyzed for mtRNA content | Research site, length of in utero exposure to ART, maternal infection with HCV or HBV, birth weight, gestational age at delivery |
| Cotter, 2006 ⁷⁵ | 999 women who received ART during pregnancy; 338 who did not receive therapy | History of preterm delivery; factors significant in univariate analysis, category of ART, race/ethnicity. Lowest CD4 count during pregnancy, CDC disease stage, illicit substance use, smoking, STD, time of initiation of prenatal care, ART duration, ART before pregnancy, year of delivery |
| El Beitune, 2005 ⁷⁶ | Treated cohort: 45 Untreated cohort: 12 | None reported |
| Grosch-Woerner, 2008 ⁷⁷ | 190 screened; 183 pairs included in analysis | AOR: race, maternal age, IDU during pregnancy, CD4 cell count at delivery, parity, and ART exposure |
| Lipschultz, 2011 ⁹⁹ | 136 ART-exposed infants; 216 non-ART exposed infants | Interaction terms of ART exposures with sex, ethnicity, age that were significant at 0.05 were included in the final models |
| Marti, 2007 ¹⁰⁹ | 179 pregnancies were recorded 12 pregnancies ended in spontaneous miscarriage or induced abortion With 3 sets of twins, there were 170 newborns | Multiple stepwise logistic regression analysis. For GDM: CD4 cell count, previous AIDS diagnosis, risk factors for HIV |
| Morris, 2005 ⁷⁸ | Records of 233 pregnancies were reviewed (11-91 per site). Outcomes for 3/231 (1.3%) lost to followup | Known risk factors for prematurity were tested using multiple logistic regression. A forward stepwise procedure was used with maximum likelihood estimation of the regression coefficients. The likelihood ratio criterion was used to determine significance of individual factors in the regression model. |
| Mussi-Pinhata, 2007 ¹⁰¹ | 803 women enrolled; 16 pregnancies excluded; 743 delivered 737 infants; 81 still on study; 21 lost to followup; 631 completed 6 month follow up after birth; 603 HIV uninfected (24 indeterminate, 8 infected) 603 infants; 541 gestational age >37 weeks, 539 discharged from hospital within 6 days of life; 533 infants mothers received one or more ARVs during pregnancy; 511 received ARVs for >28 days. | Adjusted for mother's country of residence, race/ethnicity, ARV regimen |
| Pacheco, 2006 ¹⁰² | 2171 enrolled; followup for 1-34 months; excluded not reported | Multivariate analysis adjusted for maternal antenatal use of hard drugs, maternal CD4 count at delivery, infant gestational age, infant birth weight, race/ethnicity, maternal CDC clinical classification, infant sex and age |
| Patel, 2005 ⁹³ | 3740 mother-infant pairs enrolled; 1973 infants exposed to ART in utero, including 602 exposed to ART; 789/1973 (40%) women received ART in the first trimester and had initiated treatment before conception | Multiple variable logistic regression with all variables included; race, maternal age at delivery, CD4 count, gestational age |
| Paul, 2005 ⁷⁹ | 1853 children enrolled in WITS as of October 1999. 1785 singletons, 1553 from 1st pregnancy. 1480 with known HIV status 1118 with complete HIV data 995 HIV-uninfected 163 HIV-infected | Cox proportional hazards modeling to assess effect of selected covariates on clinical events rate. For growth problems developed after 2 weeks of age: maternal education, maternal viral load at delivery, hard drug, alcohol and cigarette use during pregnancy; child's race, ethnicity and gender, number of caregiver changes |

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Number screened/eligible/enrolled/withdrawals/% analyzed | Adjusted variables for statistical analysis |
|---|--|---|
| Powis, 2011 ⁷² | 560 HIV infected pregnant women enrolled; 285 randomized to NRTI group, 27 randomized to PI group A: excluded: 1 LTFU prior to delivery, 5 stillborn birhts, 1 twin delivery, 1 preterm emergent cesarean B: excluded: 3 LTFU prior to delivery, 8 stillborn, 9 twin deliveries, 2 preterm emergent cesarean A: 263 mother infant pairs included B: 267 included | Self reported maternal income, maternal CD4 count at enrollment, HIV viral load |
| Rudin, 2011 ⁸⁰ | 1241 in database; 762 pregnancies excluded in 695 women; adjusted analysis based on 365 pregnancies in 318 women | Maternal characteristics: lowest CD4 cell count during pregnancy, last HIV RNA load before delivery, age at conception, ethnicity, illicit drug use, smoking. |
| Schulte, 2007 ⁸¹ | 11,231 HIV exposed and HIV infected infants met inclusion criteria 8793 infants were born to HIV-infected mothers with prenatal care | Excluded preterm birth from multivariate assessment of low birth weight. Excluded low birth weight in asesment of preterm birth. All variables in univariate analyses were entered into logistic regression models. Risks significant at 0.10 level remained in the model using a stepwise method. Perinatal exposure to 2 ARV drugs was used as a referent group. |
| Tariq, 2011 ⁵⁹ See also Townsend, 2008 ⁵⁶ ; European Collaborative Study, 2005 ⁹³ | 7573 mother-child pairs analyzed (n=1263 from ECS, n=6310 from NSHPC) | AOR=OR adjusted for study, maternal age group |
| Townsend, 2007 ⁸² | 5009 reported pregnancies; 4939 included | OR = adjusted for repeat pregnancies AOR = OR adjusted for repeat pregnancies, injecting drug use as source of HIV infection, ethnic origin, maternal age, clinical status AOR2 = OR adjusted for repeat pregnancies, injecting drug use as source of HIV infection, ethnic origin, maternal age, clinical status, CD4 count (subset with count n = 3761) |
| Townsend, 2009 ⁹⁴ | 8576 infants reported, including 92 stillbirths, 288 twins/triplets. Information available for 79% of inants, remainder reported only through the obstetric (10%) or pediatric (11%) scheme. Information on congenital abnormality available for 96.1% (8242/8576) infants. Timing of ART exposure data missing for 7.4% (609/8242) infants. Of these, most reports (88%, 538/609) were obtained from pediatric respondents. | Maternal CD4 count, ilntravenous drug use, age, ethnicity |
| Tuomala, 2005 ¹⁰⁸ | Maternal complications: 2543 women analyzed Obstetric outcomes: 2286 women analyzed | Major temporal changes in ART use; associations between variables and outcomes that had univariate probability values below 0.1 were included in a final logistic regression model; logistic regression using a stepwise elimination procedure with a logistic regression probability value for entry and exit into the model set at 0.05 was performed to identify independent predictors of each specified outcome. |
| Watts, 2011 ⁹⁵ | 1506 women enrolled in PACTG 316;1414 women with 1408 livebirths and 6 stillbirths analyzed for congenital defects by timing of ARV use | Only univariate analyses shown |
| Williams, 2010 ⁹⁷ | 2342 uninfected, HIV exposed infants enrolled in PACTG; 2300 in recommended age range for testing; 1910 had at least one test reported; 1840 (96%) had both valid test results and known maternal ARV exposure. | Demographic factors (age at test, gender, race/ethnicity) and potential confounders: test version, primary language, primary caregiver, caregiver education, low birth weight, birth year; geographic location, urban/rural |

3TC = lamivudine; AEs = adverse events; AIDS = acquired immunodeficiency syndrome; AOR = adjusted odds ratio; ART = antiretroviral; ARV = antiretroviral; cARV = combination antiretrovirals; BMI = body mass index; BSID = Bayley Scale of Infant Development; CDC = Centers for Disease Control and Prevention; CI = confidence interval; CHAART = cardiovascular status of HAART; ELISA = enzyme-linked immunosorbent assay; GDM = gestational diabetes mellitus; HAART = highly active antiretroviral therapy; HBV = hepatitis B virus; HCV = hepatitis C virus; Hgb = hemoglobin; IDU = injection drug user; IVDU = intravenous drug use; KAL-CBV = lopinavir/ritonavir/zidovudine/lamivudine; LBW = low birth weight; LTFU = loss to followup; LV = left ventricle; MD = mitochondrial dysfunction; MOCHIV = mothers of children with HIV; mtDNA = mitochondrial deoxyribonucleic acid; mtRNA =

Appendix B6. Key Question 3c: Studies of Adverse Outcomes Associated With Antiretroviral Therapy

mitochondrial ribonucleic acid; N/A = not applicable; NISDI = NICHD International Site Development Initiative; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NR = not reported; NSHPC = National Study of HIV in Pregnancy and Childhood; OR = odds ratio; PACTG = Pediatric AIDS Clinical Trials Group; PBMC = peripheral blood mononuclear cell; PI = protease inhibitor; RCT = randomized, controlled trial; RNA = ribonucleic acid; SD = standard deviation; SGA = small for gestational age; SHCS = Swiss HIV cohort study; SIDA = Swedish International Development Cooperation Agency; STD = sexually transmitted disease; WITS = Women and Infants Transmission Study; ZDV = zidovudine.

Appendix B7. Key Question 3c: Quality Rating of a Randomized, Controlled Trial of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Randomization adequate? | Allocation concealment adequate? | Groups similar at baseline? | Eligibility criteria specified? | Outcome assessors masked? | Care provider masked? | Patient masked? | Attrition and withdrawals reported? | Loss to followup differential/high? | Intention -to-treat analysis | Quality rating | Funding |
|---------------------------|-------------------------|----------------------------------|-----------------------------|---------------------------------|---------------------------|-----------------------|-----------------|-------------------------------------|-------------------------------------|------------------------------|----------------|---|
| Powis, 2011 ⁷² | Yes | Unclear | Yes | Yes | Unclear | Unclear | Unclear | Yes | No | Unclear | Fair | Harvard University Center for AIDS Research, Global Infectious Disease Program, Global Health Scholars Program; National Institute of Allergy and Infectious Diseases |

Appendix B8. Key Question 3c: Quality Ratings of Cohort Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)? | Were the groups comparable at baseline on key prognostic factors (by restriction or matching)? | Did the study maintain comparable groups through the study period? | Did the study use accurate methods for ascertaining exposures and potential confounders? | Were outcome assessors and/or data analysts blinded to the exposure being studied? | Did the article report attrition? | Did the study perform appropriate statistical analyses on potential confounders? |
|------------------------------------|--|---|---|---|---|--|---|
| Aldrovandi, 2009 ⁹⁰ | No | No | Unclear | Unclear | Yes | No | Yes |
| Alimenti, 2006 ⁹⁶ | Yes | Yes | Yes | Yes | No | No | Yes |
| Benhammou, 2008 ¹⁰³ | Yes | Unclear | Unclear | Yes | Unclear | Yes | Yes |
| Briand, 2009 ⁷³ | Yes | Unclear | Unclear | Yes | Unclear | No | Yes |
| Brogly, 2007 ⁹¹ | Yes | Yes | Yes | Yes | Yes | No | Yes |
| Bunders, 2005 ¹⁰⁰ | Yes | Yes | Yes | Yes | No | No | Yes |
| Carceller, 2009 ⁷⁴ | Yes | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
| Cote, 2008 ⁹² | Yes | No | Yes | Yes | Unclear | No | Yes |
| Cotter, 2006 ⁷⁵ | Yes | No | Unclear | Yes | Unclear | N/A | Yes |
| El Beitune, 2005 ⁷⁶ | Unclear | Yes | Yes | Unclear | Unclear | No | No |
| Grosch-Woerner, 2008 ⁷⁷ | Yes | Yes | Yes | Yes | Unclear | Yes | Yes |
| Lipschultz, 2011 ⁹⁹ | Yes | Yes | Yes | Yes | No | No | Yes |
| Marti, 2007 ¹⁰⁹ | Yes | Unclear | Unclear | Yes | Unclear | No | Yes |
| Morris, 2005 ⁷⁸ | Yes | NA | NA | Yes | Unclear | Yes | Yes |
| Mussi-Pinhata, 2007 ¹⁰¹ | Yes | Unclear; groups not separated by HAART regimen | Unclear | Yes | No | Yes | Yes |
| Pacheco, 2006 ¹⁰² | Yes | No; groups differ on multiple variables | Unclear | Yes | No | Unclear | Yes |
| Patel, 2005 ⁹³ | Yes | Yes | Yes | Yes | No | No | Yes |
| Paul, 2005 ⁷⁹ | Yes | Unclear | Unclear | Unclear | Unclear | No | Yes |
| Rudin, 2011 ⁸⁰ | Yes | Unclear | Unclear | Yes | No | Yes | Yes |
| Schulte, 2007 ⁸¹ | Yes | Unclear | Unclear | Yes | Unclear | Unclear | Yes |
| Tariq, 2011 ⁵⁹ | Yes | No; differences on several variables | Unclear | Yes | Unclear | Yes | Yes |
| Townsend, 2007 ⁸² | Yes | Yes | Yes | Yes | No | No | Yes |
| Townsend, 2009 ⁹⁴ | Yes | Unclear; baseline characteristics are not divided by ART groups | Yes | Yes | Unclear | Yes | Yes |
| Tuomala, 2005 ¹⁰⁸ | Yes | No; between groups on multiple variables | Unclear | Yes | Yes | No | Yes |
| Watts, 2011 ⁹⁵ | Yes | Unclear; baseline characteristics not divided by ART group | Unclear | Unclear | Yes | Yes | Yes |
| Williams, 2010 ⁹⁷ | Yes | No; differ by birth year, test used to assess neurodevelopment | Unclear | Yes | Unclear | No | Yes |

Appendix B8. Key Question 3c: Quality Ratings of Cohort Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Is there important differential loss to followup or overall high loss to followup? | Were outcomes prespecified and defined, and ascertained using accurate methods? | Quality rating | Funding source |
|------------------------------------|--|---|----------------|---|
| Aldrovandi, 2009 ⁹⁰ | Unclear | Unclear | Poor | Not reported |
| Alimenti, 2006 ⁹⁶ | No | Yes | Good | British Columbia Medical Services Foundation; Health Canada Hepatitis C Vertical Transmission Study |
| Benhamou, 2008 ¹⁰³ | No | Yes | Fair | Agence Nationale de Recherche sur le SIDA, Agence Francaise de Securite Sanitaire des Produits de Sante |
| Briand, 2009 ⁷³ | Unclear | Yes | Fair | Agence Nationale de Recherches sur le SIDA et les Hepatitis Virales |
| Brogly, 2007 ⁹¹ | No | Yes | Good | National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; Statistical and Data Analysis Center of Pediatric AIDS Clinical Trials Group, Harvard School of Public Health |
| Bunders, 2005 ¹⁰⁰ | No | Yes | Fair | Academic Medical Center, Amsterdam; International AIDS Therapy Evaluation Center |
| Carceller, 2009 ⁷⁴ | Unclear | Yes | Poor | Not reported |
| Cote, 2008 ⁹² | No | Yes | Good | Hospital for Sick Children, Toronto |
| Cotter, 2006 ⁵ | No; all data reviewed for all births in time period of interest as per study | Yes | Fair | Not reported |
| El Beitune, 2005 ⁷⁶ | Unclear | Yes | Poor | FAPESP |
| Grosch-Woerner, 2008 ⁷⁷ | No | Yes | Fair | Ministry of Health of Germany; World Childhood Foundation |
| Lipschultz, 2011 ⁹⁹ | Unclear | Yes | Fair | National Heart, Lung, and Blood Institute |
| Marti, 2007 ¹⁰⁹ | No | Yes | Fair | Not reported |
| Morris, 2005 ⁷⁸ | No | Yes | Fair | Agouron Pharmaceuticals |
| Mussi-Pinhata, 2007 ¹⁰¹ | No | Yes | Fair | National Institute of Child Health and Human Development International Site Development Initiative (NISDI) Perinatal Study Group |
| Pacheco, 2006 ¹⁰² | Unclear | Yes | Fair | National Institute of Allergy and Infectious Diseases; National Institute on Drug Abuse; National Institute of Child Health and Human Development |
| Patel, 2005 ⁹³ | No | Yes | Fair | European Comission; Medical Research Council |
| Paul, 2005 ⁹ | Unclear | Yes | Poor | National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development; National Institute on Drug Abuse; General Clinical Research Centers |
| Rudin, 2011 ⁸⁰ | No | Yes | Fair | Swiss HIV Cohort Study, Swiss National Science Foundation |
| Schulte, 2007 ⁸¹ | Unclear | Yes | Fair | Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention |
| Tariq, 2011 ⁵⁹ | No Yes | Yes | Fair | UK Medical Research Council; Wellcome Trust Research Career Development Fellowship, Health Protection Agency, Department of Health's National Institute for Health Research Biomedical Research Centers |
| Townsend, 2007 ⁸² | No | Yes | Fair | Ministry of Health and Child Welfare, Zimbabwe; Canadian International Development Agency |
| Townsend, 2009 ⁹⁴ | No | Yes | Fair | National Study of HIV in Pregnancy and Childhood, Institute of Child Health, Health Protection Agency Center for Infections and Health Protection, Scotland |
| Tuomala, 2005 ¹⁰⁸ | Unclear | Yes | Fair | National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute on Drug Abuse, General Clinical Research Centers |

Appendix B8. Key Question 3c: Quality Ratings of Cohort Studies of Adverse Outcomes Associated With Antiretroviral Therapy

| Author, Year | Is there important differential loss to followup or overall high loss to followup? | Were outcomes prespecified and defined, and ascertained using accurate methods? | Quality rating | Funding source |
|------------------------------|--|---|----------------|---|
| Watts, 2011 ⁹⁵ | No | Yes | Fair | National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute on Drug Abuse, and General Clinical Research Centers |
| Williams, 2010 ⁹⁷ | Unclear | Yes | Fair | National Institute of Allergy and Infectious Diseases and the National Institutes of Child Health and Human Development International and Domestic Pediatric and Maternal HIV Clinical Trials Network |